{{medical}}
{{noteTA
|T=zh-cn:阿尔茨海默病; zh-tw:阿茲海默症; zh-hk:阿茲海默症;
|1=zh-hans:恋恋笔记本; zh-hant:戀戀筆記本; zh-hk:忘了、忘不了; zh-tw:手札情緣; zh-mo:忘了、忘不了;
|2=zh-hans:依然爱丽丝; zh-hant:我想念我自己; zh-tw:我想念我自己; zh-hk:永遠的愛麗絲; zh-sg:我想念我自己;
|3=zh-hans:柳暗花明; zh-hant:妳的樣子; zh-hk:妳的樣子;
|4=zh-cn:阿尔茨海默; zh-tw:阿茲海默; zh-hk:阿茲海默;
|G1 = Medicine
}}
{{Infobox medical condition (new)
| name            = 阿茲海默症
| image           = Alzheimer's_disease_brain_comparison-zh.jpg
| caption         = 比較正常（左）和阿茲海默症（右）患者的腦部。
| field           = [[神經內科|神經內科]]
| synonyms        = 老年痴呆症
| symptoms        = 短期記憶喪失、{{tsl|en|primary progressive aphasia|原發性進行性失語症|語言障礙}}、{{tsl|en|Orientation (mental)|定向障礙}}、{{tsl|en|mood swing|情緒不穩}}<ref name=BMJ2009/><ref name=WHO2017/>
| complications   = 
| onset           = 大於65歲<ref name=Mend2012/>
| duration        = 慢性<ref name=WHO2017/>
| causes          = 瞭解有限<ref name=BMJ2009/>
| risks           = [[遗传学|遺傳]]、[[頭部外傷|頭部外傷]]、[[重性抑郁障碍|憂鬱症]]、[[高血壓|高血壓]]<ref name=BMJ2009/><ref name=Lancet2011/>
| diagnosis       = 排除其他可能原因後基於症狀和{{tsl|en|cognitive test|認知測試}}診斷<ref name=NICE2014Diag/>
| differential    = 正常老化<ref name=BMJ2009/>
| prevention      = 
| treatment       = 
| medication      = {{tsl|en|Acetylcholinesterase inhibitor|乙醯膽鹼抑制劑}}、{{tsl|en|NMDA receptor antagonist|NMDA受體拮抗劑}}（稍有幫助）<ref name=Pres2012/>
| prognosis       = 餘命3至9年<ref name=NEJM2010/>
| frequency       = 2980萬人（2015）
| deaths          = 190萬人（2015）
}}
{{中文译名
| putonghua = 阿尔茨海默病<ref name=nmpa>{{Cite web |url = https://www.nmpa.gov.cn/directory/web/nmpa/yaowen/ypjgyw/20191102204301440.html |title = 国家药监局有条件批准轻度至中度阿尔茨海默病药物甘露特钠胶囊上市 |author =  |date = 2019-11-02 |publisher = 国家药品监督管理局 |language = zh-cn |accessdate = 2019-11-05 }}</ref>
| taiwan    = 阿茲海默症
| cantonese = 
}}
<!-- 定義和症狀 -->
'''阿茲海默症'''（{{lang-la|''Morbus Alzheimer''}}、{{lang-de|Alzheimer-Krankheit}}、{{lang-en|Alzheimer's disease}}，[[縮寫|縮寫]]：{{lang|en|AD}}），俗稱'''早老性痴呆'''、'''老年痴呆'''，是一種發病進程緩慢、隨著時間不斷惡化的[[神經退化性疾病|神經退化性疾病]]，此病症佔了[[失智症|失智症]]中六到七成的成因<ref name="BMJ2009">{{Cite journal|title=Alzheimer’s disease|url=https://www.bmj.com/content/338/bmj.b158|last=Iliffe|first=Steve|last2=Burns|first2=Alistair|date=2009-02-05|journal=BMJ|doi=10.1136/bmj.b158|volume=338|pages=b158|language=en|issn=1468-5833|pmid=19196745|access-date=2019-01-01|archive-url=https://web.archive.org/web/20181221201846/https://www.bmj.com/content/338/bmj.b158|archive-date=2018-12-21|dead-url=no}}</ref><ref name="WHO2017" />。最常見的早期症狀為喪失[[短期记忆|短期记忆]]（難以記住最近發生的事），當疾病逐漸進展，症狀可能逐漸出現，包括{{tsl|en|primary progressive aphasia|原發性進行性失語症|語言障礙}}、{{tsl|en|Orientation (mental)|定向障礙}}（包括容易迷路）、{{tsl|en|mood swing|情感不穩|情緒不穩}}、喪失[[动机|动机]]、無法[[日常生活活動|自理]]和許多{{tsl|en|challenging behaviour|挑戰性行為|行為問題}}<ref name="BMJ2009" /><ref name="WHO2017" />。當情況惡化時，患者往往會因此和家庭或社會脫節<ref name="BMJ2009" />，並逐漸喪失身體機能，最終導致[[死亡|死亡]]<ref name="nihstages">{{cite web|title=About Alzheimer's Disease: Symptoms|url=http://www.nia.nih.gov/alzheimers/topics/symptoms|publisher=National Institute on Aging|access-date=2011-12-28|language=en|deadurl=no|archive-url=https://web.archive.org/web/20120115201854/http://www.nia.nih.gov/alzheimers/topics/symptoms|archive-date=2012-01-15}}</ref>。雖然疾程因人而異，但診斷後的平均餘命約為三到九年<ref name="NEJM2010">{{Cite journal|title=Alzheimer's Disease|url=https://doi.org/10.1056/NEJMra0909142|last=Querfurth|first=Henry W.|last2=LaFerla|first2=Frank M.|date=2010-01-28|journal=New England Journal of Medicine|issue=4|doi=10.1056/NEJMra0909142|language=en|volume=362|pages=329–344|issn=0028-4793|pmid=20107219}}</ref><ref>{{Cite journal|title=Survival in dementia and predictors of mortality: a review|url=https://onlinelibrary.wiley.com/doi/abs/10.1002/gps.3946|last=Todd|first=Stephen|last2=Barr|first2=Stephen|date=2013|journal=International Journal of Geriatric Psychiatry|issue=11|doi=10.1002/gps.3946|volume=28|pages=1109–1124|language=en|issn=1099-1166|last3=Roberts|first3=Mark|last4=Passmore|first4=A. Peter}}</ref>。

<!-- 病因、診斷和預防 -->
阿茲海默症的真正成因至今仍然不明<ref name="BMJ2009" />。目前將阿茲海默症視為一種[[神經退行性疾病|神經退化的疾病]]，並認為有將近七成的風險因子與[[遺傳|遺傳]]有關<ref name="Lancet2011">{{Cite journal|title=Alzheimer's disease|url=https://linkinghub.elsevier.com/retrieve/pii/S0140673610613499|last=Ballard|first=Clive|last2=Gauthier|first2=Serge|language=en|date=2011-03|journal=The Lancet|issue=9770|doi=10.1016/s0140-6736(10)61349-9|volume=377|pages=1019–1031|issn=0140-6736|last3=Corbett|first3=Anne|last4=Brayne|first4=Carol|last5=Aarsland|first5=Dag|last6=Jones|first6=Emma|access-date=2019-01-01|archive-date=2021-02-05|archive-url=https://web.archive.org/web/20210205064049/https://linkinghub.elsevier.com/retrieve/pii/S0140673610613499|dead-url=no}}</ref>；其他的風險因子還有[[頭部外傷|頭部外傷]]、[[憂鬱症|憂鬱症]]和[[高血壓|高血壓]]<ref name="BMJ2009" />。疾病的進程與[[大腦|大腦]]中的{{link-en|纖維狀類澱粉蛋白質斑塊沉積|Senile plaques}}和[[Tau蛋白|Tau蛋白]]有關<ref name="Lancet2011" />。要診斷阿茲海默症，需根據病人病史、行為評估、{{link-en|認知測驗|Cognitive tests}}、腦部[[醫學影像|影像]]檢查和血液採檢來排除其他可能的因素<ref name="NICE2014Diag">{{cite web|url=https://pathways.nice.org.uk/pathways/dementia/dementia-assessment-and-diagnosis.pdf|title=Dementia diagnosis and assessment|language=en|publisher=National Institute for Health and Care Excellence (NICE)|access-date=2018-12-22|archive-url=https://web.archive.org/web/20141205184403/http://pathways.nice.org.uk/pathways/dementia/dementia-diagnosis-and-assessment.pdf|archive-date=2014-12-05|dead-url=no}}</ref>。疾病初期的症狀常被誤認為是正常老化<ref name="BMJ2009" />。確診則需藉助腦部組織檢驗<ref name="Lancet2011" />。{{tsl|en|Mental exercise|腦力運動|脑力}}和身體[[運動|運動]]、避免[[肥胖症|肥胖]]都有助於減少罹患阿茲海默症的風險<ref name="Lancet2011" /><ref>{{cite web|url=https://www.nia.nih.gov/alzheimers/publication/preventing-alzheimers-disease/so-what-can-you-do|title=So, What Can You Do?|date=2016-07-29|language=en|publisher=National Institute on Aging|deadurl=yes|archive-url=https://web.archive.org/web/20170403110434/https://www.nia.nih.gov/alzheimers/publication/preventing-alzheimers-disease/so-what-can-you-do|archive-date=2017-04-03|accessdate=2019-01-01}}</ref>。目前沒有實證證明特定藥物或營養補充品對疾病治療有效<ref name="nonprevention">{{Cite journal|title=Primary and Secondary Prevention Trials in Alzheimer Disease: Looking Back, Moving Forward|url=https://www.ncbi.nlm.nih.gov/pubmed/27697063|last=Hsu|first=David|last2=Marshall|first2=Gad A.|year=2017|journal=Current Alzheimer Research|issue=4|doi=10.2174/1567205013666160930112125|language=en|volume=14|pages=426–440|issn=1875-5828|pmc=5329133|pmid=27697063|access-date=2019-01-01|archive-date=2020-05-17|archive-url=https://web.archive.org/web/20200517164230/https://www.ncbi.nlm.nih.gov/pubmed/27697063|dead-url=no}}</ref>。

<!-- 處置 -->
目前並沒有可以阻止或逆轉病程的治療，只有少數方法或許可以暫時緩解或改善症狀<ref name="WHO2017" />。疾病會使患者會越來越需要{{link-en|失智症照護|Caring for people with dementia|他人的照護}}，這對照護者是一大負擔；這樣的照護壓力涵括了[[社会|社會]]、生理、[[精神|精神]]和[[经济|經濟]]等各個層面<ref name="pmid17662119">{{Cite journal|title=Systematic review of information and support interventions for caregivers of people with dementia|url=https://doi.org/10.1186/1471-2318-7-18|last=Thompson|first=Carl A.|last2=Spilsbury|first2=Karen|date=2007-07-27|journal=BMC Geriatrics|issue=1|doi=10.1186/1471-2318-7-18|volume=7|pages=18|issn=1471-2318|language=en|pmc=1951962|pmid=17662119|last3=Hall|first3=Jill|last4=Birks|first4=Yvonne|last5=Barnes|first5=Colin|last6=Adamson|first6=Joy|access-date=2019-01-01|archive-date=2019-07-13|archive-url=https://web.archive.org/web/20190713162444/https://bmcgeriatr.biomedcentral.com/articles/10.1186/1471-2318-7-18|dead-url=no}}</ref>。運動計畫能改善病人的[[日常生活活動|日常生活]]功能，並可能可以改善預後<ref name="Forb2015">{{Cite journal|title=Exercise programs for people with dementia|url=http://dx.doi.org/10.1002/14651858.cd006489.pub4|last=Forbes|first=Dorothy|last2=Forbes|first2=Scott C|date=2015-04-15|journal=Cochrane Database of Systematic Reviews|language=en|doi=10.1002/14651858.cd006489.pub4|issn=1465-1858|last3=Blake|first3=Catherine M|last4=Thiessen|first4=Emily J|last5=Forbes|first5=Sean}}</ref>。由失智症狀引起的行為異常和[[思覺失調|思覺失調]]常以[[抗精神病藥|抗精神病藥]]治療，惟其效益不高且可能增加死亡率，因此通常不建議使用<ref>{{cite web|url=https://www.nice.org.uk/advice/ktt7/resources/non-guidance-lowdose-antipsychotics-in-people-with-dementia-pdf|title=Low-dose antipsychotics in people with dementia|author=National Institute for Health and Clinical Excellence|publisher=National Institute for Health and Care Excellence (NICE)|language=en|access-date=2014-11-29|deadurl=yes|archive-url=https://web.archive.org/web/20141205183329/https://www.nice.org.uk/advice/ktt7/resources/non-guidance-lowdose-antipsychotics-in-people-with-dementia-pdf|archive-date=2014-12-05}}</ref><ref>{{cite web|url=http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm124830.htm|title=Information for Healthcare Professionals: Conventional Antipsychotics|date=2008-06-16|publisher=US Food and Drug Administration|language=en|access-date=2014-11-29|deadurl=no|archive-url=https://web.archive.org/web/20141129015823/http://www.fda.gov/drugs/drugsafety/postmarketdrugsafetyinformationforpatientsandproviders/ucm124830.htm|archive-date=2014-11-29}}</ref>。

<!-- 流行病學、歷史、社會和研究-->
2015年，全球大約有2980萬人罹患阿茲海默症<ref name="WHO2017">{{Cite web|url=https://www.who.int/news-room/fact-sheets/detail/dementia|title=Dementia|accessdate=2018-12-21|language=en|work=www.who.int|publisher=World Health Organization|archive-url=https://web.archive.org/web/20181218091118/https://www.who.int/news-room/fact-sheets/detail/dementia|archive-date=2018-12-18|dead-url=no}}</ref><ref name="GBD2015Pre">{{Cite journal|title=Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015|url=https://linkinghub.elsevier.com/retrieve/pii/S0140673616316786|last=Vos|first=Theo|last2=Allen|first2=Christine|date=2016-10|language=en|journal=The Lancet|issue=10053|doi=10.1016/s0140-6736(16)31678-6|volume=388|pages=1545–1602|issn=0140-6736|pmc=5055577|pmid=27733282|last3=Arora|first3=Megha|last4=Barber|first4=Ryan M|last5=Bhutta|first5=Zulfiqar A|last6=Brown|first6=Alexandria|last7=Carter|first7=Austin|last8=Casey|first8=Daniel C|last9=Charlson|first9=Fiona J|access-date=2019-01-01|archive-date=2021-01-24|archive-url=https://web.archive.org/web/20210124074109/https://linkinghub.elsevier.com/retrieve/pii/S0140673616316786|dead-url=no}}</ref>。患者的發病年齡一般在65歲以上，但大約有4%到5%的患者會在65歲之前就發病，屬於{{link-en|早發性阿茲海默症|Early-onset Alzheimer's disease}}<ref name="Mend2012">{{Cite journal|title=Early-onset Alzheimer's Disease: Nonamnestic Subtypes and Type 2 AD|url=https://www.sciencedirect.com/science/article/abs/pii/S0188440912003372|date=2012-11-01|language=en|journal=Archives of Medical Research|issue=8|doi=10.1016/j.arcmed.2012.11.009|volume=43|pages=677–685|issn=0188-4409|pmc=3532551|pmid=23178565}}</ref>。65歲以上的盛行率約為6%<ref name="BMJ2009" />。2015年，失智症造成約190萬人死亡<ref name="GBD2015De">{{Cite journal|title=Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015|url=https://linkinghub.elsevier.com/retrieve/pii/S0140673616310121|last=Wang|first=Haidong|last2=Naghavi|first2=Mohsen|date=2016-10|journal=The Lancet|issue=10053|doi=10.1016/s0140-6736(16)31012-1|volume=388|pages=1459–1544|issn=0140-6736|pmc=5388903|pmid=27733281|last3=Allen|first3=Christine|last4=Barber|first4=Ryan M|last5=Bhutta|first5=Zulfiqar A|last6=Carter|first6=Austin|last7=Casey|first7=Daniel C|last8=Charlson|first8=Fiona J|last9=Chen|first9=Alan Zian|language=en|access-date=2019-01-01|archive-date=2021-02-04|archive-url=https://web.archive.org/web/20210204095615/https://linkinghub.elsevier.com/retrieve/pii/S0140673616310121|dead-url=no}}</ref>。1906年，德國精神學家與病理學家[[愛羅斯·阿茲海默|-{zh-cn:阿洛伊斯·阿尔茨海默;zh-hant:愛羅斯·阿茲海默;}-]]首先描述並隨後命名了阿茲海默症<ref name="pmid9661992">{{Cite journal|title=Evolution in the Conceptualization of Dementia and Alzheimer’s Disease: Greco-Roman Period to the 1960s|url=https://www.sciencedirect.com/science/article/pii/S0197458098000529|date=1998-05-01|journal=Neurobiology of Aging|issue=3|doi=10.1016/S0197-4580(98)00052-9|language=en|volume=19|pages=173–189|issn=0197-4580|access-date=2019-01-01|archive-date=2020-10-06|archive-url=https://web.archive.org/web/20201006013802/https://www.sciencedirect.com/science/article/pii/S0197458098000529|dead-url=no}}</ref>。在[[已開發國家|已開發國家]]中，阿茲海默症是耗費最多社會資源的一種疾病<ref name="pmid15685097">{{cite journal | authors = Bonin-Guillaume S, Zekry D, Giacobini E, Gold G, Michel JP | title = Impact économique de la démence | language = fr | journal = Presse Médicale | volume = 34 | issue = 1 | pages = 35–41 | year = 2005 | pmid = 15685097 | issn = 0755-4982| doi=10.1016/s0755-4982(05)83882-5}}</ref><ref name="pmid9543467">{{cite journal | authors = Meek PD, McKeithan K, Schumock GT | title = Economic Considerations in Alzheimer's Disease | journal = Pharmacotherapy | volume = 18 | issue = 2 Pt 2 | pages = 68–73; discussion 79–82 | year = 1998 | pmid = 9543467 |language=en| doi = 10.1002/j.1875-9114.1998.tb03880.x}}</ref>。
{{TOC limit|3}}

==症狀和徵候==
{{quote box
|title=阿茲海默症的分期<ref name="BBDAlzheimers">{{cite news | work = [[消费者报告|Consumer Reports]] Drug Effectiveness Review Project | year = 2012 | title = Evaluating Prescription Drugs Used to Treat: Alzheimer's Disease Comparing Effectiveness, Safety, and Price | publisher = Consumer Reports | url = http://www.consumerreports.org/health/resources/pdf/best-buy-drugs/AlzheimersFINAL.pdf | format = PDF | language = en | access-date = 2013-05-01 | deadurl = no | archive-url = https://web.archive.org/web/20120905164340/http://www.consumerreports.org/health/resources/pdf/best-buy-drugs/AlzheimersFINAL.pdf | archive-date = 2012-09-05 }}</ref>
|
;{{tsl|en|Memory and aging|記憶與老化|正常老化}}而非阿茲海默症造成的影響
*有時會[[遗忘|遗忘]]東西
*有時會把物品放錯地方
*輕微的[[短期记忆|短期记忆]]喪失
*不記得確切的細節
;阿茲海默症早期
*不記得自己有遺忘事情
*忘記家人或朋友的名字
*可能只有密友或家人會發現變化
*在不熟悉的情境下出現部分的意識混亂
;阿茲海默症中期
*更難記起新學到的資訊
*在許多情況下意識混亂更加嚴重
*睡眠問題
*不知道自己在哪裡
;阿茲海默症晚期
*思考能力變差
*說話問題
*重複一樣的對話
*更常辱罵、焦慮或被害妄想等
}}
阿茲海默症的病程根據[[認知|認知]]能力和身體機能的惡化程度分成四個時期，以下分段說明。

=== 失智症前期 ===
阿茲海默症最初的症狀常被誤認為是[[老化|老化]]或是[[壓力_(醫學)|壓力]]<ref name="pmid17222085">{{cite journal|authors=Waldemar G, Dubois B, Emre M|title=Recommendations for the Diagnosis and Management of Alzheimer's Disease and Other Disorders Associated with Dementia: EFNS Guideline|journal=European Journal of Neurology|language=en|volume=14|issue=1|pages=e1–26|year=2007|pmid=17222085|doi=10.1111/j.1468-1331.2006.01605.x}}</ref>，但若進行詳細的{{link-en|神經心理學檢查|Neuropsychological test}}，甚至能在確診為阿茲海默症八年前就可發現輕微的認知困難<ref name="pmid15324363">{{cite journal|authors=Bäckman L, Jones S, Berger AK, Laukka EJ, Small BJ|title=Multiple Cognitive Deficits During the Transition to Alzheimer's Disease|url=https://archive.org/details/sim_journal-of-internal-medicine_2004-09_256_3/page/195|journal=Journal of Internal Medicine|language=en|volume=256|issue=3|pages=195–204|year=2004|pmid=15324363|doi=10.1111/j.1365-2796.2004.01386.x}}</ref>。這些早期症狀可以影響大部分複雜的[[日常生活活動|日常生活活動]]<ref>{{cite journal|authors=Nygård L|title=Instrumental Activities of Daily Living: A Stepping-stone Towards Alzheimer's Disease Diagnosis in Subjects with Mild Cognitive Impairment?|journal=Acta Neurologica Scandinavica|language=en|volume=Suppl|issue=179|pages=42–46|year=2003|pmid=12603250|doi=10.1034/j.1600-0404.107.s179.8.x}}</ref>，最明顯的缺陷是短期記憶障礙，主要是難以記住最近發生的事和無法吸收新資訊<ref name="pmid15324363" /><ref name="pmid12603249">{{cite journal|authors=Arnáiz E, Almkvist O|title=Neuropsychological Features of Mild Cognitive Impairment and Preclinical Alzheimer's Disease|language=en|journal=Acta Neurologica Scandinavica|volume=179|pages=34–41|year=2003|pmid=12603249|doi=10.1034/j.1600-0404.107.s179.7.x}}</ref>。

其他症狀包括[[注意|注意力]][[管控功能|管控]]、計畫事情、彈性處理、[[抽象化|抽象思考]]和[[语义记忆|語義記憶]]等方面的問題<ref name="pmid15324363" />。[[冷漠|冷漠]]也是此時期會出現的症狀之一，並會是在病程中持續出現的{{link-en|神經精神病學|Neuropsychiatry|精神}}症狀<ref>{{cite journal|title=Apathy in Alzheimer's disease|url=https://archive.org/details/sim_journal-of-the-american-geriatrics-society_2001-12_49_12/page/1700|author=Landes AM, Sperry SD, Strauss ME, Geldmacher DS|date=2001-12|journal=J Am Geriatr Soc|language=en|issue=12|doi=10.1046/j.1532-5415.2001.49282.x|volume=49|pages=1700–7|pmid=11844006}}</ref>。阿茲海默症的臨床前期也被稱作{{link-en|輕微認知障礙|Mild cognitive impairment}}（MCI）<ref name="pmid126032492">{{cite journal|title=Neuropsychological features of mild cognitive impairment and preclinical Alzheimer's disease|author=Arnáiz E, Almkvist O|language=en|journal=Acta Neurol. Scand., Suppl.|doi=10.1034/j.1600-0404.107.s179.7.x|year=2003|volume=179|pages=34–41|pmid=12603249}}</ref>，這是一個介於正常和[[失憶症|失憶症]]之間的過渡狀態，但MCI可以是許多症候群的表現，而當它以記憶喪失為主要表現時，則稱作失憶性輕微認知障礙（amnestic MCI），此一名詞常被用來稱呼阿茲海默症的臨床前期<ref name="Grundman">{{cite journal|title=Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials|year=2004|language=en|journal=Archives of Neurology|issue=1|doi=10.1001/archneur.61.1.59|volume=61|pages=59–66|pmid=14732621|authors=Grundman M, Petersen RC, Ferris SH, Thomas RG, Aisen PS, Bennett DA, Foster NL, Jack CR, Galasko DR, Doody R, Kaye J, Sano M, Mohs R, Gauthier S, Kim HT, Jin S, Schultz AN, Schafer K, Mulnard R, van Dyck CH, Mintzer J, Zamrini EY, Cahn-Weiner D, Thal LJ}}</ref>。

=== 早期 ===
阿茲海默症病患的學習與記憶障礙會愈見明顯，最後使醫師能確認診斷。在少部分病患中，語言障礙、[[管控功能|執行]]障礙、認識障礙（[[失认症|失认症]]）或技能執行障礙（{{link-en|失用症|Apraxia}}）會比記憶障礙更明顯<ref name="pmid10653284">{{cite journal|authors=Förstl H, Kurz A|title=Clinical Features of Alzheimer's Disease|journal=European Archives of Psychiatry and Clinical Neuroscience|language=en|volume=249|issue=6|pages=288–90|year=1999|pmid=10653284|doi=10.1007/s004060050101}}</ref>。阿茲海默症並不會對所有記憶能力都有同等的影響，相對於新近發生的事情或記憶，病患[[长期记忆|長期]]的[[情节记忆|情节记忆]]、[[语义记忆|语义记忆]]和[[内隐记忆|内隐记忆]]（身體記住如何做一件事，例如使用叉子吃東西）受到的影響比較少<ref name="pmid1300219">{{cite journal|authors=Carlesimo GA, Oscar-Berman M|title=Memory Deficits in Alzheimer's Patients: A Comprehensive Review|language=en|journal=Neuropsychology Review|volume=3|issue=2|pages=119–69|year=1992|pmid=1300219|doi=10.1007/BF01108841}}</ref><ref name="pmid8821346">{{cite journal|authors=Jelicic M, Bonebakker AE, Bonke B|title=Implicit Memory Performance of Patients with Alzheimer's Disease: A Brief Review|journal=International Psychogeriatrics|language=en|volume=7|issue=3|pages=385–92|year=1995|pmid=8821346|doi=10.1017/S1041610295002134}}</ref>。

阿茲海默症患者的語言障礙主要為{{link-en|原發性進行性失語症|Primary progressive aphasia}}，特徵是病患可使用的[[詞彙|詞彙]]變少，且{{link-en|流暢度|Fluency}}降低，導致病患的口語和[[书面语|書面表達]]變得困難<ref name="pmid10653284" /><ref name="pmid1856925">{{cite journal|authors=Taler V, Phillips NA|title=Language Performance in Alzheimer's Disease and Mild Cognitive Impairment: a comparative review|journal=Journal of Clinical and Experimental Neuropsychology|language=en|volume=30|issue=5|pages=501–56|date=2008-07|pmid=18569251|doi=10.1080/13803390701550128}}</ref>。在這一時期，病患通常還能適當表達簡單的想法<ref name="pmid10653284" /><ref name="pmid1856925" /><ref name="pmid7967534">{{cite journal|authors=Frank EM|title=Effect of Alzheimer's Disease on Communication Function|url=https://archive.org/details/sim_journal-of-the-south-carolina-medical-association_1994-09_90_9/page/417|journal=Journal of the South Carolina Medical Association|language=en|volume=90|issue=9|pages=417–23|year=1994|pmid=7967534}}</ref>；當進行{{link-en|精細動作|Fine motor skill}}時（如寫作、畫圖、或是穿衣），可能會出現些微的動作不協調和計畫困難（失用症），但這些徵兆常會被忽略。隨著疾病進展，阿茲海默症病患通常仍能獨立完成許多事情，但是大部分需要認知功能的活動可能就需要協助或是監督。<ref name="pmid10653284" />

=== 中期 ===
隨著病情惡化，病患將失去獨立生活的能力，而無法進行大部分的日常活動<ref name="pmid10653284" />。患者的語言障礙逐漸變得明顯，常會無法想起詞彙（{{link-en|命名不能症|Anomic aphasia}}），會使用錯誤的字彙來替換（{{link-en|言語錯亂症|paraphasia}}），同時也漸漸失去讀寫能力，<ref name="pmid10653284" /><ref name="pmid7967534" />患者在執行複雜的動作序列時會變得不協調，增加了跌倒的風險<ref name="pmid10653284" />。在這一時期，記憶問題也會惡化，病患可能無法認出親近的家屬<ref name="pmid10653284" />，之前仍完整的长期记忆也受到影響<ref name="pmid10653284" />。

此時期行為和神經精神病學的變化也更為顯著，常見的表現包括{{le|遊蕩（醫學）|Wandering (dementia)|遊蕩}}、[[易怒|易怒]]和{{tsl|en|mood swing|情感不穩|情緒不穩}}，這些變化會導致病患突然哭泣、突發的非故意攻擊行為、或是拒絕接受照顧<ref name="pmid10653284" />，此時也會出現[[日落症候群|日落症候群]]<ref>{{cite journal|authors=Volicer L, Harper DG, Manning BC, Goldstein R, Satlin A|title=Sundowning and Circadian Rhythms in Alzheimer's Disease|url=https://archive.org/details/sim_american-journal-of-psychiatry_2001-05_158_5/page/704|language=en|journal=The American Journal of Psychiatry|volume=158|issue=5|pages=704–11|year=2001|pmid=11329390|doi=10.1176/appi.ajp.158.5.704}}</ref>。大約30%的患者會產生出現{{tsl|en|Delusional misidentification syndrome|妄想錯認症候群|妄想錯認}}或其他[[妄想|妄想]]症狀<ref name="pmid10653284" />，另外也可能會尿失禁<ref name="pmid10653284" />。患者無法體認到疾病的進展（{{tsl|en|anosognosia|病覺缺失症|病覺缺失症}}，即缺乏病識感）<ref name="pmid10653284" />。這些症狀都會對家屬或照護者帶來壓力，由[[居家照護|居家照護]]轉至{{tsl|en|Nursing home|長期照護機構}}可減輕此類壓力<ref name="pmid10653284" /><ref name="pmid7806732">{{cite journal|authors=Gold DP, Reis MF, Markiewicz D, Andres D|title=When Home Caregiving Ends: A Longitudinal Study of Outcomes for Caregivers of Relatives with Dementia|url=https://archive.org/details/sim_journal-of-the-american-geriatrics-society_1995-01_43_1/page/10|journal=Journal of the American Geriatrics Society|language=en|volume=43|issue=1|pages=10–16|year=1995|pmid=7806732|doi=10.1111/j.1532-5415.1995.tb06235.x}}</ref>。

=== 晚期 ===
在阿茲海默症的最終時期，病患已經完全依賴照護者<ref name="pmid10653284"/>，語言能力退化至簡單的詞語甚至僅有單字，最後完全失去談話能力，<ref name="pmid10653284"/><ref name="pmid7967534"/>除了失去口語能力之外，病患通常能理解並回應情感刺激<ref name="pmid10653284" />，雖然攻擊行為仍然存在，但大多時間表現得極度冷漠和[[疲倦|疲倦]]<ref name="pmid10653284" />，病患最終無法獨立進行任何簡單的事情<ref name="pmid10653284" />，[[肌肉|肌肉質量]]和行動能力退化至長期臥床，也無法自行進食<ref name="pmid10653284" />。阿茲海默症是一種絕症，但死因通常是外在因素，例如[[褥疮|褥疮]]感染或[[肺炎|肺炎]]，而不是疾病本身<ref name="pmid10653284" />。

==病因==

大部分病患罹患阿茲海默症的原因仍然不明（除了1%到5%的病患可以找到基因差異）<ref>{{cite web|url=http://www.alz.org/research/science/alzheimers_disease_causes.asp|title=What We Know Today About Alzheimer's Disease|publisher=Alzheimer's Association|access-date=2011-10-01|language=en|quote=While scientists know Alzheimer's disease involves progressive brain cell failure, the reason cells fail isn't clear.|deadurl=no|archive-url=https://web.archive.org/web/20111007055341/http://alz.org/research/science/alzheimers_disease_causes.asp|archive-date=2011-10-07}}</ref><ref>{{cite journal | authors = Reitz C, Mayeux R | title = Alzheimer disease: epidemiology, diagnostic criteria, risk factors and biomarkers | journal = Biochemical Pharmacology |language=en| volume = 88 | issue = 4 | pages = 640–51 | date =2014-04 | pmid = 24398425 | pmc = 3992261 | doi = 10.1016/j.bcp.2013.12.024 }}</ref>。目前有幾個不同的[[假说|假说]]嘗試解釋阿茲海默症的病因。

===遺傳===
根據雙胞胎和家族研究，阿茲海默症的基因遺傳性約在49%到79%之間<ref name="pmid20930268">{{cite journal | authors = Wilson RS, Barral S, Lee JH | title = Heritability of different forms of memory in the Late Onset Alzheimer's Disease Family Study.  | journal = Journal of Alzheimer's Disease |language=en| volume = 23 | issue = 2 | pages = 249–55 | year = 2011 | pmid = 20930268 | doi = 10.3233/JAD-2010-101515 | pmc=3130303}}</ref><ref name="pmid16461860">{{cite journal | authors = Gatz M, Reynolds CA, Fratiglioni L |  title = Role of genes and environments for explaining Alzheimer disease |language=en | journal = Arch. Gen. Psychiatry | volume = 63 | issue = 2 | pages = 168–74 | year = 2006| pmid = 16461860 | doi = 10.1001/archpsyc.63.2.168 }}</ref>。約0.1%家族性遺傳的患者為[[常染色体|體染色體]][[显性|顯性]]遺傳，他們常在65歲前發病，稱為{{tsl|en|Familial Alzheimer disease|家族性阿茲海默症|早發性家族性阿茲海默症}}<ref name="pmid16876668">{{cite journal | authors = Blennow K, de Leon MJ, Zetterberg H | title = Alzheimer's Disease | journal = Lancet|language=en | volume = 368 | issue = 9533 | pages = 387–403 | year = 2006 | pmid = 16876668 | doi = 10.1016/S0140-6736(06)69113-7}}</ref>。[[前類澱粉蛋白質|前類澱粉蛋白質]]基因''APP'' 、[[早老素|早老素]]基因 ''PSEN1'' 和 ''PSEN2'' 是目前家族型阿茲海默症已知的相關基因中，最有直接證據會導致阿茲海默症的基因<ref name=":2">{{Cite journal|title=Alzheimer's disease|url=https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(15)01124-1/abstract|last=Flier|first=Wiesje Maria Van der|last2=Salloway|first2=Stephen|language=en|date=2016-07-30|journal=The Lancet|issue=10043|doi=10.1016/S0140-6736(15)01124-1|volume=388|pages=505–517|issn=0140-6736|last3=Frisoni|first3=Giovanni B.|last4=Strooper|first4=Bart de|last5=Breteler|first5=Monique M. B.|last6=Blennow|first6=Kaj|last7=Scheltens|first7=Philip|access-date=2019-01-19|archive-date=2019-07-13|archive-url=https://web.archive.org/web/20190713162453/https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(15)01124-1/fulltext|dead-url=no}}</ref>。這三個突變都會影響前類澱粉蛋白（APP）的切除，導致[[類澱粉蛋白|類澱粉蛋白質]]斑塊的主要成分{{tsl|en|Beta amyloid|β類澱粉胜肽|Aβ}}42在細胞中的產量升高<ref name="Selkoe">{{cite journal | authors = Selkoe DJ | title = Translating cell biology into therapeutic advances in Alzheimer's disease | journal = Nature | volume = 399 | issue = 6738 Suppl | pages = A23–31 |language=en| year = 1999 | pmid = 10392577 | doi = 10.1038/19866}}</ref>，一些突變雖然不增加Aβ42的產量，但會改變細胞內Aβ42和其他主要同型異構物（特別是Aβ40）的比例<ref name="Borchelt">{{cite journal | authors = Borchelt DR, Thinakaran G, Eckman CB | title = Familial Alzheimer's disease-linked presenilin 1 variants elevate βA1-42/1-40 ratio in vitro and in vivo | journal = Neuron | volume = 17 | issue = 5 | pages = 1005–13|language=en | year = 1996 | pmid = 8938131 | doi = 10.1016/S0896-6273(00)80230-5 |url=http://ac.els-cdn.com/S0896627300802305/1-s2.0-S0896627300802305-main.pdf?_tid=e1a5d3c4-f405-11e4-ac9c-00000aacb362&acdnat=1430926862_7e175593a77c62b8a2646077b6b07ba4 |format=PDF}}</ref><ref name="pmid17254019">{{cite journal | authors = Shioi J, Georgakopoulos A, Mehta P | title = FAD mutants unable to increase neurotoxic Aβ 42 suggest that mutation effects on neurodegeneration may be independent of effects on Abeta | journal = Journal of Neurochemistry|language=en | volume = 101 | issue = 3 | pages = 674–81 | year = 2007 | pmid = 17254019 | doi = 10.1111/j.1471-4159.2006.04391.x }}</ref>。

阿茲海默症患者多數沒有上述的體染色體遺傳，稱為偶發型阿茲海默症。但有些基因或環境因素仍可能是罹患此病的危險因子。最著名的基因危險因子是[[载脂蛋白|载脂蛋白]]E（APOE）的ε4[[等位基因|等位基因]]<ref name="pmid8446617">{{cite journal|authors=Strittmatter WJ, Saunders AM, Schmechel D|title=Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease|journal=Proceedings of the National Academy of Sciences of the United States of America|language=en|volume=90|issue=5|pages=1977–81|year=1993|pmid=8446617|pmc=46003|doi=10.1073/pnas.90.5.1977}}</ref><ref name="pmid16567625">{{cite journal|authors=Mahley RW, Weisgraber KH, Huang Y|title=Apolipoprotein E4: a causative factor and therapeutic target in neuropathology, including Alzheimer's disease|journal=Proceedings of the National Academy of Sciences of the United States of America|language=en|volume=103|issue=15|pages=5644–51|year=2006|pmid=16567625|pmc=1414631|doi=10.1073/pnas.0600549103}}</ref>，約有40%到80%的病患帶有至少一個APOEε4等位基因<ref name="pmid16567625" />，其中異型合子的個體罹患風險增加3倍，而同型合子則增加15倍<ref name="pmid16876668" />。然而，環境或基因造成的影響並不一定會完全[[外显度|表現出來]]。舉例來說，不同於其他族群，部分奈及利亞族群罹患阿茲海默症的機率和發病年齡與其是否帶有APOEε4沒有相關<ref name="pmid16434658">{{cite journal|authors=Hall K, Murrell J, Ogunniyi A|display-authors=etal|title=Cholesterol, APOE genotype, and Alzheimer disease: an epidemiologic study of Nigerian Yoruba|journal=Neurology|language=en|volume=66|issue=2|pages=223–27|year=2006|pmid=16434658|pmc=2860622|doi=10.1212/01.wnl.0000194507.39504.17}}</ref><ref name="pmid16278853">{{cite journal|authors=Gureje O, Ogunniyi A, Baiyewu O|title=APOE ε4 is not associated with Alzheimer's disease in elderly Nigerians|url=https://archive.org/details/sim_annals-of-neurology_2006-01_59_1/page/182|journal=Annals of Neurology|language=en|volume=59|issue=1|pages=182–85|year=2006|pmid=16278853|pmc=2855121|doi=10.1002/ana.20694}}</ref>。遺傳學家已經檢驗超過400個候選基因與遲發性偶發性阿茲海默症（LOAD）的關聯，但大部分的基因都沒有發現明顯相關性<ref name="pmid16876668" /><ref name="pmid18332245">{{cite journal|authors=Waring SC, Rosenberg RN|title=Genome-wide association studies in Alzheimer disease|journal=Archives of Neurology|language=en|volume=65|issue=3|pages=329–34|year=2008|pmid=18332245|doi=10.1001/archneur.65.3.329}}</ref>。近期使用[[全基因组关联分析|全基因組關聯分析]]（GWAS）的研究則找到了19個可能會影響罹病風險的基因區塊<ref name="GW2013">{{cite journal|title=Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease|date=2013-11|journal=Nature Genetics|issue=12|doi=10.1038/ng.2802|language=en|volume=45|pages=1452–8|pmc=3896259|pmid=24162737|vauthors=Lambert JC, Ibrahim-Verbaas CA, Harold D, Naj AC, Sims R, Bellenguez C, DeStafano AL, Bis JC, Beecham GW, Grenier-Boley B, Russo G, Thorton-Wells TA, Jones N, Smith AV, Chouraki V, Thomas C, Ikram MA, Zelenika D, Vardarajan BN, Kamatani Y, Lin CF, Gerrish A, Schmidt H, Kunkle B, Dunstan ML, Ruiz A, Bihoreau MT, Choi SH, Reitz C, Pasquier F, Cruchaga C, Craig D, Amin N, Berr C, Lopez OL, De Jager PL, Deramecourt V, Johnston JA, Evans D, Lovestone S, Letenneur L, Morón FJ, Rubinsztein DC, Eiriksdottir G, Sleegers K, Goate AM, Fiévet N, Huentelman MW, Gill M, Brown K, Kamboh MI, Keller L, Barberger-Gateau P, McGuiness B, Larson EB, Green R, Myers AJ, Dufouil C, Todd S, Wallon D, Love S, Rogaeva E, Gallacher J, St George-Hyslop P, Clarimon J, Lleo A, Bayer A, Tsuang DW, Yu L, Tsolaki M, Bossù P, Spalletta G, Proitsi P, Collinge J, Sorbi S, Sanchez-Garcia F, Fox NC, Hardy J, Deniz Naranjo MC, Bosco P, Clarke R, Brayne C, Galimberti D, Mancuso M, Matthews F, Moebus S, Mecocci P, Del Zompo M, Maier W, Hampel H, Pilotto A, Bullido M, Panza F, Caffarra P, Nacmias B, Gilbert JR, Mayhaus M, Lannefelt L, Hakonarson H, Pichler S, Carrasquillo MM, Ingelsson M, Beekly D, Alvarez V, Zou F, Valladares O, Younkin SG, Coto E, Hamilton-Nelson KL, Gu W, Razquin C, Pastor P, Mateo I, Owen MJ, Faber KM, Jonsson PV, Combarros O, O'Donovan MC, Cantwell LB, Soininen H, Blacker D, Mead S, Mosley TH, Bennett DA, Harris TB, Fratiglioni L, Holmes C, de Bruijn RF, Passmore P, Montine TJ, Bettens K, Rotter JI, Brice A, Morgan K, Foroud TM, Kukull WA, Hannequin D, Powell JF, Nalls MA, Ritchie K, Lunetta KL, Kauwe JS, Boerwinkle E, Riemenschneider M, Boada M, Hiltuenen M, Martin ER, Schmidt R, Rujescu D, Wang LS, Dartigues JF, Mayeux R, Tzourio C, Hofman A, Nöthen MM, Graff C, Psaty BM, Jones L, Haines JL, Holmans PA, Lathrop M, Pericak-Vance MA, Launer LJ, Farrer LA, van Duijn CM, Van Broeckhoven C, Moskvina V, Seshadri S, Williams J, Schellenberg GD, Amouyel P}}</ref>，這些基因為''{{tsl|en|CASS4||CASS4}}''、''[[CELF1|CELF1]]''、''{{tsl|en|FERMT2||FERMT2}}''、''{{tsl|en|HLA-DRB5||HLA-DRB5}}''、''{{tsl|en|INPP5D||INPP5D}}''、''{{tsl|en|MEF2C||MEF2C}}''、''{{tsl|en|NME8||NME8}}''、''{{tsl|en|PTK2B||PTK2B}}''、''{{tsl|en|SORL1||SORL1}}''、''[[ZCWPW1|ZCWPW1]]''、''[[SlC24A4|SlC24A4]]''、''{{tsl|en|CLU (gene)||CLU}}''、''{{tsl|en|PICALM||PICALM}}''、''{{tsl|en|Complement receptor 1||CR1}}''、''{{tsl|en|BIN1||BIN1}}''、''{{tsl|en|Membrane-spanning 4A||MS4A}}''、''{{tsl|en|ABCA7||ABCA7}}''、''{{tsl|en|EPHA1||EPHA1}}''和''[[CD2AP|CD2AP]]''<ref name="GW2013" />。研究也發現''{{link-en|TREM2|TREM2}}''的某些等位基因變異會增加罹患阿茲海默症的風險達3到5倍，可能的原因是某些''TREM2''變異會使腦中的白血球將無法控制大腦中Aβ的產生量<ref>{{cite journal|authors=Jonsson T, Stefansson H, Steinberg S|title=Variant of TREM2 associated with the risk of Alzheimer's disease|journal=The New England Journal of Medicine|language=en|volume=368|issue=2|pages=107–16|year=2012|pmid=23150908|pmc=3677583|doi=10.1056/NEJMoa1211103|type=Original article}}</ref><ref>{{cite journal|author1=Guerreiro R, Wojtas A, Bras J|display-authors=etal|title=TREM2 variants in Alzheimer's disease|journal=The New England Journal of Medicine|language=en|volume=368|issue=2|pages=117–27|year=2012|pmid=23150934|pmc=3631573|doi=10.1056/NEJMoa1211851|author2=The Alzheimer Genetic Analysis Group|type=Original article}}</ref>。2018年的一項研究利用記憶、語言、視覺立體、執行，和功能等五個項目，配合新發表的30個與阿茲海默症相關的[[單核苷酸多態性|單核苷酸多態性]]（SNPs），將阿茲海默症分為6大類<ref>{{Cite journal|title=Genetic data and cognitively defined late-onset Alzheimer’s disease subgroups|url=https://www.nature.com/articles/s41380-018-0298-8|last=Crane|first=Paul K.|last2=Larson|first2=Eric B.|date=2018-12-04|journal=Molecular Psychiatry|doi=10.1038/s41380-018-0298-8|pages=1|language=en|issn=1476-5578|last3=Keene|first3=C. Dirk|last4=Bennett|first4=David A.|last5=Jager|first5=Philip L. De|last6=Lopez|first6=Oscar L.|last7=Kamboh|first7=M. Ilyas|last8=Snitz|first8=Beth E.|last9=McCurry|first9=Susan M.|access-date=2019-01-01|archive-url=https://web.archive.org/web/20181208000210/https://www.nature.com/articles/s41380-018-0298-8|archive-date=2018-12-08|dead-url=no}}</ref>。

=== 膽鹼性假說 ===
{{link-en|膽鹼性|Cholinergic}}假說是最早被提出來的假說，也是現今大部分阿茲海默症藥物所依據的理論基礎<ref name="pmid10071091">{{cite journal | authors = Francis PT, Palmer AM, Snape M, Wilcock GK | title = The Cholinergic Hypothesis of Alzheimer's Disease: a Review of Progress | journal = Journal of Neurology, Neurosurgery, and Psychiatry | volume = 66 | issue = 2 | pages = 137–47 | year = 1999 | pmid = 10071091 | pmc = 1736202 | doi = 10.1136/jnnp.66.2.137}}</ref>，該假說認為阿茲海默症是由於神經系統減少產生[[神經傳導物質|神經傳導物質]][[乙酰胆碱|乙酰胆碱]]而造成的，雖然膽鹼性假說的歷史悠久，但是沒有受到廣泛的支持，主要是由於使用藥物治療乙醯膽鹼缺乏後，對於阿茲海默症的療效有限<ref>{{cite journal | authors = Martorana A, Esposito Z, Koch G | title = Beyond the cholinergic hypothesis: do current drugs work in Alzheimer's disease? | journal = CNS Neuroscience & Therapeutics|language=en | volume = 16 | issue = 4 | pages = 235–45 | date = 2010-08 | pmid = 20560995 | doi = 10.1111/j.1755-5949.2010.00175.x }}</ref>。

=== 類澱粉胜肽假說 ===
1991年，學者提出類澱粉胜肽假說，認為{{link-en|β類澱粉胜肽|Beta amyloid}}（Aβ）在大腦堆積可能是導致阿茲海默症的根本原因<ref name="pmid1763432">{{cite journal|authors=Hardy J, Allsop D|title=Amyloid Deposition as the Central Event in the Aetiology of Alzheimer's Disease|journal=Trends in Pharmacological Sciences|language=en|volume=12|issue=10|pages=383–88|year=1991|pmid=1763432|doi=10.1016/0165-6147(91)90609-V}}</ref><ref name="pmid11801334">{{cite journal|authors=Mudher A, Lovestone S|title=Alzheimer's disease-do tauists and baptists finally shake hands?|journal=Trends in Neurosciences|language=en|volume=25|issue=1|pages=22–26|year=2002|pmid=11801334|doi=10.1016/S0166-2236(00)02031-2}}</ref>。有關[[唐氏综合症|唐氏症]]患者的研究支持了這項假說，表現Aβ的[[前類澱粉蛋白質|前類澱粉蛋白]]基因（''APP''）位在[[21號染色體|21號染色體]]上，而唐氏症病患多了一個21號染色體的副本，同時唐氏症病患幾乎全都在40歲左右時罹患阿茲海默症<ref name="pmid16904243">{{cite journal|authors=Nistor M, Don M, Parekh M|title=Alpha- and Beta-secretase Activity as a Function of Age and Beta-amyloid in Down Syndrome and Normal Brain|url=https://archive.org/details/sim_neurobiology-of-aging_2007-10_28_10/page/1493|journal=Neurobiology of Aging|language=en|volume=28|issue=10|pages=1493–506|year=2007|pmid=16904243|pmc=3375834|doi=10.1016/j.neurobiolaging.2006.06.023}}</ref><ref name="pmid15639317">{{cite journal|authors=Lott IT, Head E|title=Alzheimer Disease and Down Syndrome: Factors in Pathogenesis|journal=Neurobiology of Aging|language=en|volume=26|issue=3|pages=383–89|year=2005|pmid=15639317|doi=10.1016/j.neurobiolaging.2004.08.005}}</ref>。此外，{{link-en|E型載脂蛋白4|APOE4}}（APOE4）是上阿茲海默症的主要遺傳危險因子，雖然載脂蛋白會增強Aβ的降解，但特定的載脂蛋白異構體對此反應的效果較差（如APOE4），導致多餘的Aβ在大腦中累積<ref name="pmid7566000">{{cite journal|authors=Polvikoski T, Sulkava R, Haltia M|title=Apolipoprotein E, Dementia, and Cortical Deposition of Beta-amyloid Protein|journal=The New England Journal of Medicine|language=en|volume=333|issue=19|pages=1242–47|year=1995|pmid=7566000|doi=10.1056/NEJM199511093331902}}</ref>。進一步的證據則是來自於[[转基因生物|基因轉殖]]鼠實驗，研究人員在實驗鼠身上表現突變型人類''APP''基因，結果發現其大腦會產生纖維狀類澱粉蛋白斑塊（fibrillar amyloid plaques），並出現類似阿茲海默症的大腦病理變化及空間學習障礙<ref>基因轉殖鼠相關文獻：
* {{cite journal|authors=Games D, Adams D, Alessandrini R|title=Alzheimer-type Neuropathology in Transgenic Mice Overexpressing V717F Beta-amyloid Precursor Protein|journal=Nature|language=en|volume=373|issue=6514|pages=523–27|year=1995|pmid=7845465|doi=10.1038/373523a0}}
* {{cite journal|authors=Masliah E, Sisk A, Mallory M, Mucke L, Schenk D, Games D|title=Comparison of Neurodegenerative Pathology in Transgenic Mice Overexpressing V717F Beta-amyloid Precursor Protein and Alzheimer's Disease|journal=The Journal of Neuroscience|language=en|volume=16|issue=18|pages=5795–811|year=1996|pmid=8795633}}
* {{cite journal|authors=Hsiao K, Chapman P, Nilsen S|title=Correlative Memory Deficits, Abeta Elevation, and Amyloid Plaques in Transgenic Mice|journal=Science|language=en|volume=274|issue=5284|pages=99–102|year=1996|pmid=8810256|doi=10.1126/science.274.5284.99}}
* {{cite journal|authors=Lalonde R, Dumont M, Staufenbiel M, Sturchler-Pierrat C, Strazielle C|title=Spatial Learning, Exploration, Anxiety, and Motor Coordination in Female APP23 Transgenic Mice with the Swedish Mutation|journal=Brain Research|language=en|volume=956|issue=1|pages=36–44|year=2002|pmid=12426044|doi=10.1016/S0006-8993(02)03476-5}}</ref>。

曾有一種實驗性疫苗在早期人體試驗中可以清除類澱粉蛋白斑塊，但此種治療對失智症卻沒有顯著的效果<ref name="pmid18640458">{{cite journal | authors = Holmes C, Boche D, Wilkinson D | title = Long-term Effects of Abeta42 Immunisation in Alzheimer's Disease: Follow-up of a Randomised, Placebo-controlled Phase I Trial | journal = Lancet |language=en| volume = 372 | issue = 9634 | pages = 216–23 | year = 2008 | pmid = 18640458 | doi = 10.1016/S0140-6736(08)61075-2}}</ref>。因此研究者轉而懷疑沒有形成大型類澱粉蛋白斑塊的Aβ[[低聚物|寡聚體]]才是主要的致病型態，這些寡聚體也被稱為類澱粉蛋白質衍生可溶性[[配體_(生物化學)|配體]]（amyloid-derived diffusible ligands, ADDLs），它們會結合到神經細胞表面的[[受体_(生物化学)|受體]]並改變[[突觸|突觸]]的結構，因此會破壞神經元溝通<ref name="pmid17251419">{{cite journal | authors = Lacor PN, Buniel MC, Furlow PW | title = Aß Oligomer-Induced Aberrations in Synapse Composition, Shape, and Density Provide a Molecular Basis for Loss of Connectivity in Alzheimer's Disease | journal = The Journal of Neuroscience|language=en | volume = 27 | issue = 4 | pages = 796–807 | year = 2007 | pmid = 17251419 | doi = 10.1523/JNEUROSCI.3501-06.2007}}</ref>。其中一種可能的Aβ寡聚體受體可能是[[普利昂蛋白|普利昂蛋白]]，這種蛋白的錯誤構型會引起[[牛海綿狀腦病|狂牛症]]和人類[[庫賈氏症|庫賈氏症]]，因此暗示著阿茲海默症與其他[[神經退化性疾病|神經退化性疾病]]的機轉可能互有關聯<ref name="pmid192424752">{{cite journal|title=Cellular Prion Protein Mediates Impairment of Synaptic Plasticity by Amyloid-β Oligomers|author=Lauren J|date=2009-02|journal=Nature|accessdate=2012-12-23|issue=7233|doi=10.1038/nature07761|volume=457|pages=1128–32|pmc=2748841|pmid=19242475|language=en|last3=Nygaard|first3=Haakon B.|last4=Gilbert|first4=John W.|last5=Strittmatter|first5=Stephen M.|display-authors=2|author2=Gimbel D}}</ref>。

2009年，類澱粉胜肽假說有了新的發展，新的研究指出和Aβ關係密切的蛋白質可能才是阿茲海默症的罪魁禍首。此類與類澱粉斑塊相關的機制會在早年快速發育的時期，使腦部神經元間的連結減少，並在年紀較大後受到老化相關過程的刺激，導致阿茲海默症中的神經元退化<ref name="Nikolaev">{{cite journal|author1=Nikolaev A|author2=McLaughlin T|author3=O'Leary DD|author4={{tsl|en|Marc Tessier-Lavigne||Tessier-Lavigne M}}|title=APP Binds DR6 to Cause Axon Pruning and Neuron Death via Distinct Caspases|journal=Nature|language=en|volume=457|issue=7232|pages=981–89|date=2009-02-19|pmid=19225519|pmc=2677572|doi=10.1038/nature07767|issn=0028-0836}}</ref>。該研究發現APP是DR6的一個[[配體_(生物化學)|配體]]，{{tsl|en|beta-secretase|β-secretase|β-secretase}}會切下的APP的[[胺基端|N端]]片段產生N-APP（同樣的酵素也參與APP修飾為Aβ的過程），N-APP則會與死亡受體6（death receptor 6，DR6，或稱{{tsl|en|TNFRSF21||TNFRSF21}}）結合，啟動[[细胞凋亡|細胞凋亡]]途徑。DR6在阿茲海默症患者受影響的腦區中有高量的表現，因此在{{tsl|en|ageing brain|大腦老化|老化的大腦}}中，可能就是N-APP/DR6途徑被活化而造成了神經元損傷<ref name="Nikolaev" />。N-APP/DR6途徑所啟動的細胞凋亡包含了神經細胞本體和軸突，不同於一般細胞凋亡的機制需要活化caspase-3，[[轴突|軸突]]的退化需要活化caspase-6。此外，經由caspase-6路徑所啟動的細胞凋亡，也可能和另一種[[亨丁頓舞蹈症|杭廷頓舞蹈症]]相關<ref>{{Cite journal|title=Cleavage at the caspase-6 site is required for neuronal dysfunction and degeneration due to mutant huntingtin|url=https://www.ncbi.nlm.nih.gov/pubmed/16777606|last=Graham|first=Rona K.|last2=Deng|first2=Yu|date=2006-06-16|journal=Cell|issue=6|doi=10.1016/j.cell.2006.04.026|volume=125|pages=1179–1191|issn=0092-8674|pmid=16777606|last3=Slow|first3=Elizabeth J.|last4=Haigh|first4=Brendan|last5=Bissada|first5=Nagat|last6=Lu|first6=Ge|last7=Pearson|first7=Jacqueline|last8=Shehadeh|first8=Jacqueline|last9=Bertram|first9=Lisa|language=en|access-date=2018-08-27|archive-url=https://web.archive.org/web/20180827174032/https://www.ncbi.nlm.nih.gov/pubmed/16777606|archive-date=2018-08-27|dead-url=no}}</ref>。2017年，β-secretase抑制劑{{tsl|en|verubecestat||verubecestat}}的臨床試驗，證實該藥物在輕至中度阿茲海默症沒有顯著效益，且會增加副作用而遭到中止<ref>{{Cite journal|title=Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimer’s Disease|url=https://doi.org/10.1056/NEJMoa1706441|last=Egan|first=Michael F.|last2=Kost|first2=James|date=2018-05-03|journal=New England Journal of Medicine|issue=18|doi=10.1056/NEJMoa1706441|language=en|volume=378|pages=1691–1703|issn=0028-4793|pmid=29719179|last3=Tariot|first3=Pierre N.|last4=Aisen|first4=Paul S.|last5=Cummings|first5=Jeffrey L.|last6=Vellas|first6=Bruno|last7=Sur|first7=Cyrille|last8=Mukai|first8=Yuki|last9=Voss|first9=Tiffini|access-date=2019-01-24|archive-date=2019-07-13|archive-url=https://web.archive.org/web/20190713162442/https://www.nejm.org/doi/10.1056/NEJMoa1706441|dead-url=no}}</ref>。

中樞神經系統的血管周圍的[[膠淋巴系統|膠淋巴系統]]在大腦的廢物上具有重要功能，其中清除的對象包含{{link-en|β類澱粉胜肽|Beta amyloid}}<ref>{{Cite journal|title=The glymphatic system in CNS health and disease: past, present and future|author=|url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5803388/|last=Plog|first=Benjamin A.|last2=Nedergaard|first2=Maiken|date=2018-01-24|journal=Annual review of pathology|issue=|doi=10.1146/annurev-pathol-051217-111018|others=|year=|volume=13|page=|pages=379–394|issn=1553-4006|pmc=5803388|pmid=29195051|access-date=2019-03-09|archive-date=2019-07-13|archive-url=https://web.archive.org/web/20190713162439/https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5803388/|dead-url=no}}</ref>。睡眠期間，膠淋巴系統的清除速度會較清醒時快速，睡眠剝奪會導致膠淋巴系統的排毒效能遭到抑制，進而導致廢物累積<ref>{{Cite journal|title=Glymphatic distribution of CSF-derived apoE into brain is isoform specific and suppressed during sleep deprivation|author=|url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5146863/|last=Achariyar|first=Thiyagaragan M.|last2=Li|first2=Baoman|date=2016-12-08|journal=Molecular Neurodegeneration|issue=|doi=10.1186/s13024-016-0138-8|others=|year=|volume=11|page=|issn=1750-1326|pmc=5146863|pmid=27931262|last3=Peng|first3=Weiguo|last4=Verghese|first4=Philip B.|last5=Shi|first5=Yang|last6=McConnell|first6=Evan|last7=Benraiss|first7=Abdellatif|last8=Kasper|first8=Tristan|last9=Song|first9=Wei|access-date=2019-03-09|archive-date=2019-07-13|archive-url=https://web.archive.org/web/20190713162433/https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5146863/|dead-url=no}}</ref>。

===Tau蛋白假說===
[[File:TANGLES_HIGH.jpg|upright=1.35]]異常會造成腦細胞內的微管瓦解。]]
[[Tau蛋白|Tau蛋白]]假說認為Tau蛋白異常是引起阿茲海默症病情發展的主因<ref name="pmid11801334" />。在這個模型中，{{tsl|en|hyperphosphorylated|過度磷酸化|過度磷酸化}}的Tau蛋白會開始與其他Tau蛋白質配對結合，結果在神經細胞中形成了{{tsl|en|neurofibrillary tangle|神經纖維糾結|神經纖維糾結}}<ref name="pmid1669718">{{cite journal|author=Goedert M, Spillantini MG, Crowther RA|title=Tau Proteins and Neurofibrillary Degeneration|journal=Brain Pathology|volume=1|issue=4|pages=279–86|year=1991|pmid=1669718|doi=10.1111/j.1750-3639.1991.tb00671.x|language=en}}</ref>。在這種情形下，神經細胞內的[[微管|微管]]開始瓦解並導致由[[细胞骨架|細胞骨架]]構成的運送系統崩壞<ref name="pmid15615638">{{cite journal|authors=Iqbal K, Alonso Adel C, Chen S|title=Tau Pathology in Alzheimer Disease and Other Tauopathies|journal=Biochimica et Biophysica Acta|language=en|volume=1739|issue=2–3|pages=198–210|year=2005|pmid=15615638|doi=10.1016/j.bbadis.2004.09.008}}</ref>，這將造成神經細胞之間的化學訊息溝通失效，接著導致神經細胞死亡<ref name="pmid17127334">{{cite journal|authors=Chun W, Johnson GV|title=The Role of Tau Phosphorylation and Cleavage in Neuronal Cell Death|journal=Frontiers in Bioscience|language=en|volume=12|pages=733–56|year=2007|pmid=17127334|doi=10.2741/2097}}</ref>。

===其他假說===
新生血管假說認為[[血腦屏障|血腦屏障]]功能減低也可能和阿茲海默症有關<ref>{{cite journal | authors = Deane R, Zlokovic BV | title = Role of the blood-brain barrier in the pathogenesis of Alzheimer's disease |language=en| journal = Current Alzheimer Research | volume = 4 | issue = 2 | pages = 191–7 | date =2007-04 | pmid = 17430246 | doi = 10.2174/156720507780362245 }}</ref>。

阿茲海默症患者細胞內外{{tsl|en|biometal (biology)|生物金屬|金屬離子}}（如銅、鐵、鋅離子）會不[[稳态|平衡]]，雖然目前不清楚是蛋白質的改變造成離子不平衡，抑或離子的改變造成蛋白質的變化，這些離子會影響tau蛋白、APP和APOE<ref name="pmid24971061">{{cite journal |journal=Frontiers in  Aging Neuroscience |date=2014-06-12 |volume=6|page=121 |title=Interactions of metals and Apolipoprotein E in Alzheimer's disease |authors =Xu H, Finkelstein DI, Adlard PA |language=en|pmid=24971061 |pmc=4054654 |doi=10.3389/fnagi.2014.00121 |quote=Although we still do not know if the metal ion dyshomeostasis present in AD is a cause or consequence of the disease, there is a growing body of evidence showing a direct correlation between metal ions and key AD-related key proteins.}}</ref>，這些蛋白失調會造成細胞內部的[[氧化应激|氧化壓力]]，並因此造成相關的病變<ref>{{cite journal | authors = Su B, Wang X, Nunomura A | title = Oxidative Stress Signaling in Alzheimer's Disease | journal = Current Alzheimer Research |language=en| volume = 5 | issue = 6 | pages = 525–32 | date =2008-12 | pmid = 19075578 | pmc = 2780015 | doi = 10.2174/156720508786898451 }}</ref><ref>{{cite journal | authors = Kastenholz B, Garfin DE, Horst J, Nagel KA | title = Plant Metal Chaperones: A Novel Perspective in Dementia Therapy | journal = Amyloid |language=en| volume = 16 | issue = 2 | pages = 81–83 | year = 2009 | pmid = 20536399 | doi = 10.1080/13506120902879392 }}</ref><ref>{{cite web  |title=Aluminium and Alzheimer's disease  |publisher=Alzheimer's Society  |work=Facts about dementia  |url=http://www.alzheimers.org.uk/Facts_about_dementia/Risk_factors/info_aluminium.htm  |language=en  |access-date=2005-10-14  |deadurl=yes  |archive-url=https://web.archive.org/web/20051027165732/http://www.alzheimers.org.uk/Facts_about_dementia/Risk_factors/info_aluminium.htm  |archive-date=2005-10-27  }}</ref><ref>{{cite journal | authors = Bondy SC | title = Low levels of aluminum can lead to behavioral and morphological changes associated with Alzheimer's disease and age-related neurodegeneration |language=en| journal = Neurotoxicology | volume = 52 | pages = 222–9 | date = 2016-01 | pmid = 26687397 | doi = 10.1016/j.neuro.2015.12.002 }}</ref><ref>{{cite journal | authors = Kandimalla R, Vallamkondu J, Corgiat EB, Gill KD | title = Understanding Aspects of Aluminum Exposure in Alzheimer's Disease Development | journal = Brain Pathology |language=en| volume = 26 | issue = 2 | pages = 139–54 | date = 2016-03 | pmid = 26494454 | doi = 10.1111/bpa.12333 }}</ref>。然而有些相關研究的品質受到批評<ref>{{cite journal | authors = Santibáñez M, Bolumar F, García AM | title = Occupational Risk Factors in Alzheimer's Disease: A Review Assessing the Quality of Published Epidemiological Studies | journal = Occupational and Environmental Medicine |language=en| volume = 64 | issue = 11 | pages = 723–32 | year = 2007 | pmid = 17525096 | pmc = 2078415 | doi = 10.1136/oem.2006.028209 }}</ref><ref name="Is the Aluminum Hypothesis dead">{{cite journal | authors = Lidsky TI | title = Is the Aluminum Hypothesis dead? | journal = Journal of Occupational and Environmental Medicine |language=en| volume = 56 | issue = 5 Suppl | pages = S73-9 | date = 2014-05 | pmid = 24806729 | pmc = 4131942 | doi = 10.1097/jom.0000000000000063 }}</ref>，因此這種推論仍有爭議<ref>{{cite journal | authors = Yegambaram M, Manivannan B, Beach TG, Halden RU | title = Role of environmental contaminants in the etiology of Alzheimer's disease: a review | journal = Current Alzheimer Research |language=en| volume = 12 | issue = 2 | pages = 116–46 | year = 2015 | pmid = 25654508 | pmc = 4428475 | doi = 10.2174/1567205012666150204121719 }}</ref>。多數的研究者並不支持鋁離子和阿茲海默症有因果關係<ref name="Is the Aluminum Hypothesis dead"/>。

抽菸是阿茲海默症的顯著危險因子<ref>{{cite journal | authors = Cataldo JK, Prochaska JJ, Glantz SA | title = Cigarette smoking is a risk factor for Alzheimer's disease: An analysis controlling for tobacco industry affiliation | journal = Journal of Alzheimer's Disease |language=en| volume = 19 | issue = 2 | pages = 465–80 | year = 2010 | pmid = 20110594 | pmc = 2906761 | doi = 10.3233/JAD-2010-1240 }}</ref>，  [[先天免疫系統|先天免疫系統]]的[[炎症|發炎指標]]則是遲發型阿茲海默症的危險因子<ref>{{cite journal | authors = Eikelenboom P, van Exel E, Hoozemans JJ, Veerhuis R, Rozemuller AJ, van Gool WA | title = Neuroinflammation – An Early Event in Both the History and Pathogenesis of Alzheimer's Disease |language=en| journal = Neuro-Degenerative Diseases | volume = 7 | issue = 1–3 | pages = 38–41 | year = 2010 | pmid = 20160456 | doi = 10.1159/000283480 }}</ref>。有限的證據指出[[空氣污染|空氣污染]]可能也是促進阿茲海默症發展的一項因素<ref>{{cite journal | authors = Moulton PV, Yang W | title = Air Pollution, Oxidative Stress, and Alzheimer's Disease | journal = Journal of Environmental and Public Health|language=en | volume = 2012 | page = 472751 | year = 2012 | pmid = 22523504 | doi = 10.1155/2012/472751 | type = Review | pmc=3317180}}</ref>。

[[牙周炎|牙周炎]]發生時的[[螺旋體|螺旋體]]感染也可能造成[[失智症|失智]]，並參與阿茲海默症的{{tsl|en|pathogenesis|病理機制}} <ref>{{cite journal | authors = Miklossy J | title = Alzheimer's disease – a neurospirochetosis. Analysis of the evidence following Koch's and Hill's criteria | journal = Journal of Neuroinflammation |language=en| volume = 8 | issue = 1 | pages = 90 | date = 2011-08 | pmid = 21816039 | pmc = 3171359 | doi = 10.1186/1742-2094-8-90 }}</ref>。真菌感染也是一個可能的疾病機轉<ref>{{cite journal | authors = Pisa D, Alonso R, Rábano A, Rodal I, Carrasco L | title = Different Brain Regions are Infected with Fungi in Alzheimer's Disease | language = en | journal = Scientific Reports | volume = 5 | issue = 1 | pages = 15015 | date = 2015-10 | pmid = 26468932 | pmc = 4606562 | doi = 10.1038/srep15015 | url = http://www.nature.com/articles/srep15015 | access-date = 2019-01-01 | archive-url = https://web.archive.org/web/20161025025359/http://www.nature.com/articles/srep15015 | archive-date = 2016-10-25 | dead-url = no }}</ref>。

也有假說認為 [[寡突膠質細胞|寡突膠細胞]]功能異常以及其在老化過程中產生的髓鞘問題會造成軸突的傷害，最後導致了類澱粉生成和tau蛋白過磷酸化的副作用<ref>{{cite journal | authors = Bartzokis G | title = Alzheimer's disease as homeostatic responses to age-related myelin breakdown | journal = Neurobiology of Aging |language=en| volume = 32 | issue = 8 | pages = 1341–71 | date = 2011-08 | pmid = 19775776 | pmc = 3128664 | doi = 10.1016/j.neurobiolaging.2009.08.007 }}</ref><ref>{{cite journal | authors = Cai Z, Xiao M | title = Oligodendrocytes and Alzheimer's disease | journal = The International Journal of Neuroscience |language=en| volume = 126 | issue = 2 | pages = 97–104 | year = 2016 | pmid = 26000818 | doi = 10.3109/00207454.2015.1025778 }}</ref>。

逆生假說（Retrogenesis）是貝里·萊斯伯格（Barry Reisberg）在1980年代提出的另一項阿茲海默症假說<ref name=Kluger1999 />。胎兒發育時會歷經一連串的[[神经发生|神經發生]]，這個過程始於{{tsl|en|neurulation|神經板形成}}，終於[[髓磷脂|髓鞘]]形成，該假說認為阿茲海默症患者的[[神經退化|神經退化]]就如同此一過程的逆轉，先是{{tsl|en|demyelination|神經脫鞘}}、白質的軸突死亡、最後灰質的神經元死亡<ref name=Laks2015>{{cite journal | authors = Alves GS, Oertel Knöchel V, Knöchel C, Carvalho AF, Pantel J, Engelhardt E, Laks J | title = Integrating retrogenesis theory to Alzheimer's disease pathology: insight from DTI-TBSS investigation of the white matter microstructural integrity | journal = BioMed Research International |language=en| volume = 2015 | pages = 291658 | year = 2015 | pmid = 25685779 | pmc = 4320890 | doi = 10.1155/2015/291658 }}</ref>。同樣地，嬰兒會經歷{{tsl|en|cognitive development|認知發展}}，該假說也認為阿茲海默症患者的[[認知障礙症|認知障礙]]就如同此一過程的倒轉<ref name=Kluger1999>{{cite journal | authors = Reisberg B, Franssen EH, Hasan SM, Monteiro I, Boksay I, Souren LE, Kenowsky S, Auer SR, Elahi S, Kluger A | title = Retrogenesis: clinical, physiologic, and pathologic mechanisms in brain aging, Alzheimer's and other dementing processes | journal = European Archives of Psychiatry and Clinical Neuroscience | language = en | volume = 249 Suppl 3 | issue = 3 | pages = 28–36 | year = 1999 | pmid = 10654097 | doi = 10.1007/pl00014170 | url = http://ncbi.nlm.nih.gov/pubmed/10654097 | archive-url = https://web.archive.org/web/20160919045628/http://www.ncbi.nlm.nih.gov/pubmed/10654097 | deadurl = no | archive-date = 2016-09-19 | access-date = 2019-01-01 }}</ref>。萊斯伯格也發展出了一套稱為FAST（功能性評估分級工具，Functional Assessment Staging Tool）的照護評估工具，用以評估阿茲海默患者的病程發展到哪個階段，以此為依據為每個階段的患者提供適當的照護建議<ref name=Kluger1999 /><ref name=Carson2015>{{cite book|last1=Brenner Carson|first1=Verna|title=Caregiving for Alzheimer's Disease|year=2015|publisher=Springer New York Academy of Sciences|language=en|location=New York|isbn=978-1-4939-2406-6|pages=1–9}}</ref>。

==病生理學==
[[File:Alzheimer_dementia_(3)_presenile_onset.jpg|thumb]]
[[File:Alzheimer's_Disease.gif|thumb]]

===神經病理學===

阿茲海默症的特徵是[[大腦皮質|大腦皮質]]及特定皮質下區域的[[神經元|神經元]]和[[突触|突触]]喪失。神經元喪失過多的區域甚至會導致巨觀解剖上的[[萎縮|萎縮]]，常見主要遭到的進犯部位包含[[颞叶|颞叶]]、[[顶叶|顶叶]]、一部份的[[額葉|額葉]]，和[[扣带皮层|扣帶回]]<ref name="pmid12934968">{{cite journal | authors = Wenk GL | title = Neuropathologic Changes in Alzheimer's Disease |language=en| journal = The Journal of Clinical Psychiatry | volume = 64 Suppl 9 | pages = 7–10 | year = 2003 | pmid = 12934968 }}</ref>。某些腦幹的核區可能也會受到影響，如[[蓝斑核|蓝斑核]]等<ref>{{cite journal|authors=Braak H, Del Tredici K|title=Where, when, and in what form does sporadic Alzheimer's disease begin?|journal=Current Opinion in Neurology|language=en|volume=25|issue=Pt 6|pages=708–14|date=2012-12|pmid=23160422|doi=10.1097/WCO.0b013e32835a3432}}</ref>。[[核磁共振成像|磁振造影]]（MRI）和[[正电子发射计算机断层扫描|正子電腦斷層掃瞄]]（PET）研究已報導患者在疾病進程中部分腦區萎縮的狀況，且跟其他健康老年人比較也能發現有部分腦區萎縮<ref>{{cite journal|authors=Desikan RS, Cabral HJ, Hess CP|title=Automated MRI Measures Identify Individuals with Mild Cognitive Impairment and Alzheimer's Disease|journal=Brain|language=en|volume=132|issue=Pt 8|pages=2048–57|date=2009-08|pmid=19460794|pmc=2714061|doi=10.1093/brain/awp123}}</ref><ref>{{cite journal|author=Moan R|title=MRI Software Accurately IDs Preclinical Alzheimer's Disease|journal=Diagnostic Imaging|date=2009-07-20|url=http://www.diagnosticimaging.com/news/display/article/113619/1428344|accessdate=2013-01-07|archiveurl=http://arquivo.pt/wayback/20160516192841/http://www.diagnosticimaging.com/news/display/article/113619/1428344|archivedate=2016-05-16|deadurl=yes|language=en}}</ref>。

在顯微鏡下，阿茲海默症患者的腦皮質可以看到明顯的[[類澱粉蛋白|類澱粉斑塊]]以及{{tsl|en|neurofibrillary tangle|神經元纖維纏結}}<ref name="pmid15184601">{{cite journal|authors=Tiraboschi P, Hansen LA, Thal LJ, Corey-Bloom J|title=The Importance of Neuritic Plaques and Tangles to the Development and Evolution of AD|journal=Neurology|volume=62|issue=11|pages=1984–89|year=2004|pmid=15184601|doi=10.1212/01.WNL.0000129697.01779.0A|language=en}}</ref>。斑塊大多由緻密且[[溶解性|不溶於水]]的{{tsl|en|beta-amyloid|β類澱粉}}樣胜肽及細胞衍生物所構成，通常堆積於神經元周圍。神經纖維纏結則通常是由微管相關蛋白質Tau所構成，患者的[[Tau蛋白|Tau蛋白]]會過度磷酸化並聚集於細胞內。雖然許多老年人的大腦中都可發現這些因老化形成的斑塊和纏結，但阿茲海默症患者會在特定腦區出現更多斑塊及纏結，例如顳葉等<ref name="pmid8038565">{{cite journal|authors=Bouras C, Hof PR, Giannakopoulos P, Michel JP, Morrison JH|title=Regional Distribution of Neurofibrillary Tangles and Senile Plaques in the Cerebral Cortex of Elderly Patients: A Quantitative Evaluation of a One-year Autopsy Population from a Geriatric Hospital|language=en|journal=Cerebral Cortex|volume=4|issue=2|pages=138–50|year=1994|pmid=8038565|doi=10.1093/cercor/4.2.138}}</ref>。{{link-en|路易氏體|Lewy body}}在病患腦中也很常見<ref name="pmid11816795">{{cite journal|authors=Kotzbauer PT, Trojanowsk JQ, Lee VM|title=Lewy Body Pathology in Alzheimer's Disease|language=en|journal=Journal of Molecular Neuroscience|volume=17|issue=2|pages=225–32|year=2001|pmid=11816795|doi=10.1385/JMN:17:2:225}}</ref>。

===生物化學===
{{Multiple image|footer = 酵素將前類澱粉蛋白（APP，圖中以藍色表示）降解之後，會形成蛋白片段，其中某一段即為β類澱粉蛋白質（A<sub>β</sub>圖中以黃色表示）。A<sub>β</sub>與阿茲海默症的形成有重要關聯。|image1 = Amyloid 01big1.jpg|image2 = Amyloid 02big1.jpg|image3 = Amyloid 03big1.jpg}}

阿茲海默症也被視為一種[[蛋白质折叠|蛋白質折疊錯誤]]的疾病（[[蛋白质构象病|蛋白质构象病]]），是由於大腦中折疊異常的{{tsl|en|amyloid beta|β類澱粉蛋白}}和Tau蛋白質堆積而造成<ref name="pmid14528050">{{cite journal|authors=Hashimoto M, Rockenstein E, Crews L, Masliah E|title=Role of Protein Aggregation in Mitochondrial Dysfunction and Neurodegeneration in Alzheimer's and Parkinson's Diseases|journal=Neuromolecular Medicine|language=en|volume=4|issue=1–2|pages=21–36|year=2003|pmid=14528050|doi=10.1385/NMM:4:1-2:21}}</ref>。構成斑塊的{{le|β類澱粉蛋白質|Amyloid beta}}（A<sub>β</sub>）是由約39至43個[[氨基酸|氨基酸]]構成的短鏈胜肽。A<sub>β</sub>為[[前類澱粉蛋白質|前類澱粉蛋白]]（APP）的一小片段，該蛋白為神經元細胞膜上的一種[[跨膜蛋白|跨膜蛋白]]，對神經元的生長、存活和受傷後的修復非常重要<ref name="pmid16822978">{{cite journal|authors=Priller C, Bauer T, Mitteregger G, Krebs B, Kretzschmar HA, Herms J|title=Synapse Formation and Function is Modulated by the Amyloid Precursor Protein|journal=The Journal of Neuroscience|language=en|volume=26|issue=27|pages=7212–21|year=2006|pmid=16822978|doi=10.1523/JNEUROSCI.1450-06.2006}}</ref><ref name="pmid12927332">{{cite journal|authors=Turner PR, O'Connor K, Tate WP, Abraham WC|title=Roles of Amyloid Precursor Protein and its Fragments in Regulating Neural Activity, Plasticity and Memory|language=en|journal=Progress in Neurobiology|volume=70|issue=1|pages=1–32|year=2003|pmid=12927332|doi=10.1016/S0301-0082(03)00089-3}}</ref>。阿茲海默症患者的{{tsl|en|gamma secretase|γ分泌酶}}及{{tsl|en|beta-secretase 1|β分泌酶}}會共同進行[[蛋白酶解|蛋白酶解]]作用，將APP切成小片段<ref name="pmid15787600">{{cite journal|authors=Hooper NM|title=Roles of Proteolysis and Lipid Rafts in the Processing of the Amyloid Precursor Protein and Prion Protein|journal=Biochemical Society Transactions|language=en|volume=33|issue=Pt 2|pages=335–38|year=2005|pmid=15787600|doi=10.1042/BST0330335}}</ref>。其中某些片段即為β類澱粉蛋白，他們會在神經元的胞外間質堆積，形成[[老年斑|老年斑塊]]<ref name="pmid15184601" /><ref name="pmid15004691">{{cite journal|authors=Ohnishi S, Takano K|title=Amyloid Fibrils from the Viewpoint of Protein Folding|journal=Cellular and Molecular Life Sciences|language=en|volume=61|issue=5|pages=511–24|year=2004|pmid=15004691|doi=10.1007/s00018-003-3264-8}}</ref>。

還有一種理論認為阿茲海默症是{{link-en|Tau蛋白質異常沉積|Tauopathy}}造成。每個神經元都有由[[微管|微管]]組成的細胞內支撐系統，稱為[[細胞骨架|細胞骨架]]，這些微管的作用如同軌道，引導營養物質和其他分子在細胞本體和[[軸突|軸突]]之間來回移動。Tau蛋白質被[[磷酸化|磷酸化]]之後可以穩定微管，所以被歸類為{{link-en|微管關聯蛋白質|microtubule-associated protein}}<ref name="pmid17604998">{{cite journal|authors=Hernández F, Avila J|title=Tauopathies|url=https://archive.org/details/sim_cellular-and-molecular-life-sciences_2007-09_64_17/page/2219|journal=Cellular and Molecular Life Sciences|language=en|volume=64|issue=17|pages=2219–33|year=2007|pmid=17604998|doi=10.1007/s00018-007-7220-x}}</ref>。在阿茲海默症病患中，Tau蛋白質發生突變而{{link-en|過度磷酸化|Hyperphosphorylation}}，進而造成微管瓦解。釋出的Tau蛋白質會聚集起來，產生神經纖維團塊並且瓦解神經元的運輸系統<ref>{{Cite journal|title=Tau Protein Hyperphosphorylation and Aggregation in Alzheimer’s Disease and Other Tauopathies, and Possible Neuroprotective Strategies|language=en|url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4808800/|last=Šimić|first=Goran|last2=Babić Leko|first2=Mirjana|date=2016-01-06|journal=Biomolecules|issue=1|doi=10.3390/biom6010006|volume=6|issn=2218-273X|pmc=4808800|pmid=26751493|last3=Wray|first3=Selina|last4=Harrington|first4=Charles|last5=Delalle|first5=Ivana|last6=Jovanov-Milošević|first6=Nataša|last7=Bažadona|first7=Danira|last8=Buée|first8=Luc|last9=de Silva|first9=Rohan}}</ref>。變性後的tau蛋白質將使[[转座子|轉座子]]運作異常，導致神經元死亡<ref>{{cite journal |last1=Sun |first1=Wenyan |last2=Samimi |first2=Hanie |last3=Gamez |first3=Maria |last4=Zare |first4=Habil |last5=Frost |first5=Bess |title=Pathogenic tau-induced piRNA depletion promotes neuronal death through transposable element dysregulation in neurodegenerative tauopathies |journal=Nature Neuroscience |language=en|date=2018-07-23 |volume=21 |issue=8 |pages=1038–48 |doi=10.1038/s41593-018-0194-1|pmid=30038280 |pmc=6095477 }}</ref>。

===疾病機轉===
目前仍不清楚A<sub>β</sub>蛋白的異常合成與異常聚集，如何導致阿茲海默症的病理變化<ref name="pmid17622778">{{cite journal|authors=Van Broeck B, Van Broeckhoven C, Kumar-Singh S|title=Current Insights into Molecular Mechanisms of Alzheimer Disease and Their Implications for Therapeutic Approaches|journal=Neuro-Degenerative Diseases|language=en|volume=4|issue=5|pages=349–65|year=2007|pmid=17622778|doi=10.1159/000105156}}</ref><ref>{{cite journal|authors=Huang Y, Mucke L|title=Alzheimer Mechanisms and Therapeutic strategies|journal=Cell|volume=148|issue=6|pages=1204–22|year=2012|pmid=22424230|doi=10.1016/j.cell.2012.02.040|pmc=3319071}}</ref>。類澱粉蛋白假說指出A<sub>β</sub>蛋白的堆積是造成神經元退化的主要原因，聚集的類澱粉蛋白纖維會瓦解細胞的鈣離子平衡，並造成[[細胞凋亡|細胞凋亡]]<ref name="pmid2218531">{{cite journal|authors=Yankner BA, Duffy LK, Kirschner DA|title=Neurotrophic and Neurotoxic Effects of Amyloid Beta Protein: Reversal by Tachykinin Neuropeptides|journal=Science|language=en|volume=250|issue=4978|pages=279–82|year=1990|pmid=2218531|doi=10.1126/science.2218531}}</ref>。A<sub>β</sub>蛋白也會選擇性地堆積於病灶處細胞的[[线粒体|线粒体]]中，抑制部分酵素的功能以及神經元使用[[葡萄糖|葡萄糖]]的能力<ref name="pmid17424907">{{cite journal|authors=Chen X, Yan SD|title=Mitochondrial Abeta: A Potential Cause of Metabolic Dysfunction in Alzheimer's Disease|journal=IUBMB Life|language=en|volume=58|issue=12|pages=686–94|year=2006|pmid=17424907|doi=10.1080/15216540601047767}}</ref>。

多種發炎反應和[[細胞激素|細胞激素]]也可能在阿茲海默症的病理變化相關<ref name="pmid15681814">{{cite journal|authors=Greig NH, Mattson MP, Perry T|title=New Therapeutic Strategies and Drug Candidates for Neurodegenerative Diseases: p53 and TNF-alpha Inhibitors, and GLP-1 Receptor Agonists|journal=Annals of the New York Academy of Sciences|language=en|volume=1035|pages=290–315|year=2004|pmid=15681814|doi=10.1196/annals.1332.018}}</ref>。越來越多證據顯示腦部神經元與免疫系統之間有很強的交互作用。肥胖與全身性發炎反應等干擾免疫反應的因子，可能都會引起疾病惡化<ref>{{cite journal|title=Neuroinflammation in Alzheimer's disease|language=en|date=2015-04|journal=The Lancet. Neurology|issue=4|doi=10.1016/S1474-4422(15)70016-5|volume=14|pages=388–405|pmid=25792098|vauthors=Heneka MT, Carson MJ, El Khoury J, Landreth GE, Brosseron F, Feinstein DL, Jacobs AH, Wyss-Coray T, Vitorica J, Ransohoff RM, Herrup K, Frautschy SA, Finsen B, Brown GC, Verkhratsky A, Yamanaka K, Koistinaho J, Latz E, Halle A, Petzold GC, Town T, Morgan D, Shinohara ML, Perry VH, Holmes C, Bazan NG, Brooks DJ, Hunot S, Joseph B, Deigendesch N, Garaschuk O, Boddeke E, Dinarello CA, Breitner JC, Cole GM, Golenbock DT, Kummer MP}}</ref>。

不同{{tsl|en|neurotrophic factor|神經滋養因子}}（如[[脑源性神经营养因子|脑源性神经营养因子]]）的分布變化，以及其受體的表現狀況，都曾有研究指出與阿茲海默症有關<ref>{{cite journal|authors=Tapia-Arancibia L, Aliaga E, Silhol M, Arancibia S|title=New insights into brain BDNF function in normal aging and Alzheimer disease|language=en|journal=Brain Research Reviews|volume=59|issue=1|pages=201–20|year=2008|pmid=18708092|doi=10.1016/j.brainresrev.2008.07.007}}</ref><ref>{{cite journal|authors=Schindowski K, Belarbi K, Buée L|title=Neurotrophic factors in Alzheimer's disease: role of axonal transport|journal=Genes, Brain, and Behavior|volume=7|issue=Suppl 1|pages=43–56|year=2008|pmid=18184369|pmc=2228393|doi=10.1111/j.1601-183X.2007.00378.x}}</ref>。

==診斷==
[[File:PET_Alzheimer.jpg|thumb]]（PET）顯示這名患者的顳葉功能喪失。]]
阿茲海默症的診斷一般透過[[病史|病史]]收集和行為觀察獲得。臨床醫師可透過觀察患者[[神經內科|神經學]]及[[神经心理学|神經心理學]]上的特徵，並{{link-en|除外診斷|Diagnosis of exclusion|排除其他診斷}}來佐證診斷<ref name="pmid17407994">{{cite journal|authors=Mendez MF|title=The Accurate Diagnosis of Early-onset Dementia|journal=International Journal of Psychiatry in Medicine|language=en|volume=36|issue=4|pages=401–12|year=2006|pmid=17407994|doi=10.2190/Q6J4-R143-P630-KW41}}</ref><ref name="pmid17018549">{{cite journal|authors=Klafki HW, Staufenbiel M, Kornhuber J, Wiltfang J|title=Therapeutic Approaches to Alzheimer's Disease|language=en|journal=Brain|volume=129|issue=Pt 11|pages=2840–55|year=2006|pmid=17018549|doi=10.1093/brain/awl280}}</ref>。一些[[醫學影像|醫學影像技術]]，可以協助排除其他大腦病變或失智症亞型<ref name=":3">{{cite book|url=http://www.nice.org.uk/nicemedia/pdf/CG042quickrefguide.pdf|title=Dementia: Quick Reference Guide|language=en|date=2006-11|publisher=(UK) National Institute for Health and Clinical Excellence|isbn=1-84629-312-X|location=London|format=PDF|deadurl=yes|access-date=2008-02-22|archive-url=https://web.archive.org/web/20080227161412/http://www.nice.org.uk/nicemedia/pdf/CG042quickrefguide.pdf|archive-date=2008-02-27}}</ref>。此外，醫學影像也可以用於預測從輕微認知失調到阿茲海默症的轉變<ref name="Schroeter">{{cite journal|authors=Schroeter ML, Stein T, Maslowski N, Neumann J|title=Neural Correlates of Alzheimer's Disease and Mild Cognitive Impairment: A Systematic and Quantitative Meta-Analysis involving 1,351 Patients|journal=NeuroImage|volume=47|language=en|issue=4|pages=1196–206|year=2009|pmid=19463961|pmc=2730171|doi=10.1016/j.neuroimage.2009.05.037}}</ref>。

{{link-en|神經心理學評估|Neuropsychological assessment}}（包括記憶測試）可以進一步鑑別疾病狀態<ref name="pmid17222085" />，醫學組織已經為臨床醫師建立診斷標準以簡化及標準化診斷程序。阿茲海默症最準確的診斷方法為屍體[[驗屍|病理解剖]]，直接取得腦組織，經由[[組織學|組織學]]免疫染色法進行確認診斷<ref name="pmid6610841">{{cite journal|authors=McKhann G, Drachman D, Folstein M|title=Clinical Diagnosis of Alzheimer's Disease: Report of the NINCDS-ADRDA Work Group under the Auspices of Department of Health and Human Services Task Force on Alzheimer's Disease|url=https://archive.org/details/sim_neurology_1984-07_34_7/page/939|language=en|journal=Neurology|volume=34|issue=7|pages=939–44|year=1984|pmid=6610841|doi=10.1212/wnl.34.7.939}}</ref>。

===診斷標準===
{{tsl|en|National Institute of Neurological and Communicative Disorders and Stroke|美國神經與中風研究院|美國神經與溝通疾患及中風研究院}}（NINCDS，現改名為美國神經與中風研究院）及{{tsl|en|Alzheimer's Disease and Related Disorders Association|阿茲海默症及相關疾病協會}}（ADRDA）於1984年制定了{{tsl|en|NINCDS-ADRDA Alzheimer's Criteria|NINCDS-ADRDA阿茲海默症診斷標準}}，為目前最常用的診斷標準之一<ref name="pmid6610841"/>，最新一版於2007年更新<ref name="pmid176164822">{{cite journal|authors=Dubois B, Feldman HH, Jacova C|title=Research Criteria for the Diagnosis of Alzheimer's Disease: Revising the NINCDS-ADRDA Criteria|journal=Lancet Neurology|language=en|volume=6|issue=8|pages=734–46|year=2007|pmid=17616482|doi=10.1016/S1474-4422(07)70178-3}}</ref>。臨床診斷標準包含{{tsl|en|Developmental disability|發展性障礙|認知功能損害}}、疑似失智症狀，並經由{{tsl|en|Neuropsychological assessment|神經心理學評估}}確認。

腦組織的[[微觀|顯微鏡檢]]可以提供阿茲海默症的{{tsl|en|histopathologic|組織病理學}}確認診斷。上述的診斷標準在藉由組織病理學進行評估後，顯示該標準的[[信度|信度]]及[[效度|效度]]都不錯<ref name="pmid7986174">{{cite journal|authors=Blacker D, Albert MS, Bassett SS|title=Reliability and validity of NINCDS-ADRDA criteria for Alzheimer's disease. The National Institute of Mental Health Genetics Initiative|journal=Archives of Neurology|language=en|volume=51|issue=12|pages=1198–204|year=1994|pmid=7986174|doi=10.1001/archneur.1994.00540240042014}}</ref>。阿茲海默症最常損害的八個智能區塊為[[記憶|記憶]]、[[語言|語言]]、[[知觉|知觉]]、[[注意|注意力]]、[[动作技能|动作技能]]、{{tsl|en|orientation (mental)|定向力}}、[[解决问题|問題解決能力]]、[[管控功能|執行能力]]等。這些問題在NINCDS-ADRDA診斷標準及[[美國精神醫學學會|美國精神醫學學會]]發行的《[[精神疾病診斷與統計手冊|精神疾病診斷與統計手冊]]》（DSM-IV-TR）皆有提到<ref>{{cite book|title=Diagnostic and statistical manual of mental disorders: DSM-IV-TR|last=American Psychiatric Association|publisher=American Psychiatric Association|language=en|year=2000|isbn=0-89042-025-4|edition=4th Edition Text Revision|location=Washington, DC}}</ref><ref name="pmid8752526">{{cite journal|authors=Ito N|title=[Clinical aspects of dementia]|language=ja|journal=Hokkaido Igaku Zasshi|volume=71|issue=3|pages=315–20|year=1996|pmid=8752526}}</ref>。

===檢測技術===
[[File:InterlockingPentagons.svg|right]]

[[簡短智能測驗|簡短智能測驗]]（MMSE）等{{tsl|en|Neuropsychological test|神經心理學檢查}}常被用於評估認知功能障礙，以利於後續診斷。若要取得更可信的結果，可以進行更全面的測試，特別是在疾病初期的患者<ref name="pmid1512391">{{cite journal|authors=Tombaugh TN, McIntyre NJ|title=The mini-mental state examination: a comprehensive review|journal=Journal of the American Geriatrics Society|language=en|volume=40|issue=9|pages=922–35|year=1992|pmid=1512391|doi=10.1111/j.1532-5415.1992.tb01992.x}}</ref><ref name="pmid9987708">{{cite journal|authors=Pasquier F|title=Early diagnosis of dementia: neuropsychology|journal=Journal of Neurology|language=en|volume=246|issue=1|pages=6–15|year=1999|pmid=9987708|doi=10.1007/s004150050299}}</ref>。除非有明顯的認知功能障礙，{{tsl|en|Neurological examination|神經學檢察}}結果在疾病初期一般會呈現正常，可能無法與其他疾病做出鑑別，包含其他原因造成的失智症。

進一步的神經學檢查對於阿茲海默症的鑑別診斷相當重要<ref name="pmid17222085"/>，與家人會談也有助於評估病情。主要照護人能夠提供患者日常活動功能的重要資訊，以及病人{{tsl|en|mental function|心智功能}}下降的情形<ref name="pmid16327345">{{cite journal|authors=Harvey PD, Moriarty PJ, Kleinman L|title=The Validation of a Caregiver Assessment of Dementia: the Dementia Severity Scale|journal=Alzheimer Disease and Associated Disorders|language=en|volume=19|issue=4|pages=186–94|year=2005|pmid=16327345|doi=10.1097/01.wad.0000189034.43203.60}}</ref>。由於患者通常自己{{tsl|en|anosognosia|病覺缺失症|無法查覺自身的異狀}}，因此旁觀者的觀點對於疾病的評估相當重要<ref name="pmid15738860">{{cite journal|authors=Antoine C, Antoine P, Guermonprez P, Frigard B|title=Awareness of Deficits and Anosognosia in Alzheimer's Disease|language=fr|journal=L'Encéphale|volume=30|issue=6|pages=570–77|year=2004|pmid=15738860|doi=10.1016/S0013-7006(04)95472-3}}</ref>。但在失智症初期時，家人通常也無法察覺病人的症狀，而無法提供醫師準確的資訊<ref name="pmid16197855">{{cite journal|authors=Cruz VT, Pais J, Teixeira A, Nunes B|title=The Initial Symptoms of Alzheimer Disease: Caregiver Perception|language=pt|journal=Acta Médica Portuguesa|volume=17|issue=6|pages=435–44|year=2004|pmid=16197855}}</ref>。

輔助性檢查可以提供一些額外資訊，以利排除其他診斷。[[血液检查|血液检查]]也可以協助排除阿茲海默症以外的診斷<ref name="pmid17222085" />，偶見有些病因是可以治癒的<ref>{{cite journal | authors = Clarfield AM | title = The Decreasing Prevalence of Reversible Dementias: An Updated Meta-analysis | journal = Archives of Internal Medicine |language=en| volume = 163 | issue = 18 | pages = 2219–29 | year = 2003 | pmid = 14557220 | doi = 10.1001/archinte.163.18.2219}}</ref>。常見的血檢項目包含{{tsl|en|thyroid function tests|甲狀腺功能測試}}、[[维生素B12全合成|维生素B<sub>12</sub>]]、[[梅毒|梅毒]]檢測、代謝性疾病檢查（如腎功能檢查、電解質水平，以及糖尿病檢查）、重金屬水平，以及貧血等等。另外也必須[[譫妄|譫妄]]的可能性。

針對[[重性抑郁障碍|抑鬱症]]的[[心理測驗|心理測驗]]也建議進行，因為阿茲海默症常{{tsl|en|Depression of Alzheimer disease|阿茲海默症的抑鬱症狀|同時伴隨抑鬱症狀}}，也是認知功能損傷的早期症狀之一<ref>{{cite journal | authors = Sun X, Steffens DC, Au R | display-authors = etal | title = Amyloid-Associated Depression: A Prodromal Depression of Alzheimer Disease? | journal = Archives of General Psychiatry | language = en | volume = 65 | issue = 5 | pages = 542–50 | year = 2008 | pmid = 18458206 | pmc = 3042807 | doi = 10.1001/archpsyc.65.5.542 | url = http://archpsyc.ama-assn.org/cgi/content/short/65/5/542 | deadurl = yes | accessdate = 2019-01-01 | archiveurl = https://web.archive.org/web/20080706023907/http://archpsyc.ama-assn.org/cgi/content/short/65/5/542 | archivedate = 2008-07-06 }}</ref>，甚至是原因<ref name="pmid9153154">{{cite journal | authors = Geldmacher DS, Whitehouse PJ | title = Differential Diagnosis of Alzheimer's Disease | journal = Neurology |language=en| volume = 48 | issue = 5 Suppl 6 | pages = S2–9 | year = 1997 | pmid = 9153154| doi =  10.1212/WNL.48.5_Suppl_6.2S}}</ref><ref name="pmid17495754">{{cite journal | authors = Potter GG, Steffens DC | title = Contribution of Depression to Cognitive Impairment and Dementia in Older adults | journal = The Neurologist | volume = 13 | issue = 3 | pages = 105–17 | year = 2007 | pmid = 17495754 | doi = 10.1097/01.nrl.0000252947.15389.a9}}</ref>。

=== 影像學 ===
[[電腦斷層掃瞄|電腦斷層掃瞄]]（CT）、[[核磁共振成像|核磁共振成像]]（MRI）、{{link-en|單光子電腦斷層攝影|Single-photon emission computed tomography}}（SPECT），和[[正电子发射计算机断层扫描|正子電腦斷層攝影]]（PET）等高階[[醫學影像|醫學影像技術]]，可以協助排除{{Le|腦膜瘤|meningioma}}、[[硬膜下血肿|硬膜下出血]]等其他腦部疾病或失智症亞型<ref name=":3" />。此外，醫學影像也可以用於預測從輕微認知失調到阿茲海默症的轉變<ref name="Schroeter" />。海馬迴計量（Hippocampal volumetry）的診斷價值或許較高，但大多數醫院不易取得<ref name=":2" />。目前核磁共振已經有影像評分系統，可以協助識別皮質萎縮的區域。

C-PIB正子照影（C-PIB PET）在疾病初期的準確率不高，因此不建議用於早期診斷，或預測輕度知能障礙患者進展到阿茲海默症的機會<ref>{{Cite journal|title=<sup>11</sup>C-PIB-PET for the early diagnosis of Alzheimer’s disease dementia and other dementias in people with mild cognitive impairment (MCI)|language=en|url=http://dx.doi.org/10.1002/14651858.cd010386.pub2|last=Zhang|first=Shuo|last2=Smailagic|first2=Nadja|date=2014-07-23|journal=Cochrane Database of Systematic Reviews|doi=10.1002/14651858.cd010386.pub2|issn=1465-1858|last3=Hyde|first3=Chris|last4=Noel-Storr|first4=Anna H|last5=Takwoingi|first5=Yemisi|last6=McShane|first6=Rupert|last7=Feng|first7=Juan|access-date=2019-01-19|archive-date=2019-07-13|archive-url=https://web.archive.org/web/20190713162446/https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010386.pub2/full|dead-url=no}}</ref>。¹⁸F-FDG正子照影（¹⁸F-FDG PET）在預測阿茲海默症的發生機會上也沒有實證支持<ref>{{cite journal|title=¹⁸F-FDG PET for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI)|language=en|date=2015-01|journal=The Cochrane Database of Systematic Reviews|doi=10.1002/14651858.CD010632.pub2|volume=1|pages=CD010632|pmid=25629415|authors=Smailagic N, Vacante M, Hyde C, Martin S, Ukoumunne O, Sachpekidis C}}</ref>。

目前用於阿茲海默症的放射性示踪劑中，針對檢測大腦中的類澱粉樣斑塊（可能是阿爾茨海默氏症的生物標記），美國FDA核准的藥物有florbetapir F18，flutemetamol F18和florbetabenF18。針對tau20，它們都用於檢測大腦中的澱粉樣β斑塊（可能是阿爾茨海默氏症的生物標記）。{{cn}}

澱粉樣蛋白的PET診斷藥物目前已有3個藥物被FDA核准，但在tau蛋白病變中，Tauvid是第一個可以診斷tau蛋白病變的藥物。{{cn}}

目前全球醫學界認為阿茲海默症病患，主要是在大腦中發現有tau蛋白以及類澱粉樣蛋白(amyloid)堆積，並且認為這兩種蛋白質可能是造成阿茲海默症的病變原因。目前FDA針對澱粉樣蛋白的PET診斷藥物已有3個藥物(florbetapir F18，flutemetamol F18和florbetaben F18)被A核准，但在tau蛋白病變中，flortaucipir F18 (Tauvid)是第一個可以診斷tau蛋白病變的PET藥物。{{cn}}

==預防==
[[File:Honoré_Daumier_032.jpg|right]]及日常社交等益智活動，於流行病學上顯示與較低的阿茲海默症發生風險相關，但目前其因果性尚未證實。]]

目前實證上沒有任何能有效預防阿茲海默症的方式<ref name="nonprevention" />，有關預防及推遲阿茲海默症進程的跨國研究結果經常不一致。流行病學研究推測阿茲海默症可能與某些飲食、心血管風險、藥物等因子相關。某些智力活動及族群發生阿茲海默症的機會可能也不同。但這些相關性是否真的可以用來預防阿茲海默症，仍需進一步的研究闡明<ref name=nonprevention/>。

===藥物===
雖然[[高膽固醇血症|高膽固醇]]、[[高血壓|高血壓]]、[[糖尿病|糖尿病]]，及[[吸煙|吸菸]]等心血管風險增強因子，可能與較高的阿茲海默症發生率相關<ref name="pmid18299540">{{cite journal|authors=Patterson C, Feightner JW, Garcia A|title=Diagnosis and Treatment of Dementia: 1. Risk Assessment and Primary Prevention of Alzheimer Disease|journal=Canadian Medical Association Journal|language=en|volume=178|issue=5|pages=548–56|year=2008|pmid=18299540|pmc=2244657|doi=10.1503/cmaj.070796}}</ref><ref name="pmid17483665">{{cite journal|authors=Rosendorff C, Beeri MS, Silverman JM|title=Cardiovascular Risk Factors for Alzheimer's Disease|journal=The American Journal of Geriatric Cardiology|volume=16|issue=3|pages=143–49|year=2007|pmid=17483665|doi=10.1111/j.1076-7460.2007.06696.x}}</ref>。但服用降膽固醇用的[[羟甲基戊二酸单酰辅酶A还原酶抑制剂|他汀類藥物]]（Statins）無法有效預防阿茲海默症的發生或推遲其進程<ref name="pmid17877925">{{cite journal | authors = Kuller LH | title = Statins and Dementia | journal = Current Atherosclerosis Reports | volume = 9 | issue = 2 | pages = 154–61 | year = 2007 | pmid = 17877925 | doi = 10.1007/s11883-007-0012-9|language=en}}</ref><ref>{{cite journal | authors = McGuinness B, Craig D, Bullock R, Malouf R, Passmore P | title = Statins for the treatment of dementia | journal = The Cochrane Database of Systematic Reviews | volume = 7 | issue = 7 | pages = CD007514|language=en | date = 2014-07 | pmid = 25004278 | doi = 10.1002/14651858.CD007514.pub3 }}</ref>。

長期使用[[非甾体抗炎药|非甾体抗炎药]]（NSAIDs）在2007年時被認為可能與較低的阿茲海默症發生率相關<ref name="pmid17612054">{{cite journal|authors=Szekely CA, Town T, Zandi PP|title=NSAIDs for the Chemoprevention of Alzheimer's Disease|language=en|journal=Sub-Cellular Biochemistry|volume=42|pages=229–48|year=2007|pmid=17612054|doi=10.1007/1-4020-5688-5_11|isbn=978-1-4020-5687-1|series=Subcellular Biochemistry}}</ref>。亦有證據顯示NSAID可以減少與[[類澱粉蛋白|類澱粉斑塊]]相關的{{tsl|en|chronic inflammation|慢性發炎|發炎}}反應。但由於副作用過高，相關的臨床實驗提早中止<ref name="nonprevention" />。截至目前為止，尚無預防研究完成試驗<ref name="nonprevention" />。NSAID對於治療阿茲海默症沒有任何功效，但為預防的候選藥物之一<ref>{{cite journal|title=Soothing the inflamed brain: effect of non-steroidal anti-inflammatory drugs on Alzheimer's disease pathology|year=2011|journal=CNS & Neurological Disorders Drug Targets|language=en|issue=1|doi=10.2174/187152711794488665|volume=10|pages=57–67|pmid=21143138|authors=Hoozemans JJ, Veerhuis R, Rozemuller JM, Eikelenboom P}}</ref>。[[更年期|更年期]]的[[激素替代療法|激素替代療法]]可能會增加失智的風險，即使已經停藥也一樣<ref>{{cite journal|authors=Marjoribanks J, Farquhar C, Roberts H, Lethaby A, Lee J|title=Long term hormone therapy for perimenopausal and postmenopausal women|journal=The Cochrane Database of Systematic Reviews|language=en|volume=1|page=CD004143|year=2017|pmid=28093732|doi=10.1002/14651858.CD004143.pub5}}</ref>。

最新研究顯示，[[威而鋼|威而鋼]]可能具有降低阿茲海默症發生率的效果，但仍未確定。<ref>[https://news.ltn.com.tw/news/world/breakingnews/3760642 威而鋼好猛！美研究：或可預防阿茲海默症 服用者患病率少69％]</ref>

===生活型態===
從事某些益智活動的人群罹患阿茲海默症的風險似乎較低，如[[閱讀|閱讀]]、[[圖版遊戲|圖版遊戲]]、[[填字游戏|填字游戏]]、演奏[[樂器|樂器]]，及從事日常[[社交|社交活動]]等<ref name="pmid16917199">{{cite journal|authors=Stern Y|title=Cognitive reserve and Alzheimer disease|journal=Alzheimer Disease and Associated Disorders|language=en|volume=20|issue=2|pages=112–17|date=2006-07|pmid=16917199|doi=10.1097/01.wad.0000213815.20177.19|issn=0893-0341}}</ref>。這點符合{{tsl|en|cognitive reserve|認知存量}}假說，該假說認為有些生活經歷會增進神經功能的效能，並擴充個人的認知存量，進而延遲失智症的發生<ref name="pmid16917199" />。接受[[教育|教育]]也會延遲阿茲海默症的發生，但並不會改變病程的長短<ref name="pmid19026089">{{cite journal|authors=Paradise M, Cooper C, Livingston G|title=Systematic Review of the Effect of Education on Survival in Alzheimer's Disease|journal=International Psychogeriatrics|language=en|volume=21|issue=1|pages=25–32|year=2009|pmid=19026089|doi=10.1017/S1041610208008053}}</ref>。學習[[第二語言|第二語言]]也有可能可以延遲疾病發生<ref>{{cite news|url=http://www.denverpost.com/ci_17427474|title=Speaking 2 Languages May Delay Getting Alzheimer's|last=Neergaard|first=Lauran|date=2011-02-19|publisher=The Denver Post|deadurl=no|language=en|agency=Associated Press|archive-url=https://web.archive.org/web/20140502013633/http://www.denverpost.com/ci_17427474|archive-date=2014-05-02|accessdate=2019-01-01}}</ref>。[[體能鍛鍊|體能鍛鍊]]亦顯示可以降低阿茲海默症的風險<ref name="pmid19026089" />，且發生失智症的比率較低<ref>{{cite journal|title=Cognitive Reserve and the Prevention of Dementia: the Role of Physical and Cognitive Activities|date=2016-09|journal=Current Psychiatry Reports|language=en|issue=9|doi=10.1007/s11920-016-0721-2|volume=18|pages=85|pmc=4969323|pmid=27481112|authors=Cheng ST}}</ref>，另外也能減輕患者症狀嚴重程度<ref>{{cite journal|title=The effect of exercise interventions on cognitive outcome in Alzheimer's disease: a systematic review|url=https://www.cambridge.org/core/product/identifier/S1041610213001385/type/JOURNAL_ARTICLE|language=en|date=2014-01|journal=International Psychogeriatrics|issue=1|doi=10.1017/S1041610213001385|volume=26|pages=9–18|pmid=23962667|authors=Farina N, Rusted J, Tabet N|access-date=2019-01-01|archive-date=2019-07-13|archive-url=https://web.archive.org/web/20190713162444/https://www.cambridge.org/core/journals/international-psychogeriatrics/article/effect-of-exercise-interventions-on-cognitive-outcome-in-alzheimers-disease-a-systematic-review/49E5C885C501B58066A024CC114DADDF|dead-url=no}}</ref>。

===飲食===
<!--Diets  -->
平時身體健康者、[[日本人|日本人]]、[[地中海飲食|地中海飲食]]者顯示罹患阿茲海默症的機會較小<ref name="Hu2013">{{cite journal|authors=Hu N, Yu JT, Tan L|title=Nutrition and the Risk of Alzheimer's Disease|journal=BioMed Research International|language=en|volume=2013|pmid=23865055|year=2013|doi=10.1155/2013/524820|type=Review|pmc=3705810}}</ref>。地中海飲食同時也能改善患病者的預後<ref>{{cite journal|authors=Solfrizzi V, Panza F, Frisardi V|title=Diet and Alzheimer's disease risk factors or prevention: the current evidence|journal=Expert Review of Neurotherapeutics|language=en|volume=11|issue=5|pages=677–708|date=2011-05|pmid=21539488|doi=10.1586/ern.11.56}}</ref>。飲食含有高脂肪酸及簡單碳水化合物（simple carbohydrates，[[單醣|單醣]]或[[雙醣|雙醣]]等）患病機率也較高<ref>{{cite journal|authors=Kanoski SE, Davidson TL|title=Western diet consumption and cognitive impairment: links to hippocampal dysfunction and obesity|journal=Physiology & Behavior|language=en|volume=103|issue=1|pages=59–68|date=2011-04-18|pmid=21167850|pmc=3056912|doi=10.1016/j.physbeh.2010.12.003|type=Review}}</ref>。地中海飲食對心血管正面影響的機制也已有文獻發表<ref name="pmid18088206">{{cite journal|authors=Solfrizzi V, Capurso C, D'Introno A|title=Lifestyle-related Factors in Predementia and Dementia Syndromes|journal=Expert Review of Neurotherapeutics|language=en|volume=8|issue=1|pages=133–58|year=2008|pmid=18088206|doi=10.1586/14737175.8.1.133}}</ref>。

<!--Dietary components  -->
飲食的配方與阿茲海默症間的關係目前仍不明朗，因為相關的研究結果沒有定論<ref name=Hu2013/>。有限證據顯示適量飲酒，與較低的阿茲海默症發生率相關，特別是紅酒<ref name=Hu2013 />。另有證據表明[[咖啡因|咖啡因]]可能為阿茲海默症的保護因子<ref name="pmid20182026">{{cite journal|authors=Santos C, Costa J, Santos J, Vaz-Carneiro A, Lunet N|title=Caffeine intake and dementia: systematic review and meta-analysis|journal=Journal of Alzheimer's Disease|language=en|volume=20 Suppl 1|pages=S187–204|year=2010|pmid=20182026|doi=10.3233/JAD-2010-091387}}</ref>。含有高量[[黄酮类化合物|黄酮类]]的食物，如[[可可|可可]]、紅酒、茶，等，也可能與較低的阿茲海默症風險相關<ref>{{cite journal | authors = Nehlig A | title = The neuroprotective effects of cocoa flavanol and its influence on cognitive performance | journal = British Journal of Clinical Pharmacology |language=en| volume = 75 | issue = 3 | pages = n/a–n/a | date =2012-07 | pmid = 22775434 | doi = 10.1111/j.1365-2125.2012.04378.x | type = Review | pmc=3575938}}</ref><ref>{{cite journal | authors = Stoclet JC, Schini-Kerth V | title = [Dietary flavonoids and human health] | journal = Annales Pharmaceutiques Françaises|language=en | volume = 69 | issue = 2 | pages = 78–90 | date = 2011-03 | pmid = 21440100 | doi = 10.1016/j.pharma.2010.11.004 }}</ref>。

<!--Vitamins and minerals  -->
目前沒有有力證據支持攝取[[維生素|維生素]]或[[礦物質|礦物質]]對疾病有幫助，此部分已研究的物質包含維生素A<ref>{{cite journal|authors=Ono K, Yamada M|title=Vitamin A and Alzheimer's disease|journal=Geriatrics & Gerontology International|language=en|volume=12|issue=2|pages=180–88|date=2012-04|pmid=22221326|doi=10.1111/j.1447-0594.2011.00786.x|type=Review}}</ref><ref>{{cite journal|authors=Lerner AJ, Gustaw-Rothenberg K, Smyth S, Casadesus G|title=Retinoids for treatment of Alzheimer's disease|journal=BioFactors|language=en|volume=38|issue=2|pages=84–89|year=2012|pmid=22419567|doi=10.1002/biof.196}}</ref>、C<ref>{{cite journal|authors=Heo JH, Lee KM|title=The possible role of antioxidant vitamin C in Alzheimer's disease treatment and prevention|journal=American Journal of Alzheimer's Disease & Other Dementias|language=en|volume=28|issue=2|pages=120–25|date=2013-03|pmid=23307795|doi=10.1177/1533317512473193|type=Review}}</ref><ref name="pmid16227450">{{cite journal|authors=Boothby LA, Doering PL|title=Vitamin C and Vitamin E for Alzheimer's Disease|url=https://archive.org/details/sim_annals-of-pharmacotherapy_2005-12_39_12/page/2073|journal=The Annals of Pharmacotherapy|language=en|volume=39|issue=12|pages=2073–80|year=2005|pmid=16227450|doi=10.1345/aph.1E495}}</ref>、α-生育酚態的[[維生素E|維生素E]]<ref name=":0">{{Cite journal|title=Vitamin E for Alzheimer's dementia and mild cognitive impairment|url=https://www.ncbi.nlm.nih.gov/pubmed/28418065|last=Farina|first=Nicolas|last2=Llewellyn|first2=David|year=2017|journal=The Cochrane Database of Systematic Reviews|language=en|doi=10.1002/14651858.CD002854.pub5|volume=4|pages=CD002854|issn=1469-493X|pmid=28418065|last3=Isaac|first3=Mokhtar Gad El Kareem Nasr|last4=Tabet|first4=Naji|access-date=2019-01-01|archive-url=https://web.archive.org/web/20181004151957/https://www.ncbi.nlm.nih.gov/pubmed/28418065|archive-date=2018-10-04|dead-url=no}}</ref>、[[硒|硒]]<ref>{{cite journal|authors=Loef M, Schrauzer GN, Walach H|title=Selenium and Alzheimer's disease: a systematic review|language=en|journal=Journal of Alzheimer's Disease|volume=26|issue=1|pages=81–104|year=2011|pmid=21593562|doi=10.3233/JAD-2011-110414|type=Review}}</ref>、[[鋅|鋅]]<ref>{{cite journal|authors=Loef M, von Stillfried N, Walach H|title=Zinc diet and Alzheimer's disease: a systematic review|language=en|journal=Nutritional Neuroscience|volume=15|issue=5|pages=2–12|date=2012-09-01|pmid=22583839|doi=10.1179/1476830512Y.0000000010|type=Review}}</ref><ref>{{cite journal|title=Zinc and Copper in Alzheimer's Disease|journal=Journal of Alzheimer's Disease|language=en|issue=1|doi=10.3233/JAD-150186|year=2015|volume=46|pages=89–92|type=Review|pmid=25835420|authors=Avan A, Hoogenraad TU}}</ref>、[[叶酸|叶酸]]，以及B<sub>12</sub>等<ref>{{cite journal|authors=Malouf R, Grimley Evans J|title=Folic Acid with or without Vitamin B<sub>12</sub> for the Prevention and Treatment of Healthy Elderly and Demented people|journal=The Cochrane Database of Systematic Reviews|language=en|issue=4|page=CD004514|year=2008|pmid=18843658|doi=10.1002/14651858.CD004514.pub2}}</ref>。一項證據品質中等的隨機分派研究指出，α-生育酚態的維生素E可以減緩認知功能下降的速度<ref name=":0" />；而葉酸及其他維生素B的臨床試驗則無法證明有同樣功能<ref>{{cite journal|authors=Wald DS, Kasturiratne A, Simmonds M|title=Effect of Folic Acid, with or without other B vitamins, on Cognitive Decline: Meta-analysis of Randomized trials|url=https://archive.org/details/sim_american-journal-of-medicine_2010-06_123_6/page/522|language=en|journal=The American Journal of Medicine|volume=123|issue=6|pages=522–27.e2|date=2010-06|pmid=20569758|doi=10.1016/j.amjmed.2010.01.017}}</ref>。植物油及魚油中常見的Omega-3脂肪酸，以及[[二十二碳六烯酸|二十二碳六烯酸]]（DHA）對於改善阿茲海默症沒有已知助益<ref>{{cite journal|authors=Cunnane SC, Chouinard-Watkins R, Castellano CA, Barberger-Gateau P|title=Docosahexaenoic acid homeostasis, brain aging and Alzheimer's disease: Can we reconcile the evidence?|journal=Prostaglandins, Leukotrienes, and Essential Fatty Acids|volume=88|issue=1|pages=61–70|language=en|date=2013-01|pmid=22575581|doi=10.1016/j.plefa.2012.04.006}}</ref><ref>{{cite journal|title=Omega-3 fatty acids for the treatment of dementia|date=2016-04|journal=The Cochrane Database of Systematic Reviews|language=en|doi=10.1002/14651858.CD009002.pub3|volume=4|pages=CD009002|pmid=27063583|authors=Burckhardt M, Herke M, Wustmann T, Watzke S, Langer G, Fink A}}</ref>。

[[姜黄素|薑黃]]在動物實驗中顯示對阿茲海默症有幫助，但截至2010年為止，尚無人體實驗證實有效<ref>{{cite journal | authors = Hamaguchi T, Ono K, Yamada M | title = Curcumin and Alzheimer's disease |type=review |language=en| journal = CNS Neuroscience & Therapeutics | volume = 16 | issue = 5 | pages = 285–97 | date = 2010-10 | pmid = 20406252 | doi = 10.1111/j.1755-5949.2010.00147.x}}</ref>。[[银杏|银杏]]及大麻素目前也尚無有力證據支持其在失智症的效果<ref>{{cite journal | authors = Birks J, Grimley Evans J | title = Ginkgo Biloba for Cognitive Impairment and Dementia | journal = The Cochrane Database of Systematic Reviews | issue = 1 | page = CD003120 |language=en| year = 2009 | pmid = 19160216 | doi = 10.1002/14651858.CD003120.pub3 }}</ref><ref name="pmid19370677">{{cite journal | authors = Krishnan S, Cairns R, Howard R | title = Cannabinoids for the treatment of dementia | journal = The Cochrane Database of Systematic Reviews |language=en| issue = 2 | page = CD007204 | year = 2009 | pmid = 19370677 | doi = 10.1002/14651858.CD007204.pub2 | editor1-last = Krishnan | editor1-first = Sarada }}</ref>，但內源性大麻素（endocannabinoids）似乎有一些證據顯示有所助益<ref name="pmid23108550">{{cite journal | authors = Bilkei-Gorzo A | title = The endocannabinoid system in normal and pathological brain ageing | journal = Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences |language=en| volume = 367 | issue = 1607 | pages = 3326–41 | date = 2012-12 | pmid = 23108550 | pmc = 3481530 | doi = 10.1098/rstb.2011.0388 }}</ref>。

=== 熬夜 ===
熬夜也會增加患上阿茲海默症的風險，有充足睡眠減少阿茲海默症的風險。

=== 風險預測 ===
CAIDE風險量表（CAIDE risk score）能夠評估20年內罹患失智症的機會，該量表考量了年齡、教育水平、性別、血壓、BMI、總膽固醇，及日常活動等因子<ref>{{Cite journal|title=Lifestyle interventions to prevent cognitive impairment, dementia and Alzheimer disease|language=en|url=https://www.nature.com/articles/s41582-018-0070-3|last=Ngandu|first=Tiia|last2=Mangialasche|first2=Francesca|date=2018-11|journal=Nature Reviews Neurology|issue=11|doi=10.1038/s41582-018-0070-3|volume=14|pages=653–666|issn=1759-4766|last3=Kivipelto|first3=Miia|access-date=2019-01-05|archive-date=2019-07-13|archive-url=https://web.archive.org/web/20190713162433/https://www.nature.com/articles/s41582-018-0070-3|dead-url=no}}</ref>。

==治療==
目前阿茲海默症尚無法根治，僅有一些症狀性治療，此類療法大多屬於[[和缓医疗|和緩醫療]]。現行治療可分為藥物治療、心理治療和醫療照護。

===藥物治療===
[[File:Donepezil_1EVE.png|right]]
[[File:Memantine.svg|right]]
常見用於改善阿茲海默症認知障礙的藥物有五種，其中四種為{{tsl|en|acetylcholinesterase inhibitor|乙醯膽鹼酯酶抑制劑}}（[[塔克寧|塔克寧]]、{{tsl|en|rivastigmine|憶思能}}、[[加蘭他敏|加蘭他敏]]、{{tsl|en|donepezil|愛憶欣}}），另外一種為{{tsl|en|NMDA receptor antagonist|NMDA受體拮抗劑}}（{{tsl|en|memantine|美金剛胺}}）。但這些藥物的效益都不大<ref name="Pres2012">{{cite journal||author=Commission de la transparence|title=Médicaments de la maladie d'Alzheimer|journal=Prescrire International|language=fr|volume=21|issue=128|page=150|date= 2012-06|pmid=22822592}}</ref><ref name="pmid16437430">{{cite journal|authors=Birks J, Harvey RJ|title=Donepezil for dementia due to Alzheimer's disease|journal=The Cochrane Database of Systematic Reviews|issue=1|page=CD001190|date=2006-01-25|pmid=16437430|doi=10.1002/14651858.CD001190.pub2|editor1-last=Birks|editor1-first=Jacqueline|language=en}}</ref><ref name="Birks2015">{{cite journal|title=Rivastigmine for Alzheimer's disease|date=2015-04|journal=The Cochrane Database of Systematic Reviews|issue=4|doi=10.1002/14651858.CD001191.pub3|pages=CD001191|pmid=25858345|language=en|authors=Birks JS, Grimley Evans J}}</ref>，且截至目前為止，仍沒有證據這些藥物能延緩或停止疾病的進程。

阿茲海默症會降低膽鹼性神經元的活性<ref name="pmid8534419">{{cite journal | authors = Geula C, Mesulam MM | title = Cholinesterases and the pathology of Alzheimer disease | journal = Alzheimer Disease and Associated Disorders |language=en| volume = 9 Suppl 2 | pages = 23–28 | year = 1995 | pmid = 8534419 | doi = 10.1097/00002093-199501002-00005 }}</ref>，而乙醯膽鹼酯酶抑制劑可以減緩[[乙酰胆碱|乙醯膽鹼]]（ACh）的降解速率，藉此提升突觸間的乙酰胆碱濃度，以補足因膽鹼性神經元死亡而造成乙醯膽鹼濃度下降的現象<ref name="pmid11105732">{{cite journal|authors=Stahl SM|title=The new cholinesterase inhibitors for Alzheimer's disease, part 2: illustrating their mechanisms of action|journal=The Journal of Clinical Psychiatry|language=en|volume=61|issue=11|pages=813–14|year=2000|pmid=11105732|doi=10.4088/JCP.v61n1101}}</ref>。目前此類藥品在輕度至中度的阿茲海默症的症狀控制上，已經證實有效<ref name="Birks2015" /><ref name="pmid16437532">{{cite journal|authors=Birks J|title=Cholinesterase inhibitors for Alzheimer's disease|journal=The Cochrane Database of Systematic Reviews|language=en|issue=1|pages=CD005593|year=2006|pmid=16437532|doi=10.1002/14651858.CD005593|editor1-last=Birks|editor1-first=Jacqueline}}</ref><ref name=":1">{{Cite journal|title=Donepezil for dementia due to Alzheimer's disease|url=https://www.ncbi.nlm.nih.gov/pubmed/29923184|last=Birks|first=Jacqueline S.|last2=Harvey|first2=Richard J.|language=en|year=2018|journal=The Cochrane Database of Systematic Reviews|doi=10.1002/14651858.CD001190.pub3|volume=6|pages=CD001190|issn=1469-493X|pmid=29923184|access-date=2019-01-01|archive-url=https://web.archive.org/web/20180909103939/https://www.ncbi.nlm.nih.gov/pubmed/29923184|archive-date=2018-09-09|dead-url=no}}</ref>，有一些證據甚至表示重度患者使用也有效果<ref name=":1" />。{{tsl|en|mild cognitive impairment|輕度知能障礙}}患者用藥並不能延遲阿茲海默症的發生<ref name="pmid18044984">{{cite journal|authors=Raschetti R, Albanese E, Vanacore N, Maggini M|title=Cholinesterase inhibitors in mild cognitive impairment: a systematic review of randomised trials|journal=PLoS Medicine|language=en|volume=4|issue=11|page=e338|year=2007|pmid=18044984|pmc=2082649|doi=10.1371/journal.pmed.0040338}}</ref>。此類藥物最常見的[[药物不良反应|副作用]]為[[恶心|噁心]]和[[呕吐|嘔吐]]，兩者皆為膽鹼過量的副作用。約10–20%的患者用藥後會產生副作用，嚴重程度從輕度到中度皆有。如有此類問題，可以緩慢調降藥量來改善<ref>{{cite book|title=Applied therapeutics : the clinical use of drugs|author=Brian K. Alldredge|language=en|year=2013|publisher=Wolters Kluwer Health/Lippincott Williams & Wilkins|isbn=978-1609137137|edition=10th|location=Baltimore|page=2385}}</ref>。比較少見的副作用包含肌肉[[抽搐|抽搐]]、[[心跳过缓|心搏過緩]]、[[食慾|食慾]]及體重下降，以及[[胃酸|胃酸]]製造增加等等<ref name="pmid16437532"/>。

[[谷氨酸|麩胺酸]]為興奮性[[神经递质|神經傳遞物質]]，若在腦中含量過多可能會引起{{tsl|en|excitotoxicity|神經興奮性毒性反應|興奮性毒性反應}}，使細胞因受體過度刺激而死亡。興奮性毒性反應存在於阿茲海默症、[[帕金森氏症|帕金森氏症]]，以及[[多发性硬化症|多發性硬化症]]等神經性疾病中<ref name="pmid16424917">{{cite journal | authors = Lipton SA | title = Paradigm shift in neuroprotection by NMDA receptor blockade: memantine and beyond | journal = Nature Reviews. Drug Discovery |language=en| volume = 5 | issue = 2 | pages = 160–70 | year = 2006 | pmid = 16424917 | doi = 10.1038/nrd1958 }}</ref>。{{tsl|en|Memantine|美金剛胺}}為一種非競爭性{{tsl|en|NMDA receptor antagonist|NMDA受體拮抗劑}}，一開始被用於治療[[流行性感冒|流行性感冒]]，但後來發現它可以藉由抑制[[N-甲基-D-天門冬胺酸受體|NMDA受體]]來達到抑制麩胺酸系統的效果<ref name="pmid16424917" /><ref>{{cite web|url=https://www.nlm.nih.gov/medlineplus/druginfo/meds/a604006.html|title=Memantine|access-date=2010-02-03|date=2004-01-04|publisher=US National Library of Medicine (Medline)|language=en|archive-url=https://web.archive.org/web/20100222203921/https://www.nlm.nih.gov/medlineplus/druginfo/meds/a604006.html|archive-date=2010-02-22|deadurl=no}}</ref>。後來的研究顯示美金剛胺對於阿茲海默症有些許效益<ref>{{cite journal | authors = McShane R, Areosa Sastre A, Minakaran N | title = Memantine for dementia | journal = The Cochrane Database of Systematic Reviews |language=en| issue = 2 | pages = CD003154 | date = 2006-04 | pmid = 16625572 | doi = 10.1002/14651858.CD003154.pub5 }}</ref>。本品已知的[[不良反應_(醫學)|不良反應]]包含偶爾產生輕微[[幻觉|幻覺]]、{{tsl|en|confusion|意識混亂}}、[[頭暈|暈眩]]、[[頭痛|頭痛]]，以及[[疲勞|疲勞]]<ref>{{cite web |url=http://www.frx.com/pi/namenda_pi.pdf |title=Namenda prescribing information |access-date=2008-02-19 |format=PDF |publisher=Forest Pharmaceuticals |archive-url=https://web.archive.org/web/20080227161413/http://www.frx.com/pi/namenda_pi.pdf |archive-date=2008-02-27 |language=en |deadurl=yes }} (primary source)<!-- also available at https://web.archive.org/web/*/http://www.frx.com/pi/namenda_pi.pdf --></ref>。美金剛胺與愛憶欣併用的效果統計上呈現顯著，但臨床效益不大<ref name="pmid18316756">{{cite journal|authors=Raina P, Santaguida P, Ismaila A|title=Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline|journal=Annals of Internal Medicine|language=en|volume=148|issue=5|pages=379–97|year=2008|pmid=18316756|doi=10.7326/0003-4819-148-5-200803040-00009}}</ref>。

{{tsl|en|Atypical antipsychotic|非典型抗精神病藥}}對於緩解患者的[[侵略_(社會科學)|攻擊性]]及[[思覺失調|思覺失調]]症狀具有一些效果，但同時此類藥物也會造成一些嚴重副作用，例如[[中風|中風]]、[[錐體外症候群|動作障礙]]，已及認知功能損傷等等<ref>{{cite journal|authors=Ballard C, Waite J|title=The Effectiveness of Atypical Antipsychotics for the Treatment of Aggression and Psychosis in Alzheimer's Disease|journal=The Cochrane Database of Systematic Reviews|language=en|issue=1|page=CD003476|year=2006|pmid=16437455|doi=10.1002/14651858.CD003476.pub2|editor1-last=Ballard|editor1-first=Clive G}}</ref>。長期使用此類藥物可能會增加死亡風險<ref name="pmid19138567">{{cite journal|authors=Ballard C, Hanney ML, Theodoulou M|title=The Dementia Antipsychotic Withdrawal Trial (DART-AD): Long-term Follow-up of a Randomised Placebo-controlled Trial|journal=Lancet Neurology|language=en|volume=8|issue=2|pages=151–17|date=2009-01-09|pmid=19138567|doi=10.1016/S1474-4422(08)70295-3|laysummary=http://www.physorg.com/news150695213.html|access-date=2019-01-01|archive-date=2011-11-05|archive-url=https://web.archive.org/web/20111105041217/http://www.physorg.com/news150695213.html|dead-url=no}}</ref>，而對於精神症狀輕度至中度的長期服藥者，停藥似乎為安全的選擇<ref>{{cite journal | authors = Declercq T, Petrovic M, Azermai M, Vander Stichele R, De Sutter AI, van Driel ML, Christiaens T | title = Withdrawal versus continuation of chronic antipsychotic drugs for behavioural and psychological symptoms in older people with dementia | journal = The Cochrane Database of Systematic Reviews |language=en| volume = 3 | issue = 3 | pages = CD007726 | date = 2013-03 | pmid = 23543555 | doi = 10.1002/14651858.CD007726.pub2 }}</ref>。{{tsl|en|Huperzine A|石杉鹼甲}}對改善認知功能似乎有正面影響，但目前仍需進一步研究證實其效果<ref>{{cite journal | authors = Li J, Wu HM, Zhou RL, Liu GJ, Dong BR | title = Huperzine A for Alzheimer's disease | journal = The Cochrane Database of Systematic Reviews | issue = 2 | page = CD005592 | language = en | year = 2008 | pmid = 18425924 | doi = 10.1002/14651858.CD005592.pub2 | url = http://www2.cochrane.org/reviews/en/ab005592.html | editor1-last = Wu | editor1-first = Hong Mei | deadurl = no | accessdate = 2019-01-01 | archiveurl = https://web.archive.org/web/20110317114141/http://www2.cochrane.org/reviews/en/ab005592.html | archivedate = 2011-03-17 }}</ref>。

2019年11月中国[[国家药品监督管理局|国家药品监督管理局]]批准國產研發公司[[绿谷制药|绿谷制药]]的「[[九期一|九期一]]」製劑上市是一種甘露特钠胶囊<ref name=nmpa />，是長達17年來阿茲海默症首次有新藥出現上市，根據[[上海交通大学|上海交通大学]]医学院附属精神卫生中心和[[北京协和医院|北京协和医院]]聯合的三年臨床實驗證明，此藥能顯著反轉中期患者的病況，且完全無副作用，甚至有病人入组时的認知功能分數26分藥後涨到了29分（常人满分30分），据药物研发团队负责人[[中国科学院上海药物研究所|中国科学院上海药物研究所]][[耿美玉|耿美玉]]研究员介绍：GV-971是一种新型的海洋来源的[[寡糖|寡糖]]，具有多种靶向机制，包括抑制[[淀粉样β纤维|淀粉样β纤维]]的形成，[[神经炎症|神经炎症]]和[[肠道菌群失调|肠道菌群失调]]的修复。但需要进一步研究以进一步阐明和确认其有希望的生物学和临床效果。<ref>{{Cite web |url = http://www.bjd.com.cn/a/201911/04/WS5dbf80d6e4b05b28cd03d850.html |title = 中国原创老年痴呆药疗效如何？79岁教授治疗后变化大 |author = 李祺瑶 |date = 2019-11-04 |publisher = 京报网 |language = zh-cn |accessdate = 2019-11-04 |archive-date = 2020-08-12 |archive-url = https://web.archive.org/web/20200812031229/http://www.bjd.com.cn/a/201911/04/WS5dbf80d6e4b05b28cd03d850.html |dead-url = no }}</ref><ref>{{Cite web |url=https://www.thepharmaletter.com/article/chinese-answer-to-alzheimer-s-puzzle |title=Chinese answer to Alzheimer’s puzzle? |accessdate=2019-11-07 |archive-date=2021-02-05 |archive-url=https://web.archive.org/web/20210205065420/https://www.thepharmaletter.com/article/chinese-answer-to-alzheimer-s-puzzle |dead-url=no }}</ref>“九期一”引起了不少质疑，包括研发单位绿谷制药曾贩卖假药[[中华灵芝宝|中华灵芝宝]]（[[双灵固本散|双灵固本散]]），[[PubPeer|PubPeer]]网站对耿美玉课题组发表的4篇论文发出质疑，认为存在图片不当裁剪、一图多用等问题。<ref>{{Cite web|title=PubPeer网站对于耿美玉课题组若干研究论文的质疑_腾讯新闻|url=https://new.qq.com/omn/20191106/20191106A0N3SF00.html|accessdate=2019-11-29|work=new.qq.com|archive-date=2020-02-04|archive-url=https://web.archive.org/web/20200204152004/https://new.qq.com/omn/20191106/20191106A0N3SF00.html|dead-url=no}}</ref><ref>{{Cite web|title=PubPeer - Search publications and join the conversation.|url=https://pubpeer.com/search?q=(Mei-yu+OR+Meiyu)+AND+Geng|accessdate=2019-11-29|work=pubpeer.com|archive-date=2020-02-06|archive-url=https://web.archive.org/web/20200206030744/https://pubpeer.com/search?q=(Mei-yu+OR+Meiyu)+AND+Geng|dead-url=no}}</ref>此外，2019年11月29日，[[首都医科大学|首都医科大学]]校长[[饶毅|饶毅]]实名举报[[李红良|李红良]]、[[裴钢|裴钢]]、耿美玉造假，称耿美玉的文章“不造假是不可能的”。<ref>{{Cite web|title=首都医科大学校长饶毅实名打假中国科学院院士裴钢_研究|url=http://www.sohu.com/a/357261452_105067|accessdate=2019-11-29|work=www.sohu.com|language=en|archive-date=2019-11-30|archive-url=https://web.archive.org/web/20191130090827/http://www.sohu.com/a/357261452_105067|dead-url=no}}</ref><ref>{{Cite web|title=网传饶毅实名举报学术造假，国家自然科学基金委：正了解|url=http://www.bjnews.com.cn/news/2019/11/29/655857.html|accessdate=2019-11-29|last=新京报|work=www.bjnews.com.cn|archive-date=2019-11-29|archive-url=https://web.archive.org/web/20191129093144/http://www.bjnews.com.cn/news/2019/11/29/655857.html|dead-url=no}}</ref>

===心理治療===
[[社会心理学|社會心理]]治療可用於輔助藥物治療，分為行為性、情緒性、認知性、刺激性等介入方式。但此類治療的效度無法測量，且此類研究的研究對象大多收錄了所有失智症，鮮少明確針對阿茲海默症<ref name="pracGuideAPA">{{cite journal | authors = Rabins PV, Blacker D, Rovner BW | title = American Psychiatric Association practice guideline for the treatment of patients with Alzheimer's disease and other dementias | journal = The American Journal of Psychiatry |language=en| volume = 164 | issue = 12 Suppl | pages = 5–56 | date = 2007-12 | pmid = 18340692 | author9 = Steering Committee on Practice Guidelines }}</ref>。

{{tsl|en|Behavior modification|行為調整|行為治療}}乃是藉由識別問題行為的前因及結果，進而試圖減少之。此類治療雖然無法改善整體功能<ref name="pmid16323385">{{cite journal|authors=Bottino CM, Carvalho IA, Alvarez AM|title=Cognitive rehabilitation combined with drug treatment in Alzheimer's disease patients: a pilot study|journal=Clinical Rehabilitation|language=en|volume=19|issue=8|pages=861–69|year=2005|pmid=16323385|doi=10.1191/0269215505cr911oa}}</ref>，但可以減少一些特定的問題行為，例如[[尿失禁|尿失禁]]<ref name="pmid11342679">{{cite journal | authors = Doody RS, Stevens JC, Beck C | title = Practice parameter: management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology | journal = Neurology |language=en| volume = 56 | issue = 9 | pages = 1154–66 | year = 2001 | pmid = 11342679 | doi = 10.1212/WNL.56.9.1154 }}</ref>。但目前對於遊走（wandering）等其他問題並沒有足夠實證顯示其效果<ref name="pmid17253573">{{cite journal | authors = Hermans DG, Htay UH, McShane R | title = Non-pharmacological interventions for wandering of people with dementia in the domestic setting|language=en | journal = The Cochrane Database of Systematic Reviews | issue = 1 | page = CD005994 | year = 2007 | pmid = 17253573 | doi = 10.1002/14651858.CD005994.pub2 }}</ref><ref name="pmid17096455">{{cite journal | authors = Robinson L, Hutchings D, Dickinson HO | title = Effectiveness and acceptability of non-pharmacological interventions to reduce wandering in dementia: a systematic review | journal = International Journal of Geriatric Psychiatry |language=en| volume = 22 | issue = 1 | pages = 9–22 | year = 2007 | pmid = 17096455 | doi = 10.1002/gps.1643 }}</ref>。音樂治療可能對於減少行為性或心理性症狀有些效果<ref>{{cite journal |authors=Abraha I, Rimland JM, Trotta FM, Dell'Aquila G, Cruz-Jentoft A, Petrovic M, Gudmundsson A, Soiza R, O'Mahony D, Guaita A, Cherubini A |title=Systematic review of systematic reviews of non-pharmacological interventions to treat behavioural disturbances in older patients with dementia. The SENATOR-OnTop series |journal=BMJ Open |language=en|date=2017-03-16 |volume=7 |issue=3 |page=e012759 |doi=10.1136/bmjopen-2016-012759 |pmid=28302633 |pmc=5372076 }}</ref>。

情緒導向治療包括{{tsl|en|reminiscence therapy|懷舊療法}}、{{tsl|en|validation therapy|確認療法}}、支持性[[心理治療|心理治療]]、 {{tsl|en|sensory integration therapy|感官統合治療|感官統合}}（或稱為{{tsl|en|snoezelen|多感官治療}}）和{{tsl|en|simulated presence therapy|情境模擬治療}}。一份[[考科藍|考科藍]]的回顧性文章認為此類療法並無足夠實證支持效果<ref>{{cite journal | authors = Chung JC, Lai CK, Chung PM, French HP | title = Snoezelen for dementia | journal = The Cochrane Database of Systematic Reviews |language=en| issue = 4 | pages = CD003152 | year = 2002 | pmid = 12519587 | doi = 10.1002/14651858.CD003152 }}</ref>。 支持性心理治療的正式學術研究相當少，但有些治療者認為對於改善病人的病感有些許效果<ref name="pracGuideAPA"/>。懷舊療法的做法是與病患引導病人回憶過去的經驗，治療者會反覆藉由[[照片|照片]]、日常用品、[[音樂|音樂]]、錄音檔，或是病患熟悉的事物引導病人回憶並組織過去的經驗。懷舊療法可以個別進行或以小組模式進行。一份2018年的回顧性文章認為懷舊療法的一致性不足，且對象規模過小、各團體差異過大，以致不足以彰顯其臨床意義<ref>{{cite journal |last1=Woods |first1=B |last2=O'Philbin |first2=L |last3=Farrell |first3=EM |last4=Spector |first4=AE |last5=Orrell |first5=M |title=Reminiscence therapy for dementia. |language=en|journal=The Cochrane Database of Systematic Reviews |date=2018-03-01 |volume=3 |pages=CD001120 |doi=10.1002/14651858.CD001120.pub3 |pmid=29493789}}</ref>。情境模擬治療的理論是建基於[[依附理論|依附理論]]上，治療者會播放病患熟悉的聲音。此療法在改善病患的{{tsl|en|challenging behaviour|挑釁行為}}有部分證據<ref name="pmid19023729">{{cite journal | authors = Zetteler J | title = Effectiveness of simulated presence therapy for individuals with dementia: a systematic review and meta-analysis |language=en| journal = Aging & Mental Health | volume = 12 | issue = 6 | pages = 779–85 | date = 2008-11 | pmid = 19023729 | doi = 10.1080/13607860802380631 }}</ref>。最後，確認療法是基於接受患者所感受到的真實和個人信念，而感官統合療法則以刺激訓練患者的感知為目標。目前沒有證據支持這些療法是否有效<ref name="pmid12917907">{{cite journal | authors = Neal M, Briggs M | title = Validation therapy for dementia | journal = The Cochrane Database of Systematic Reviews |language=en| issue = 3 | page = CD001394 | year = 2003 | pmid = 12917907 | doi = 10.1002/14651858.CD001394 | editor1-last = Neal | editor1-first = Martin }}</ref><ref name="pmid12519587">{{cite journal | authors = Chung JC, Lai CK, Chung PM, French HP | title = Snoezelen for dementia | journal = The Cochrane Database of Systematic Reviews |language=en| issue = 4 | page = CD003152 | year = 2002 | pmid = 12519587 | doi = 10.1002/14651858.CD003152 | editor1-last = Chung | editor1-first = Jenny CC }}</ref>。

認知導向治療的目標包含協助病人恢復現實定向（reality orientation）以及{{tsl|en|Rehabilitation (neuropsychology)|復健 (神經心理學)|認知功能再訓練}}（cognitive retraining）。現實定向的做法是提供病人當下的人、事、時、地、物等現實資訊，以協助病人了解其環境。認知功能再訓練則旨在協助病人改善其心智功能。上述兩者對於改善認知能力都有一些效果<ref name="pmid17636652">{{cite journal | authors = Spector A, Orrell M, Davies S, Woods B | title = Withdrawn: reality orientation for dementia | journal = The Cochrane Database of Systematic Reviews | issue = 3 | page = CD001119 |language=en| year = 2000 | pmid = 17636652 | doi = 10.1002/14651858.CD001119.pub2 | editor1-last = Spector | editor1-first = Aimee E }}</ref><ref name="pmid12948999">{{cite journal | authors = Spector A, Thorgrimsen L, Woods B | title = Efficacy of an evidence-based cognitive stimulation therapy programme for people with dementia: randomised controlled trial | journal = The British Journal of Psychiatry |language=en| volume = 183 | issue = 3 | pages = 248–54 | year = 2003 | pmid = 12948999 | doi = 10.1192/bjp.183.3.248 }}</ref>，雖然在部分研究中，這些效果短暫的，負面效果如使患者感到沮喪也曾被提出<ref name="pracGuideAPA"/>。

刺激導向治療（Stimulation-oriented treatments）包括以[[藝術治療|藝術]]、[[音樂治療|音樂]]、{{tsl|en|Animal-assisted therapy|寵物治療|寵物}}、[[物理治療|運動]]或其他任何娛樂活動來進行治療。刺激可以適當地協助患者改善行為、心情和少部分的功能。雖然如此，這些治療提供的支持除了其本身的效果外，患者習慣的改變也是同等重要的<ref name="pracGuideAPA"/>。非侵入性腦刺激和侵入性腦刺激在阿茲海默症的效用目前還不明瞭<ref name=ChangLane2018>{{cite journal|last1=Chang|first1=Chun-Hung|last2=Lane|first2=Hsien-Yuan|last3=Lin|first3=Chieh-Hsin|title=Brain Stimulation in Alzheimer's Disease|journal=Frontiers in Psychiatry|language=en|volume=9|year=2018|issn=1664-0640|doi=10.3389/fpsyt.2018.00201|pmc=5992378|pmid=29910746}}</ref>。

===醫療照護===
由於阿茲海默症無法治癒，且會逐漸使患者無法自理，因此照護實質上是治療的核心，在整個疾病進程中必須小心處理。在疾病早期，改善居住環境和生活模式可以增進[[病人安全|病人安全]]，並減少照護者的負擔<ref name="pmid11220813">{{cite journal|authors=Gitlin LN, Corcoran M, Winter L, Boyce A, Hauck WW |title=A Randomized, Controlled Trial of a Home Environmental Intervention: Effect on Efficacy and Upset in Caregivers and on Daily Function of Persons with Dementia |journal=The Gerontologist |volume=41 |issue=1 |pages=4–14 |date=2001-02-01 |pmid=11220813 |doi=10.1093/geront/41.1.4|language=en}}</ref><ref name="pmid15860476">{{cite journal | authors = Gitlin LN, Hauck WW, Dennis MP, Winter L | title = Maintenance of Effects of the Home Environmental Skill-building Program for Family Caregivers and Individuals with Alzheimer's Disease and Related Disorders | journal = The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences | volume = 60 | issue = 3 | pages = 368–74 | year = 2005 | pmid = 15860476 | doi = 10.1093/gerona/60.3.368|language=en}}</ref>，實務上包括讓患者的生活作息符合固定簡單的模式、使用安全防護裝置、在居家物品上做標示（用以提示患者）或使用特殊設計的生活用具<ref name="pracGuideAPA" /><ref>{{cite web|url=http://www.alz.org/Health/Treating/agitation.asp|title=Treating Behavioral and Psychiatric Symptoms|year=2006|access-date=2006-09-25|publisher=Alzheimer's Association|archive-url=https://web.archive.org/web/20060925112503/http://www.alz.org/Health/Treating/agitation.asp|archive-date=2006-09-25|dead-url=yes}}</ref><ref name="pmid15297089">{{cite journal | authors = Dunne TE, Neargarder SA, Cipolloni PB, Cronin-Golomb A | title = Visual Contrast Enhances Food and Liquid Intake in Advanced Alzheimer's Disease | journal = Clinical Nutrition (Edinburgh, Scotland) | volume = 23 | issue = 4 | pages = 533–38 | year = 2004 | pmid = 15297089 | doi = 10.1016/j.clnu.2003.09.015 |language=en}}</ref>。若有進食問題，則須將食物切成小塊或甚至做成泥狀<ref>{{cite book|author=Dudek, Susan G.|title=Nutrition Essentials for Nursing Practice|publisher=Lippincott Williams & Wilkins|location=Hagerstown, Maryland|year=2007|page=360|isbn=0-7817-6651-6|url=https://books.google.com/?id=01zo6yf0IUEC&pg=PA360&dq=alzheimer%27s+chew|access-date=2008-08-19|language=en}}</ref>；當出現[[吞嚥障礙|吞嚥障礙]]時，則可能需使用{{tsl|en|feeding tube|餵食管}}，對於這樣的患者，照護者和家人必須仔細考量藥物療效和餵食與否等倫理議題<ref name="pmid16415742">{{cite journal | authors = Dennehy C | title = Analysis of Patients' Rights: Dementia and PEG Insertion | journal = British Journal of Nursing | volume = 15 | issue = 1 | pages = 18–20 | year = 2006 | pmid = 16415742 | doi=10.12968/bjon.2006.15.1.20303|language=en}}</ref><ref name="pmid16556924">{{cite journal | authors = Chernoff R | title = Tube Feeding Patients with Dementia | url = https://archive.org/details/sim_nutrition-in-clinical-practice_2006-04_21_2/page/142 | journal = Nutrition in Clinical Practice | volume = 21 | issue = 2 | pages = 142–46 | year = 2006 | pmid = 16556924 | doi = 10.1177/0115426506021002142|language=en}}</ref>。無論是哪個階段的阿茲海默症的患者，通常都不需要身體拘束，雖然在少數狀況下，為了保護患者或照護者仍必須執行拘束<ref name="pracGuideAPA" />。

當疾病逐漸惡化，各式病症也會逐漸出現如{{tsl|en|dental disease|牙科疾病|口腔或牙科疾病}}、[[褥疮|褥瘡]]、[[營養不良|營養不良]]、[[衛生|衛生]]問題、呼吸道感染」皮膚感染、眼感染等。小心的照護管理能避免上述問題產生，但若真的發生了，則需要專業的治療<ref name="pmid10369823">{{cite journal | authors = Gambassi G, Landi F, Lapane KL, Sgadari A, Mor V, Bernabei R | title = Predictors of Mortality in Patients with Alzheimer's Disease Living in Nursing Homes | journal = Journal of Neurology, Neurosurgery, and Psychiatry | volume = 67 | issue = 1 | pages = 59–65 | year = 1999 | pmid = 10369823 | pmc = 1736445 | doi = 10.1136/jnnp.67.1.59|language=en }}</ref><ref>醫療議題：
*{{cite journal | authors = Head B | title = Palliative Care for Persons with Dementia | journal = Home Healthcare Nurse | volume = 21 | issue = 1 | pages = 53–60; quiz 61 | year = 2003 | pmid = 12544465 | doi = 10.1097/00004045-200301000-00012|language=en}}
*{{cite journal | authors = Friedlander AH, Norman DC, Mahler ME, Norman KM, Yagiela JA | title = Alzheimer's Disease: Psychopathology, Medical Management and Dental Implications | journal = Journal of the American Dental Association | volume = 137 | issue = 9 | pages = 1240–51 | year = 2006 | pmid = 16946428|language=en}}
*{{cite journal | authors = Belmin J | title = Practical Guidelines for the Diagnosis and Management of Weight Loss in Alzheimer's Disease: A Consensus from Appropriateness Ratings of a Large Expert Panel | journal = The Journal of Nutrition, Health & Aging | volume = 11 | issue = 1 | pages = 33–37 | year = 2007 | pmid = 17315078|language=en }}
*{{cite journal | authors = McCurry SM, Gibbons LE, Logsdon RG, Vitiello M, Teri L | title = Training Caregivers to Change the Sleep Hygiene Practices of Patients with Dementia: The NITE-AD Project | journal = Journal of the American Geriatrics Society | volume = 51 | issue = 10 | pages = 1455–60 | year = 2003 | pmid = 14511168 | doi = 10.1046/j.1532-5415.2003.51466.x|language=en }}
*{{cite journal | authors = Perls TT, Herget M | title = Higher Respiratory Infection Rates on an Alzheimer's Special Care Unit and successful intervention | journal = Journal of the American Geriatrics Society | volume = 43 | issue = 12 | pages = 1341–44 | year = 1995 | pmid = 7490383| doi=10.1111/j.1532-5415.1995.tb06611.x|language=en}}</ref>。在疾病的最末期，治療著重於在患者死亡前緩解其痛楚，通常會需要[[和缓医疗|緩和醫療]]的協助<ref name="pmid12854952">{{cite journal | authors = Shega JW, Levin A, Hougham GW | title = Palliative Excellence in Alzheimer Care Efforts (PEACE): A Program Description | journal = Journal of Palliative Medicine | volume = 6 | issue = 2 | pages = 315–20 | year = 2003 | pmid = 12854952 | doi = 10.1089/109662103764978641|language=en }}</ref>。

==預後==
[[File:Alzheimer_and_other_dementias_world_map_-_DALY_-_WHO2004.svg|thumb]]。
{{colbegin}}
{{legend|#b3b3b3|無資料}}
{{legend|#ffff65|≤ 50}}
{{legend|#fff200|50–70}}
{{legend|#ffdc00|70–90}}
{{legend|#ffc600|90–110}}
{{legend|#ffb000|110–130}}
{{legend|#ff9a00|130–150}}
{{legend|#ff8400|150–170}}
{{legend|#ff6e00|170–190}}
{{legend|#ff5800|190–210}}
{{legend|#ff4200|210–230}}
{{legend|#ff2c00|230–250}}
{{legend|#cb0000|≥ 250}}
{{colend}}]]
阿茲海默症早期十分難診斷，通常要到認知障礙影響到日常生活後才會確診，雖然此時患者可能仍能獨立生活。患者的症狀會由輕度的認知功能問題（例如記憶力衰退）開始逐漸惡化，到疾病後期完全不可能獨自生活。<ref name="pmid10653284"/>

阿茲海默症患者的[[预期寿命|預期壽命]]較短<ref name=Za2009>{{cite journal | authors = Zanetti O, Solerte SB, Cantoni F | title = Life expectancy in Alzheimer's disease (AD) | journal = Archives of Gerontology and Geriatrics | volume = 49 Suppl 1 | pages = 237–43 | year = 2009 | pmid = 19836639 | doi = 10.1016/j.archger.2009.09.035|language=en }}</ref>，診斷後的預期餘命約三到十年<ref name=Za2009/>，少於3%的人能活超過14年<ref name="pmid7793228">{{cite journal | authors = Mölsä PK, Marttila RJ, Rinne UK | title = Long-Term Survival and Predictors of Mortality in Alzheimer's Disease and Multi-Infarct Dementia | journal = Acta Neurologica Scandinavica | volume = 91 | issue = 3 | pages = 159–64 | year = 1995 | pmid = 7793228| doi=10.1111/j.1600-0404.1995.tb00426.x|language=en}}</ref>。會造成存活年數顯著減少的特徵包括認知障礙嚴重度增加、生活功能減退、曾經跌倒和神經學檢查出現問題。其他共病如[[心血管疾病|心血管疾病]]、[[糖尿病|糖尿病]]、曾經[[酗酒|酗酒]]都和存活年數減少有關<ref name="pmid8757016">{{cite journal | authors = Bowen JD, Malter AD, Sheppard L | title = Predictors of Mortality in Patients Diagnosed with Probable Alzheimer's Disease | url = https://archive.org/details/sim_neurology_1996-08_47_2/page/433 | journal = Neurology | volume = 47 | issue = 2 | pages = 433–39 | year = 1996 | pmid = 8757016 | doi = 10.1212/wnl.47.2.433|language=en }}</ref><ref name="pmid15068977">{{cite journal | authors = Larson EB, Shadlen MF, Wang L | title = Survival after Initial Diagnosis of Alzheimer Disease | journal = Annals of Internal Medicine | volume = 140 | issue = 7 | pages = 501–09 | year = 2004 | pmid = 15068977 | doi=10.7326/0003-4819-140-7-200404060-00008|language=en}}</ref><ref name="pmid7792352">{{cite journal | authors = Jagger C, Clarke M, Stone A | title = Predictors of Survival with Alzheimer's Disease: A Community-based Study | url = https://archive.org/details/sim_psychological-medicine_1995-01_25_1/page/171 | journal = Psychological Medicine | volume = 25 | issue = 1 | pages = 171–77 | year = 1995 | pmid = 7792352 | doi = 10.1017/S0033291700028191|language=en}}</ref>。雖然越年輕時就診斷的患者有越長的存活年數，但事實上年輕的患者相對於健康族群來說壽命較短<ref name="pmid12580712">{{cite journal | authors = Dodge HH, Shen C, Pandav R, DeKosky ST, Ganguli M | title = Functional Transitions and Active Life Expectancy Associated with Alzheimer Disease | journal = Archives of Neurology | volume = 60 | issue = 2 | pages = 253–59 | year = 2003 | pmid = 12580712 | doi = 10.1001/archneur.60.2.253|language=en}}</ref>。男性的預後也較女性差<ref name="pmid7793228" /><ref name="pmid15883266">{{cite journal | authors = Ganguli M, Dodge HH, Shen C, Pandav RS, DeKosky ST | title = Alzheimer Disease and Mortality: A 15-year Epidemiological Study | journal = Archives of Neurology | volume = 62 | issue = 5 | pages = 779–84 | year = 2005 | pmid = 15883266 | doi = 10.1001/archneur.62.5.779|language=en}}</ref>。

[[肺炎|肺炎]]和[[脱水|脫水]]是最常造成阿茲海默症患者立即死亡的原因；相較於一般人，阿茲海默症患者因癌症死亡的比率較少。<ref name="pmid15883266" />
{{clear}}

==流行病學==
{| class="wikitable" style="float:right; text-align:center;"
|+65歲以上年長者的發生率<ref name="pmid17727890"/>
|-
! 年齡 !! 年發生率（每千人）
|-
!65–69
| 3
|-
!70–74
| 6
|-
!75–79
| 9
|-
!80–84
|23
|-
!85–89
|40
|-
!90–    <!-- The nonbreaking spaces to the left of this comment make the numbers line up properly. -->
|69
|}

阿茲海默症的[[流行病学|流行病學]]研究主要著重在[[患病率|盛行率]]和[[发病率|發生率]]上：盛行率指的是某種疾病在任一時間點占群體總人數的比例；發生率則是指特定時期內某人群新發生某一疾病的比率。

在發生率方面，[[纵向研究|縱貫性]][[队列研究|世代研究]]（追蹤一群無疾病人口的發病比率）指出，每年失智症發生風險約為1-1.5%，而其中阿茲海默症的風險則為0.5-0.8%<ref name="pmid17727890">{{cite journal | authors = Bermejo-Pareja F, Benito-León J, Vega S, Medrano MJ, Román GC | title = Incidence and subtypes of dementia in three elderly populations of central Spain | journal = Journal of the Neurological Sciences | volume = 264 | issue = 1–2 | pages = 63–72 | year = 2008 | pmid = 17727890 | doi = 10.1016/j.jns.2007.07.021|language=en}}</ref><ref name="pmid12028245">{{cite journal | authors = Di Carlo A, Baldereschi M, Amaducci L | title = Incidence of dementia, Alzheimer's disease, and vascular dementia in Italy. The ILSA Study | journal = Journal of the American Geriatrics Society | volume = 50 | issue = 1 | pages = 41–48 | year = 2002 | pmid = 12028245 | doi = 10.1046/j.1532-5415.2002.50006.x|language=en}}</ref>。這代表在每年新發生的失智症中，有幾乎一半是阿茲海默症。高齡是阿茲海默症的主要風險因子，本病在每個年齡層的發生率不同，年齡越大者發生風險越高。65歲以上的長者，每五年的罹病風險就會增加一倍，<ref name="pmid17727890"/><ref name="pmid12028245"/>除年齡外，阿茲海默症的發生率還存在性別差異，女性的發生率較男性為高，特別是85歲以上的年長女性<ref name="pmid12028245"/><ref>{{cite journal | authors = Andersen K, Launer LJ, Dewey ME | title = Gender Differences in the Incidence of AD and Vascular Dementia: The EURODEM Studies. EURODEM Incidence Research Group |language=en| journal = Neurology | volume = 53 | issue = 9 | pages = 1992–97 | year = 1999 | pmid = 10599770| doi = 10.1212/wnl.53.9.1992 }}</ref>。在[[美国|美國]]，非拉丁裔白人死於阿茲海默症的風險，比起非裔高出了26%，更比拉丁裔高出了30%<ref>{{Cite web|url=https://permanent.fdlp.gov/gpo41882/DB116.pdf|title=Mortality From Alzheimer’s Disease in the United States: Data for 2000 and 2010|language=en|format=pdf|accessdate=2021-02-25|archive-date=2020-06-29|archive-url=https://web.archive.org/web/20200629055340/https://permanent.fdlp.gov/gpo41882/DB116.pdf|dead-url=no}}</ref>。

[[File:Alzheimer's_disease_and_other_dementias_world_map-Deaths_per_million_persons-WHO2012.svg|thumb]]
阿茲海默症的盛行率取決於許多因素，包括當地患者的存活率。由於阿茲海默症的發生率隨年齡增加，考量當地人口的平均年齡是相當重要的。美國的阿茲海默症的總人口盛行率和65–74歲的族群盛行率皆為1.6%，但在75–84歲的族群盛行率則為19%，85歲以上的族群更達到42%<ref>2000年美國估計
* {{cite journal | authors = Hebert LE, Scherr PA, Bienias JL, Bennett DA, Evans DA | title = Alzheimer Disease in the US population: Prevalence Estimates Using the 2000 census | journal = Archives of Neurology | volume = 60 | issue = 8 | pages = 1119–22 | year = 2003 | pmid = 12925369 | doi = 10.1001/archneur.60.8.1119|language=en}}
* {{cite web|title=Profiles of General Demographic Characteristics, 2000 Census of Population and Housing, United States|year=2001|publisher=U.S. Census Bureau|url=https://www.census.gov/prod/cen2000/dp1/2kh00.pdf|format=PDF|access-date=2008-08-27|archive-url=https://web.archive.org/web/20080819203118/http://www.census.gov/prod/cen2000/dp1/2kh00.pdf|archive-date=2008-08-19|deadurl=no|language=en}}</ref>。低度開發地區的盛行率也因此較低<ref name="pmid16360788"/>。[[世界卫生组织|世界衛生組織]]估計2005年全球的失智症盛行率為0.379%，2015年會增加到0.441%，並在2030年達到0.556%<ref name="isbn9789241563369">{{cite book|last=World Health Organization|title=Neurological Disorders: Public Health Challenges|publisher=World Health Organization|year=2006|location=Switzerland|pages=204–07|url=http://www.who.int/mental_health/neurology/neurodiso/en/index.html|isbn=978-92-4-156336-9|deadurl=no|archive-url=https://web.archive.org/web/20100210144936/http://www.who.int/mental_health/neurology/neurodiso/en/index.html|archive-date=2010-02-10|language=en|access-date=2019-01-01}}</ref>；其他研究也有類似的結論<ref name="pmid16360788">{{cite journal | authors = Ferri CP, Prince M, Brayne C, Brodaty H | title = Global Prevalence of Dementia: A Delphi Consensus Study | journal = Lancet |language=en| volume = 366 | issue = 9503 | pages = 2112–17 | year = 2005 | pmid = 16360788 | pmc = 2850264 | doi = 10.1016/S0140-6736(05)67889-0}}</ref>。另一項研究估計2006年全球約有0.40%（範圍從0.17到0.89%；實際人數約2660萬人，範圍從1140萬到5940萬人）的人口受阿茲海默症的影響，在2050年以前，盛行率會是現在的三倍，實際人數則會高達四倍<ref name="Brookmeyer2007">2006年流行率估計：
* {{cite journal | authors = Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM | title = Forecasting the global burden of Alzheimer's disease | journal = Alzheimer's & Dementia | volume = 3 | issue = 3 | pages = 186–91 | year = 2007 | pmid = 19595937 | doi = 10.1016/j.jalz.2007.04.381 | url = http://works.bepress.com/cgi/viewcontent.cgi?article=1022&context=rbrookmeyer | deadurl = yes | accessdate = 2019-01-01 | archiveurl = https://web.archive.org/web/20081207025403/http://works.bepress.com/cgi/viewcontent.cgi?article=1022&context=rbrookmeyer | archivedate = 2008-12-07 | language = en }}
* {{cite journal|url=http://un.org/esa/population/publications/wpp2006/WPP2006_Highlights_rev.pdf|format=PDF|year=2007|title=World population prospects: the 2006 revision, highlights|publisher=Population Division, Department of Economic and Social Affairs, United Nations|version=Working Paper No. ESA/P/WP.202|author1=<!-- Please add first missing authors to populate metadata. -->|deadurl=yes|accessdate=2019-01-01|archiveurl=https://web.archive.org/web/20080819191533/http://www.un.org/esa/population/publications/wpp2006/WPP2006_Highlights_rev.pdf|archivedate=2008-08-19|language=en|journal=|author=}}</ref>。
{{clear}}

==歷史==
[[File:Auguste_D_aus_Marktbreit.jpg|thumb]]
早在[[古典时代|古希臘羅馬時代]]，當時的[[哲學家|哲學家]]和[[医生|醫師]]就已經發現年老與[[失智症|失智]]的關聯性<ref name="pmid9661992"/>。1901年，德國[[精神病学|精神科醫師]][[愛羅斯·阿茲海默|愛羅斯·阿茲海默]]描述了第一個阿茲海默症病例。這名病患是一名名叫{{tsl|en|Auguste D|奧古斯特·迪特}}的50歲女性，阿茲海默持續追蹤迪特的病程進展至病人於1906年死亡為止，並在之後發表該病例<ref>奧古斯特·迪特（Auguste D.）相關研究：
* {{cite journal|author=Alzheimer Alois|title=Über eine eigenartige Erkrankung der Hirnrinde|trans_title=About a peculiar disease of the cerebral cortex|journal=Allgemeine Zeitschrift für Psychiatrie und Psychisch-Gerichtlich Medizin|volume=64|issue=1–2|pages=146–48|year=1907|language=de}}
* {{cite journal | author1 = Alzheimer Alois | title = About a Peculiar Disease of the Cerebral Cortex | journal = Alzheimer Disease and Associated Disorders | volume = 1 | issue = 1 | pages = 3–8 | year = 1987 | pmid = 3331112 | author2 = L. Jarvik |translator= H. Greenson |language=en}}
* {{cite book |author1=Maurer Ulrike |author2=Maurer Konrad |title=Alzheimer: The Life of a Physician and the Career of a Disease|url=https://archive.org/details/alzheimerlifeofp00maur |publisher=Columbia University Press|location=New York|year=2003|page=[https://archive.org/details/alzheimerlifeofp00maur/page/270 270]|isbn=0-231-11896-1|language=en}}</ref>。其後五年，陸續又出現了11例類似的病例報告，其中有些論文已經用「阿茲海默症」來稱呼此疾病<ref name="pmid9661992" />。1910年7月15日，[[艾米爾·克雷珀林|艾米爾·克雷珀林]]於《精神科學課本》（''Textbook of Psychiatry''）第八版中首次將這些症狀描述為一個單一疾病，並將奧古斯特的部分症狀（如幻覺和妄想）及病理特徵（血管硬化）劃出該病的描述範圍<ref>{{cite journal|author=Berrios G E|title=Alzheimer's Disease: A Conceptual History|journal=Int. J. Ger. Psychiatry|volume=5|issue=6|pages=355–65|year=1990|doi=10.1002/gps.930050603|language=en}}</ref>。艾米爾採用了「阿茲海默症」這個名字，並同時將其稱為「早發性老年失智症」（presenile dementia）將其視為是老年失智症的一個亞型<ref name="isbn1-4325-0833-4">{{cite book|title=Clinical Psychiatry: A Textbook For Students And Physicians (Reprint)|author=Kraepelin Emil|date=2007-01-17|publisher=Kessinger Publishing|isbn=1-4325-0833-4|page=568|translator=Diefendorf A. Ross|language=en}}</ref>。

截至1970年代為止，阿茲海默症的診斷仍然僅限於描述45至65歲之間，提早出現特定失智症狀的患者。直到1977年，一場阿茲海默症研討會共識認定，阿茲海默症和老年失智症的臨床和病理表徵大致相同。雖然同時也強調兩者的病因學可能不同<ref name="isbn0-89004-225-X">{{cite book|title=Alzheimer's Disease: Senile Dementia and Related Disorders|publisher=Raven Press|year=1978|isbn=0-89004-225-X|editor=Katzman Robert|location=New York|page=595|editor2=Terry Robert D|editor3=Bick Katherine L|language=en}}</ref>，但這樣的共識已促使阿茲海默症的診斷，不再應該限定於特定年紀的的患者<ref>{{Cite journal|title=History of dementia and dementia in history: An overview|url=https://linkinghub.elsevier.com/retrieve/pii/S0022510X98001282|last=Boller|first=François|language=en|last2=Forbes|first2=Margaret M|date=1998-06|journal=Journal of the Neurological Sciences|issue=2|doi=10.1016/s0022-510x(98)00128-2|volume=158|pages=125–133|issn=0022-510X|access-date=2019-01-01|archive-url=https://web.archive.org/web/20180615205627/https://linkinghub.elsevier.com/retrieve/pii/S0022510X98001282|archive-date=2018-06-15|dead-url=no}}</ref>。此後一段時期，超過65歲且擁有阿茲海默症症狀的患者，另被描述為「阿茲海默型老年失智症」（senile dementia of the Alzheimer type，SDAT）。如今，阿茲海默症已經被接受為醫學的正式名詞，描述各年齡患者某種共同特定症狀的病徵<ref>{{Cite journal|title=Origin of the distinction between Alzheimer's disease and senile dementia: How history can clarify nosology|url=http://n.neurology.org/content/36/11/1497|last=Schoenberg|first=Bruce S.|last2=Rocca|first2=Walter A.|date=1986-11-01|journal=Neurology|issue=11|doi=10.1212/WNL.36.11.1497|volume=36|pages=1497–1497|issn=1526-632X|pmid=3531918|last3=Amaducci|first3=Luigi A.|access-date=2019-01-01|archive-url=https://web.archive.org/web/20181106181647/http://n.neurology.org/content/36/11/1497|archive-date=2018-11-06|dead-url=no|language=en}}</ref>。
{{-}}

==社會及文化==
===社會成本===
失智症（特別是阿茲海默症）已成為歐美社會花費最多的疾病之一<ref name="pmid15685097"/><ref name="pmid9543467"/>，其他如[[阿根廷|阿根廷]]<ref name="pmid16870037">{{cite journal|authors=Allegri RF, Butman J, Arizaga RL|title=Economic Impact of Dementia in Developing Countries: An Evaluation of Costs of Alzheimer-type Dementia in Argentina|journal=International Psychogeriatrics|language=en|volume=19|issue=4|pages=705–18|year=2007|pmid=16870037|doi=10.1017/S1041610206003784}}</ref>和[[大韩民国|南韓]]<ref name="pmid16858741">{{cite journal|authors=Suh GH, Knapp M, Kang CJ|title=The Economic Costs of Dementia in Korea, 2002|url=https://archive.org/details/sim_international-journal-of-geriatric-psychiatry_2006-08_21_8/page/722|journal=International Journal of Geriatric Psychiatry|language=en|volume=21|issue=8|pages=722–28|year=2006|pmid=16858741|doi=10.1002/gps.1552}}</ref>等國家的花費也節節攀升。這些花費可能會使社會結構老化，進而成為[[社会问题|社会问题]]。與阿茲海默症有關的社會成本包括直接的醫療費用（如護理之家照護、在宅日間照護）和間接的成本（如病人和照護者[[生产率|生產力]]降低）<ref name="pmid9543467"/>。雖然各個研究的數據有差異，但全球每年在失智症上花費約1600億美元<ref name="pmid16401889">{{cite journal | authors = Wimo A, Jonsson L, Winblad B | title = An Estimate of the Worldwide Prevalence and Direct Costs of Dementia in 2003 | journal = Dementia and Geriatric Cognitive Disorders | volume = 21 | issue = 3 | pages = 175–81 |language=en| year = 2006 | pmid = 16401889 | doi = 10.1159/000090733 }}</ref>，單是美國每年就可能花費了約1000億美元<ref name="pmid9543467"/>。

社會成本最大的來源為醫療專業人員的[[長期照護|長期照護]]，特別是{{tsl|en|institutionalisation|機構化|機構照護}}的費用可能佔了總花費的2/3<ref name="pmid15685097"/>。患者在家的{{tsl|en|Cost-of-living index|生活費用指數|生活花費}}通常很高<ref name="pmid15685097"/>，尤其還需考慮患者家人的非正式成本，如照護時間和因照顧患者而減少的收入<ref name="pmid11445614">{{cite journal | authors = Moore MJ, Zhu CW, Clipp EC | title = Informal Costs of Dementia Care: Estimates from the National Longitudinal Caregiver Study | journal = The Journals of Gerontology. Series B, Psychological Sciences and Social Sciences |language=en| volume = 56 | issue = 4 | pages = S219–28 | year = 2001 | pmid = 11445614 | doi = 10.1093/geronb/56.4.S219}}</ref>。

隨著失智的嚴重度和行為問題增加，患者的花費將會上升<ref name="pmid16676288">{{cite journal | authors = Jönsson L, Eriksdotter Jönhagen M, Kilander L | title = Determinants of Costs of Care for Patients with Alzheimer's Disease | url = https://archive.org/details/sim_international-journal-of-geriatric-psychiatry_2006-05_21_5/page/449 | journal = International Journal of Geriatric Psychiatry |language=en| volume = 21 | issue = 5 | pages = 449–59 | year = 2006 | pmid = 16676288 | doi = 10.1002/gps.1489}}</ref>，需要醫療照護的時間也會增加<ref name="pmid11445614"/>。因此，任何能減緩認知功能下降、延遲機構照護或減少照護時間的治療都對經濟有幫助，目前的治療方法在經濟評估上已顯示正向的結果<ref name="pmid9543467"/>。

===照護負擔===
患者的主要照護者通常是其配偶或關係較密切的親屬<ref name="metlife.com">{{cite web|title=The MetLife study of Alzheimer's disease: The caregiving experience|date=2006-08|publisher=MetLife Mature Market Institute|format=PDF|language=en|access-date=2011-02-05|url=http://www.metlife.com/assets/cao/mmi/publications/studies/mmi-alzheimers-disease-caregiving-experience-study.pdf|archive-url=https://web.archive.org/web/20110108073750/http://www.metlife.com/assets/cao/mmi/publications/studies/mmi-alzheimers-disease-caregiving-experience-study.pdf|archive-date=2011-01-08|deadurl=yes}}</ref>。阿茲海默症會帶給照護者社會上、心理上、生理上，和經濟上極沉重的負擔<ref name="pmid17662119"/><ref name="pmid10489656">{{cite journal | authors = Schneider J, Murray J, Banerjee S, Mann A | title = EUROCARE: a cross-national study of co-resident spouse carers for people with Alzheimer's disease: I—Factors associated with carer burden | url = https://archive.org/details/sim_international-journal-of-geriatric-psychiatry_1999-08_14_8/page/651 |language=en | journal = International Journal of Geriatric Psychiatry | volume = 14 | issue = 8 | pages = 651–61 | year = 1999 | pmid = 10489656 | doi = 10.1002/(SICI)1099-1166(199908)14:8<651::AID-GPS992>3.0.CO;2-B}}</ref><ref name="pmid10489657">{{cite journal | authors = Murray J, Schneider J, Banerjee S, Mann A | title = EUROCARE: A Cross-National Study of Co-resident Spouse Carers for People with Alzheimer's Disease: II—A Qualitative Analysis of the Experience of Caregiving | url = https://archive.org/details/sim_international-journal-of-geriatric-psychiatry_1999-08_14_8/page/662 | journal = International Journal of Geriatric Psychiatry |language=en | volume = 14 | issue = 8 | pages = 662–67 | year = 1999 | pmid = 10489657 | doi = 10.1002/(SICI)1099-1166(199908)14:8<662::AID-GPS993>3.0.CO;2-4}}</ref>。居家照護可以延遲或減少病人接受更昂貴和更專業的照護<ref name="pmid18044111" /><ref>{{cite journal | authors = Gaugler JE, Kane RL, Kane RA, Newcomer R | title = Early Community-based Service Utilization and Its Effects on Institutionalization in Dementia Caregiving | journal = The Gerontologist |language=en| volume = 45 | issue = 2 | pages = 177–85 | year = 2005 | pmid = 15799982 | doi = 10.1093/geront/45.2.177}}</ref>，因此通常家屬和患者會傾向選擇居家照護<ref name="pmid18044111">{{cite journal | authors = Zhu CW, Sano M | title = Economic Considerations in the Management of Alzheimer's Disease | journal = Clinical Interventions in Aging |language=en| volume = 1 | issue = 2 | pages = 143–54 | year = 2006 | pmid = 18044111 | pmc = 2695165 | doi = 10.2147/ciia.2006.1.2.143 }}</ref>。但即使如此，失智症患者仍然佔了護理之家住院人數的三分之二<ref name="pracGuideAPA"/>。

失智症患者的照護者罹患生理和[[心理疾患|心理疾患]]的機會較高<ref name="pmid12480441">{{cite journal | authors = Ritchie K, Lovestone S | title = The Dementias | journal = Lancet |language=en| volume = 360 | issue = 9347 | pages = 1759–66 | year = 2002 | pmid = 12480441 | doi = 10.1016/S0140-6736(02)11667-9}}</ref>。 造成主要照護者有較大心理問題的因素包括患者住在家中、患者為其配偶、患者有令照護較為吃力的行為（如憂鬱、行為干擾、幻覺、睡眠問題、行走問題或[[社交孤立|社交孤立]]）等<ref name="pmid2241719">{{cite journal | authors = Brodaty H, Hadzi-Pavlovic D | title = Psychosocial Effects on Carers of Living with Persons with Dementia | journal = The Australian and New Zealand Journal of Psychiatry |language=en| volume = 24 | issue = 3 | pages = 351–61 | year = 1990 | pmid = 2241719 | doi = 10.3109/00048679009077702}}</ref><ref name="pmid9646153">{{cite journal | authors = Donaldson C, Tarrier N, Burns A | title = Determinants of Carer Stress in Alzheimer's Disease | url = https://archive.org/details/sim_international-journal-of-geriatric-psychiatry_1998-04_13_4/page/248 | journal = International Journal of Geriatric Psychiatry |language=en| volume = 13 | issue = 4 | pages = 248–56 | year = 1998 | pmid = 9646153 | doi = 10.1002/(SICI)1099-1166(199804)13:4<248::AID-GPS770>3.0.CO;2-0}}</ref>。在經濟層面上，作為照護者的家人平均每週放棄47小時的工作時間來照護阿茲海默症患者，照護的代價相當高昂。在美國，每年直接和間接的照護支出從18,000到77,500美元不等，數值因研究而異，<ref name="pmid11445614"/><ref name="metlife.com"/>

[[认知行为疗法|认知行为疗法]]和教導{{tsl|en|Coping (psychology)|應對策略}}（不論是個別指導或在團體中教導）都能有效提升照護者的心裡健康<ref name="pmid17662119"/><ref name="pmid11511058">{{cite journal | authors = Pusey H, Richards D | title = A Systematic Review of the Effectiveness of Psychosocial Interventions for Carers of People with Dementia | journal = Aging & Mental Health |language=en| volume = 5 | issue = 2 | pages = 107–19 | year = 2001 | pmid = 11511058 | doi = 10.1080/13607860120038302}}</ref>。

===媒體===
許多電影或影集描述過阿茲海默症，例如《{{tsl|en|Iris (2001 film)|長路將盡}}》（2001，取材自{{tsl|en|John Bayley (writer)|約翰·貝禮}}描述其妻的回憶錄）<ref>{{cite book|title=Iris: A Memoir of Iris Murdoch|author=Bayley John|publisher=Abacus|location=London|language=en|year=2000|isbn=978-0-349-11215-2|oclc=41960006}}</ref>、《[[忘了、忘不了|忘了、忘不了]]》（2004，取材自[[尼可拉斯·史派克|尼可拉斯·史派克]]1996年的{{tsl|en|The Notebook (novel)|手札情緣 (小說)|同名小說}}）<ref>{{cite book|title=The notebook|url=https://archive.org/details/notebook00spar_1|author=Sparks Nicholas|language=en|year=1996|publisher=Thorndike Press|location=Thorndike, Maine|page=[https://archive.org/details/notebook00spar_1/page/268 268]|isbn=0-7862-0821-X}}</ref>、《[[我腦海中的橡皮擦|我腦海中的橡皮擦]]》（2004）、《{{tsl|en|Thanmathra|Thanmathra}}》（2005）<ref>{{cite web|url=http://www.webindia123.com/movie/regional/thanmatra/index.htm|title=Thanmathra|publisher=Webindia123.com|access-date=2008-01-24|deadurl=no|archive-url=https://web.archive.org/web/20071106105455/http://www.webindia123.com/movie/regional/thanmatra/index.htm|archive-date=2007-11-06|language=en}}</ref>、《[[明日的記憶|明日的記憶]]》 (2006，取材自荻原浩的同名小說）<ref>{{cite book|author=Ogiwara Hiroshi|year=2004|title=Ashita no Kioku|url=https://archive.org/details/ashitanokioku0000ogiw|location=Tōkyō|publisher=Kōbunsha|isbn=978-4-334-92446-1|oclc=57352130|language=ja}}</ref>、《[[妳的樣子|妳的樣子]]》（2006，取材自[[艾丽斯·芒罗|艾丽斯·芒罗]]的[[短篇小说|短篇小说]]《[[恨，友谊，追求，爱情，婚姻|恨，友谊，追求，爱情，婚姻]]》）<ref>{{cite book|title=[[恨，友谊，追求，爱情，婚姻|Hateship, Friendship, Courtship, Loveship, Marriage: Stories]]|author=Munro Alice|location=New York|publisher=A.A. Knopf|year=2001|isbn=978-0-375-41300-1|oclc=46929223|language=en}}</ref>、《[[我想念我自己|我想念我自己]]》（2014，內容描述一位罹患早發型阿茲海默症的[[哥伦比亚大学|哥伦比亚大学]]教授，取材自{{tsl|en|Lisa Genova|莉莎·潔諾娃}}的{{tsl|en|Still Alice (novel)|我想念我自己 (小說)|同名小說}}，並以[[茱莉安·摩爾|茱莉安·摩爾]]為英語的片名角色）。與阿茲海默症相關的紀錄片有《馬爾柯姆與芭芭拉：愛的故事》（1999，Malcolm and Barbara: A Love Story）和《馬爾柯姆與芭芭拉：愛的告別》（2007，Malcolm and Barbara: Love's Farewell），兩者都以鋼琴家{{tsl|en|Malcolm Pointon|馬爾柯姆·波因頓}}為主角<ref>{{cite web |url=http://www.dfgdocs.com/Directory/Titles/700.aspx |title=Malcolm and Barbara: A love story |publisher=Dfgdocs |access-date=2008-01-24 |deadurl=yes |archive-url=https://web.archive.org/web/20080524213821/http://www.dfgdocs.com/Directory/Titles/700.aspx |archive-date=2008-05-24 |language=en }}</ref><ref>{{cite web|url=http://www.bbc.co.uk/cambridgeshire/content/articles/2007/08/06/pointon_audio_feature.shtml|title=Malcolm and Barbara: A love story|publisher=BBC Cambridgeshire|access-date=2008-03-02|deadurl=no|archive-url=https://web.archive.org/web/20121110084233/http://www.bbc.co.uk/cambridgeshire/content/articles/2007/08/06/pointon_audio_feature.shtml|archive-date=2012-11-10|language=en}}</ref><ref>{{cite news|url=https://www.theguardian.com/media/2007/aug/07/broadcasting.itv|title=Alzheimer's film-maker to face ITV lawyers|publisher=Guardian Media|date=2007-08-07|access-date=2008-01-24|location=London|author=Plunkett J|archive-url=https://web.archive.org/web/20080115132419/http://www.guardian.co.uk/media/2007/aug/07/broadcasting.itv|archive-date=2008-01-15|deadurl=no|language=en}}</ref>。

==研究方向==
===藥物===
在2002到2012的十年中，244種化合物進入了第一、第二和第三期臨床試驗，但僅有{{tsl|en|memantine|美金剛胺}}獲得[[美国食品药品监督管理局|美國食品藥品監督管理局]]的核准（有部分仍在申請程序）<ref>{{cite journal|title=Alzheimer's disease drug-development pipeline: few candidates, frequent failures|date= 2014-07|journal=Alzheimer's Research & Therapy|issue=4|doi=10.1186/alzrt269|volume=6|pages=37|pmid=25024750|authors=Cummings JL, Morstorf T, Zhong K|language=en}}</ref>。現今治療阿茲海默症的藥物研究，大體來說可以分成下列幾個路徑：活化膽鹼路徑、抑制麩胺酸路徑、減少類澱粉斑塊、減少神經纖維纏結，以及減少神經發炎反應等<ref name=":4">{{Cite journal|title=Drug candidates in clinical trials for Alzheimer’s disease|url=https://doi.org/10.1186/s12929-017-0355-7|last=Hung|first=Shih-Ya|last2=Fu|first2=Wen-Mei|date=2017-07-19|journal=Journal of Biomedical Science|issue=1|doi=10.1186/s12929-017-0355-7|volume=24|pages=47|issn=1423-0127|pmc=5516350|pmid=28720101|language=en|access-date=2019-01-19|archive-date=2019-07-13|archive-url=https://web.archive.org/web/20190713162433/https://jbiomedsci.biomedcentral.com/articles/10.1186/s12929-017-0355-7|dead-url=no}}</ref>。

膽鹼路徑可分為膽鹼脂酶抑制劑、5-HT<sub>6</sub>受體拮抗劑、H<sub>3</sub>受體拮抗劑、α7菸鹼性膽鹼受體興奮劑。目前已核准的阿茲海默症藥物，除美金剛胺外為NMDA受體拮抗劑之外，其他全為膽鹼脂酶抑制劑，但此類藥物目前僅知能暫時減少記憶損失的程度，但不能延緩病程。<ref name=":4" />

減少{{le|β類澱粉蛋白質|Amyloid beta}}是此類開發中藥物常見的目標（例如{{tsl|en|apomorphine|去水嗎啡}}）<ref>{{cite journal | authors = Lashuel HA, Hartley DM, Balakhaneh D | display-authors = etal | title = New Class of Inhibitors of Beta-amyloid Fibril Formation. Implications for the Mechanism of Pathogenesis in Alzheimer's Disease | journal = The Journal of Biological Chemistry | volume = 277 | issue = 45 | pages = 42881–90 | year = 2002 | pmid = 12167652 | doi = 10.1074/jbc.M206593200 | url = http://www.jbc.org/cgi/content/abstract/277/45/42881 | deadurl = no | archive-url = https://web.archive.org/web/20090520012443/http://www.jbc.org/cgi/content/abstract/277/45/42881 | archive-date = 2009-05-20 | language = en | access-date = 2019-01-10 }}</ref>。[[免疫治疗|免疫治療]]或針對類澱粉蛋白的[[疫苗接種|疫苗]]也是一種研究中的療法<ref>{{cite journal | authors = Dodel R, Neff F, Noelker C | display-authors = etal | title = Intravenous Immunoglobulins as a Treatment for Alzheimer's Disease: Rationale and Current Evidence | journal = Drugs | volume = 70 | issue = 5 | pages = 513–28 | year = 2010 | pmid = 20329802 | doi = 10.2165/11533070-000000000-00000 | url = http://adisonline.com/drugs/Abstract/2010/70050/Intravenous_Immunoglobulins_as_a_Treatment_for.1.aspx | deadurl = yes | archive-url = https://web.archive.org/web/20110917191608/http://adisonline.com/drugs/Abstract/2010/70050/Intravenous_Immunoglobulins_as_a_Treatment_for.1.aspx | archive-date = 2011-09-17 | language = en | access-date = 2019-01-10 }}</ref>。和預防接種不同的是，開發中的疫苗預計是給已被診斷的患者施打的，希望藉由訓練免疫系統辨識、攻擊、並逆轉類澱粉蛋白的堆積來改變疾病的進程<ref>疫苗相關的參考資料：

*{{cite journal | authors = Hawkes CA, McLaurin J | title = Immunotherapy as Treatment for Alzheimer's Disease | journal = Expert Review of Neurotherapeutics | volume = 7 | issue = 11 | pages = 1535–48 | year = 2007 | pmid = 17997702 | doi = 10.1586/14737175.7.11.1535|language=en }}
*{{cite journal | authors = Solomon B | title = Clinical Immunologic Approaches for the Treatment of Alzheimer's Disease | journal = Expert Opinion on Investigational Drugs | volume = 16 | issue = 6 | pages = 819–28 | year = 2007 | pmid = 17501694 | doi = 10.1517/13543784.16.6.819|language=en}}
*{{cite journal | authors = Woodhouse A, Dickson TC, Vickers JC | title = Vaccination Strategies for Alzheimer's Disease: A New Hope? | journal = Drugs & Aging | volume = 24 | issue = 2 | pages = 107–19 | year = 2007 | pmid = 17313199 | doi = 10.2165/00002512-200724020-00003 |language=en}}</ref>。然而目前已發現免疫治療藥物會導致一些令人擔憂的[[药物不良反应|藥物不良反應]]，例如{{tsl|en|amyloid-related imaging abnormalities|類澱粉蛋白相關影像異常}}<ref>{{cite journal | authors = Sperling RA, Jack CR, Black SE, Frosch MP, Greenberg SM, Hyman BT, Scheltens P, Carrillo MC, Thies W, Bednar MM, Black RS, Brashear HR, Grundman M, Siemers ER, Feldman HH, Schindler RJ | title = Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association Research Roundtable Workgroup | journal = Alzheimer's & Dementia | volume = 7 | issue = 4 | pages = 367–85 | date = 2011-07 | pmid = 21784348 | pmc = 3693547 | doi = 10.1016/j.jalz.2011.05.2351 |language=en}}</ref>。其他研究中的方法還有神經保護物質和降低金屬蛋白交互作用的物質（如{{tsl|en|PBT2||PBT2}}）<ref>{{cite web|url=http://clinicaltrials.gov/ct2/show/NCT00471211|title=Study Evaluating the Safety, Tolerability and Efficacy of PBT2 in Patients with Early Alzheimer's Disease|type=Clinical Trial|access-date=2008-03-23|publisher=US National Institutes of Health|date=2008-01-13|deadurl=no|archive-url=https://web.archive.org/web/20080831021630/http://clinicaltrials.gov/ct2/show/NCT00471211|archive-date=2008-08-31|language=en}}</ref>。[[恩博|恩博]]是一種能阻斷[[肿瘤坏死因子-α|TNFα]]受體的[[融合蛋白|融合蛋白]]，近年已有部分令人振奮的初步結果<ref name="pmid16926764">恩博 （Etanercept）研究：
*{{cite journal | journal=CNS Drugs |language=en|date=2009-09 |volume=23 |issue=9 |pages=713–25 |doi=10.2165/11310810-000000000-00000 |title=Tumour necrosis factor modulation for treatment of Alzheimer's disease: rationale and current evidence |author=Tobinick E | pmid=19689163 }}
*{{cite journal | authors = Tobinick E, Gross H, Weinberger A, Cohen H | title = TNF-alpha Modulation for Treatment of Alzheimer's Disease: A 6-Month Pilot Study | journal = Medscape General Medicine|language=en| volume = 8 | issue = 2 | page = 25 | year = 2006 | pmid = 16926764 | pmc = 1785182 }}
*{{cite journal | authors = Griffin WS | title = Perispinal etanercept: Potential as an Alzheimer Therapeutic | journal = Journal of Neuroinflammation |language=en| volume = 5 | page = 3 | year = 2008 | pmid = 18186919 | pmc = 2241592 | doi = 10.1186/1742-2094-5-3 }}
*{{cite journal | authors = Tobinick E | title = Perispinal Etanercept for Treatment of Alzheimer's Disease |language=en| journal = Current Alzheimer Research | volume = 4 | issue = 5 | pages = 550–52 | year = 2007 | pmid = 18220520 | doi = 10.2174/156720507783018217}}
*{{cite journal | journal=Drug Discovery Today | date=2014-07-04 | doi=10.1016/j.drudis.2014.06.029 | title=Targeting TNF: a therapeutic strategy for Alzheimer's disease|language=en | authors=Cheng X, Shen Y, Li R | pmid=24998784 }}
</ref>。

2008年，兩項個別的臨床試驗顯示[[亞甲藍|亞甲藍]]對輕至中度阿茲海默症有效果，可以抑制tau蛋白的聚集<ref>{{cite journal |title=Tau aggregation inhibitor (TAI) therapy with remberTM arrests disease progression in mild and moderate Alzheimer's disease over 50 weeks |authors=Wischik Claude M, Bentham Peter, Wischik Damon J, Seng Kwang Meng |journal=Alzheimer's & Dementia |publisher=Alzheimer's Association |language=en|year=2008|volume=4 |issue=4 |page=T167 |url=http://www.abstractsonline.com/viewer/viewAbstractPrintFriendly.asp?CKey={E7C717CF-8D73-41E0-8DB0-FA92205978CD}&SKey={68E04DB5-AB1C-4F7B-9511-DA3173F4F755}&MKey={CFC5F7C6-CB6A-40C4-BC87-B30C9E64B1CC}&AKey={50E1744A-0C52-45B2-BF85-2A798BF24E02} |access-date=2008-07-30 |doi=10.1016/j.jalz.2008.05.438 }}</ref><ref>{{cite journal |authors=Harrington C, Rickard J, Horsley D |title=Methylthioninium chloride (MTC) acts as a tau aggregation inhibitor (TAI) in a cellular model and reverses tau pathology in transgenic mouse models of Alzheimer's disease|journal=Alzheimer's & Dementia|publisher=Alzheimer's Association|language=en|year=2008|pages=T120–T121|doi=10.1016/j.jalz.2008.05.259|volume=4|issue=4}}</ref>。[[抗組織胺藥|抗組織胺藥]]{{tsl|en|dimebon||Dimebon}}<ref name="pmid18640457">{{cite journal | authors = Doody RS, Gavrilova SI, Sano M | title = Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study |language=en| journal = Lancet | volume = 372 | issue = 9634 | pages = 207–15 | year = 2008 | pmid = 18640457 | doi = 10.1016/S0140-6736(08)61074-0}}</ref>的第三期試驗則未顯示顯著效果<ref>{{cite journal | authors = Bezprozvanny I | title = The rise and fall of Dimebon | journal = Drug News & Perspectives |language=en| volume = 23 | issue = 8 | pages = 518–23 | date = 2010-10 | pmid = 21031168 | doi = 10.1358/dnp.2010.23.8.1500435 | type = Original article }}</ref><ref>{{cite press release |url=http://investors.medivation.com/releasedetail.cfm?ReleaseID=448818 |title=Pfizer And Medivation announce results from two phase 3 studies in Dimebon (latrepirdine*) Alzheimer's disease clinical development program (NASDAQ:MDVN) |language=en |access-date=2012-11-16 |deadurl=yes |archive-url=https://web.archive.org/web/20120904163533/http://investors.medivation.com/releasedetail.cfm?ReleaseID=448818 |archive-date=2012-09-04 }}</ref><ref>{{cite journal | authors = Wendler A, Wehling M | title = Translatability scoring in drug development: eight case studies |language=en| journal = Journal of Translational Medicine | volume = 10 | issue = 10 | page = 39 | year = 2012 | pmid = 22397594 | doi = 10.1186/1479-5876-10-39 | pmc=3330010}}</ref>。但口服亞甲藍的腸道生物利用度會被胃酸影響，因此其劑量難以控制<ref>{{cite journal | authors = Baddeley TC, McCaffrey J, Storey JM, Cheung JK, Melis V, Horsley D, Harrington CR, Wischik CM | title = Complex disposition of methylthioninium redox forms determines efficacy in tau aggregation inhibitor therapy for Alzheimer's disease | journal = The Journal of Pharmacology and Experimental Therapeutics |language=en| volume = 352 | issue = 1 | pages = 110–8 | date =2015-01 | pmid = 25320049 | doi = 10.1124/jpet.114.219352 }}</ref>。亞甲藍的[[前体药物|前驅藥物]]{{tsl|en|LMTX||LMTX}}已經完成第三期試驗，相關結果仍待公布。

===行為預防===
有研究顯示，睡眠可以促進腦脊髓液排除Tau蛋白的功能，慢性[[睡眠不足|睡眠剝奪]]則會使腦間質中的tau蛋白累積，可能進而造成阿茲海默症<ref>{{Cite journal|title=The sleep-wake cycle regulates brain interstitial fluid tau in mice and CSF tau in humans|url=http://science.sciencemag.org/content/early/2019/01/23/science.aav2546|last=Holtzman|first=David M.|last2=Lucey|first2=Brendan P.|date=2019-01-24|journal=Science|doi=10.1126/science.aav2546|pages=eaav2546|language=en|issn=0036-8075|pmid=30679382|last3=Fuller|first3=Patrick M.|last4=Geerling|first4=Joel C.|last5=Manis|first5=Melissa|last6=Finn|first6=Mary Beth|last7=Mahan|first7=Thomas E.|last8=Cirrito|first8=John R.|last9=Pedersen|first9=Nigel P.|access-date=2019-02-01|archive-date=2019-02-13|archive-url=https://web.archive.org/web/20190213171421/http://science.sciencemag.org/content/early/2019/01/23/science.aav2546|dead-url=no}}</ref>。

有前端研究顯示冥想在失智症恢復記憶和認知功能上或有效果<ref>{{cite journal | authors = Marciniak R, Sheardova K, Čermáková P, Hudeček D, Šumec R, Hort J | title = Effect of Meditation on Cognitive Functions in Context of Aging and Neurodegenerative Diseases |language=en| journal = Frontiers in Behavioral Neuroscience | volume = 8 | page = 17 | year = 2014 | pmid = 24478663 | pmc = 3903052 | doi = 10.3389/fnbeh.2014.00017}}</ref>。一篇2015年的回顧性文章認為[[正念療法|正念療法]]可能在預防和延遲輕度認知損傷及阿茲海默症上有效<ref name="Larouche">{{cite journal | authors = Larouche E, Hudon C, Goulet S | title = Potential benefits of mindfulness-based interventions in mild cognitive impairment and Alzheimer's disease: an interdisciplinary perspective |language=en| journal = Behavioural Brain Research | volume = 276 | issue = 276 | pages = 199–212 | date = 2015-01 | pmid = 24893317 | doi = 10.1016/j.bbr.2014.05.058 }}</ref>。

===傳播性===
目前已有少數疑似阿茲海默症傳播的病例報導<ref>{{cite journal | authors = Jaunmuktane Z, Mead S, Ellis M, Wadsworth JD, Nicoll AJ, Kenny J, Launchbury F, Linehan J, Richard-Loendt A, Walker AS, Rudge P, Collinge J, Brandner S | title = Evidence for human transmission of amyloid-β pathology and cerebral amyloid angiopathy | journal = Nature | language = en | volume = 525 | issue = 7568 | pages = 247–50 | date = 2015-09 | pmid = 26354483 | doi = 10.1038/nature15369 | url = http://www.nature.com/nature/journal/v525/n7568/full/nature15369.html | archive-url = https://web.archive.org/web/20150911203127/http://www.nature.com/nature/journal/v525/n7568/full/nature15369.html | deadurl = no | archive-date = 2015-09-11 | access-date = 2019-01-10 }}</ref>，如注射[[生长激素|生長激素]]的病患<ref>{{Cite journal|title=Autopsies reveal signs of Alzheimer’s in growth-hormone patients|url=http://www.nature.com/news/autopsies-reveal-signs-of-alzheimer-s-in-growth-hormone-patients-1.18331|last=Abbott|first=Alison|date=2015-09-10|journal=Nature News|issue=7568|doi=10.1038/525165a|volume=525|page=165|language=en|access-date=2019-01-10|archive-date=2015-09-11|archive-url=https://web.archive.org/web/20150911011244/http://www.nature.com/news/autopsies-reveal-signs-of-alzheimer-s-in-growth-hormone-patients-1.18331|dead-url=no}}</ref>。

===感染===
研究發現一型[[单纯疱疹|单纯疱疹]]病毒（HSV-1）會出現在和類澱粉斑塊相同的區域<ref name="pmid22051760">{{cite journal | authors = Martin C, Solís L, Concha MI, Otth C | title = Herpes simplex virus tipo 1 como factor de riesgo asociado con la enfermedad de Alzheimer | language = es | journal = Revista Médica De Chile | volume = 139 | issue = 6 | pages = 779–86 | date = 2011-06 | pmid = 22051760 | doi = 10.4067/S0034-98872011000600013 | trans_title = Herpes Simplex Virus Type 1 as Risk Factor Associated to Alzheimer Disease }}</ref><ref>{{Cite journal|title=Corroboration of a Major Role for Herpes Simplex Virus Type 1 in Alzheimer’s Disease|url=https://www.frontiersin.org/articles/10.3389/fnagi.2018.00324/full|last=Itzhaki|first=Ruth F.|year=2018|journal=Frontiers in Aging Neuroscience|doi=10.3389/fnagi.2018.00324|volume=10|language=en|issn=1663-4365|access-date=2019-02-01|archive-date=2021-02-05|archive-url=https://web.archive.org/web/20210205064630/https://www.frontiersin.org/articles/10.3389/fnagi.2018.00324/full|dead-url=no}}</ref>，這項發現開啟了以[[抗病毒药物|抗病毒药物]]治療或預防阿茲海默症的可能性<ref name="pmid22051760"/><ref>{{cite journal | authors = Wozniak MA, Mee AP, Itzhaki RF | title = Herpes Simplex Virus type 1 DNA Is Located within Alzheimer's Disease Amyloid Plaques | journal = The Journal of Pathology |language=en| volume = 217 | issue = 1 | pages = 131–38 | year = 2008 | pmid = 18973185 | doi = 10.1002/path.2449 | type = Original study }}</ref>。抗病毒藥物在[[细胞培养|细胞培养]]實驗中已展現了十分有潛力的結果<ref>{{cite journal | authors = Itzhaki RF | title = Herpes simplex virus type 1 and Alzheimer's disease: increasing evidence for a major role of the virus | journal = Frontiers in Aging Neuroscience |language=en| volume = 6 | pages = 202 | year = 2014 | pmid = 25157230 | pmc = 4128394 | doi = 10.3389/fnagi.2014.00202 }}</ref>。

阿茲海默症與腦部真菌感染的關聯也曾被提出<ref name="pmid26967229">{{cite journal | authors = Itzhaki RF, Lathe R, Balin BJ, Ball MJ, Bearer EL, Braak H, Bullido MJ, Carter C, Clerici M, Cosby SL, Del Tredici K, Field H, Fulop T, Grassi C, Griffin WS, Haas J, Hudson AP, Kamer AR, Kell DB, Licastro F, Letenneur L, Lövheim H, Mancuso R, Miklossy J, Otth C, Palamara AT, Perry G, Preston C, Pretorius E, Strandberg T, Tabet N, Taylor-Robinson SD, Whittum-Hudson JA | title = Microbes and Alzheimer's Disease | language = en | journal = Journal of Alzheimer's Disease | volume = 51 | issue = 4 | pages = 979–84 | year = 2016 | pmid = 26967229 | doi = 10.3233/JAD-160152 | url = http://content.iospress.com/articles/journal-of-alzheimers-disease/jad160152 | archive-url = https://web.archive.org/web/20161110115259/http://content.iospress.com/articles/journal-of-alzheimers-disease/jad160152 | deadurl = no | archive-date = 2016-11-10 | access-date = 2019-01-10 }}</ref>，這項假說由[[微生物学|微生物学]]家卡拉斯科（L. Carrasco）提出，他的研究團隊發現瀰漫性真菌症和阿茲海默症有統計關聯<ref name="pmid24452965">{{cite journal | authors = Alonso R, Pisa D, Rábano A, Carrasco L | title = Alzheimer's disease and disseminated mycoses | journal = European Journal of Clinical Microbiology & Infectious Diseases |language=en| volume = 33 | issue = 7 | pages = 1125–32 | date = 2014-07 | pmid = 24452965 | doi = 10.1007/s10096-013-2045-z }}</ref>。進一步的研究顯示，阿茲海默氏症患者的各個腦區都出現真菌感染的現象，但對照組的一般大眾卻沒有<ref name="pmid26468932">{{cite journal | authors = Pisa D, Alonso R, Rábano A, Rodal I, Carrasco L | title = Different Brain Regions are Infected with Fungi in Alzheimer's Disease | journal = Scientific Reports | volume = 5 | pages = 15015 | date = 2015-10 | language = en | pmid = 26468932 | pmc = 4606562 | doi = 10.1038/srep15015 | url = http://www.nature.com/articles/srep15015 | archive-url = https://web.archive.org/web/20161025025359/http://www.nature.com/articles/srep15015 | deadurl = no | archive-date = 2016-10-25 | access-date = 2019-01-01 }}</ref><ref>{{cite web | title=Fungus, the bogeyman | url=https://www.economist.com/news/science-and-technology/21676754-curious-result-hints-possibility-dementia-caused-fungal | publisher=[[经济学人|The Economist]] | language=en | deadurl=no | archive-url=https://web.archive.org/web/20170808112542/https://www.economist.com/news/science-and-technology/21676754-curious-result-hints-possibility-dementia-caused-fungal | archive-date=2017-08-08 | accessdate=2019-01-10 }}</ref>。真菌感染似乎解釋了阿茲海默氏症患者的症狀。阿茲海默氏症患者緩慢的病程，似乎也與一些慢性的全身性真菌感染類似，症狀一樣不顯著、一樣難已注意到，自然也難以治癒<ref name="pmid26468932"/>。真菌感染的假說，也呼應了阿茲海默氏症某些現在已經較為確立的假說，例如[[類澱粉蛋白|類澱粉蛋白]]假說，同樣可以將阿茲海默氏症解釋為某種免疫系統對於[[中樞神經系統|中樞神經系統]]感染的反應<ref name="pmid27225182">{{cite journal | authors = Kumar DK, Choi SH, Washicosky KJ, Eimer WA, Tucker S, Ghofrani J, Lefkowitz A, McColl G, Goldstein LE, Tanzi RE, Moir RD | title = Amyloid-β peptide protects against microbial infection in mouse and worm models of Alzheimer's disease | journal = Science Translational Medicine | volume = 8 | issue = 340 | pages = 340ra72 | date = 2016-05 | pmid = 27225182 | doi = 10.1126/scitranslmed.aaf1059 |language=en}}</ref><ref>{{cite web | title=Could Alzheimer’s Stem From Infections? It Makes Sense, Experts Say | url=https://www.nytimes.com/2016/05/26/health/alzheimers-disease-infection.html | publisher=[[纽约时报|The New York Times]] | deadurl=no | archive-url=https://web.archive.org/web/20170204010325/https://www.nytimes.com/2016/05/26/health/alzheimers-disease-infection.html | archive-date=2017-02-04 | language=en | accessdate=2019-01-10 }}</ref><ref>{{cite web | title=Alzheimer’s culprit may fight other diseases | url=https://www.sciencenews.org/article/alzheimer%E2%80%99s-culprit-may-fight-other-diseases | publisher=Science News | deadurl=no | archive-url=https://web.archive.org/web/20160526113100/https://www.sciencenews.org/article/alzheimer%E2%80%99s-culprit-may-fight-other-diseases | archive-date=2016-05-26 | language=en | accessdate=2019-01-10 }}</ref>。該阿茲海默氏症成因的假說由莫伊爾（R. Moir）和譚茲（R. Tanzi）在大鼠與蠕蟲上所建立。

===影像學===
在現在既存的[[醫學影像|醫學影像]]技術中，[[單光子電腦斷層掃描|單光子電腦斷層掃描]]似乎是用於鑑別阿茲海默氏症與其他認知症的最佳方式，比起心智能力測試與病史分析，也能提供更為精確的資料<ref name="pmid15545324">{{cite journal | authors = Dougall NJ, Bruggink S, Ebmeier KP | title = Systematic Review of the Diagnostic Accuracy of 99mTc-HMPAO-SPECT in Dementia | journal = The American Journal of Geriatric Psychiatry |language=en| volume = 12 | issue = 6 | pages = 554–70 | year = 2004 | pmid = 15545324 | doi = 10.1176/appi.ajgp.12.6.554 }}</ref>。這樣的進展也促進診斷標準的更新，<ref name="pmid17222085" /><ref name="pmid176164822"/>

雖然{{tsl|en|Pittsburgh compound B||PiB PET}}目前還僅供研究使用，但已有醫療團隊使用類似的正子電腦斷層技術，將核醫放射示蹤劑藥物{{tsl|en|florbetapir||florbetapir}}用於治療。Florbetapir於2011年通過美國食品藥物管理局審查，可用於阿茲海默症的診斷<ref>{{cite journal | authors = Carpenter AP, Pontecorvo MJ, Hefti FF, Skovronsky DM | title = The use of the exploratory IND in the evaluation and development of<sup>18</sup>F-PET radiopharmaceuticals for amyloid imaging in the brain: a review of one company's experience | journal = The Quarterly Journal of Nuclear Medicine and Molecular Imaging |language=en| volume = 53 | issue = 4 | pages = 387–93 | date = 2009-08 | pmid = 19834448 }}</ref><ref>{{Cite book|url=http://www.ncbi.nlm.nih.gov/books/NBK32300/|title=Molecular Imaging and Contrast Agent Database (MICAD)|last=Leung|first=Kam|year=2004|language=en|publisher=National Center for Biotechnology Information (US)|location=Bethesda (MD)|chapter=(E)-4-(2-(6-(2-(2-(2-([18F]-fluoroethoxy)ethoxy)ethoxy)pyridin-3-yl)vinyl)-N-methylbenzenamine|pmid=20641982|access-date=2019-01-10|archive-date=2019-07-13|archive-url=https://web.archive.org/web/20190713162436/https://www.ncbi.nlm.nih.gov/books/NBK32300/|dead-url=no}}</ref>。這項藥物可以偵測患者腦中的澱粉蛋白斑塊<ref>{{cite journal|authors=Clark CM, Schneider JA, Bedell BJ|title=FDA recommends approval of new compound in Alzheimer's detection|language=en|journal=JAMA|volume=305|issue=3|pages=275–83|date=2011-01-19|pmid=21245183|doi=10.1001/jama.2010.2008|laysource=https://www.usatoday.com/yourlife/health/medical/alzheimers/2011-01-22-alzheimersfda21_ST_N.htm}}</ref>，若結果顯示為陰性，表示澱粉斑塊不存在或數量極為稀少，那麼就可以考慮排除阿茲海默症<ref>{{cite web|url=https://ec.europa.eu/health/documents/community-register/html/h805.htm|title=Amyvid|language=en|accessdate=2018-04-18|date=2013-01-17|work=Community register of medicinal products for human use|publisher=European Community|archive-date=2020-05-29|archive-url=https://web.archive.org/web/20200529001717/https://ec.europa.eu/health/documents/community-register/html/h805.htm|dead-url=no}}</ref>。2017年一項大型研究亦顯示類澱粉斑塊追跡藥物對於輕度失智患者的臨床決策有幫助<ref name="GrillApostolova2017">{{cite journal|language=en|title=Communicating mild cognitive impairment diagnoses with and without amyloid imaging|first1=Joshua D.|last2=Apostolova|first2=Liana G.|journal=Alzheimer's Research & Therapy|issue=1|doi=10.1186/s13195-017-0261-y|year=2017|volume=9|issn=1758-9193|last3=Bullain|first3=Szofia|last4=Burns|first4=Jeffrey M.|last5=Cox|first5=Chelsea G.|last6=Dick|first6=Malcolm|last7=Hartley|first7=Dean|last8=Kawas|first8=Claudia|last9=Kremen|first9=Sarah|last1=Grill|last10=Lingler|first10=Jennifer|last11=Lopez|first11=Oscar L.|last12=Mapstone|first12=Mark|last13=Pierce|first13=Aimee|last14=Rabinovici|first14=Gil|last15=Roberts|first15=J. Scott|last16=Sajjadi|first16=Seyed Ahmad|last17=Teng|first17=Edmond|last18=Karlawish|first18=Jason}}</ref>。

而類澱粉蛋白顯影技術與掃描其他生物標記的技術能相輔相成，並不互相取代<ref name="pmid19847050">{{cite journal | language = en | authors = Rabinovici GD, Jagust WJ | title = Amyloid Imaging in Aging and Dementia: Testing the Amyloid Hypotheses in Vivo | journal = Behavioural Neurology | volume = 21 | issue = 1 | pages = 117–28 | year = 2009 | pmid = 19847050 | pmc = 2804478 | doi = 10.3233/BEN-2009-0232 | url = http://iospress.metapress.com/content/23338q121v142311/ | deadurl = yes | archive-url = https://web.archive.org/web/20130730122115/http://iospress.metapress.com/content/23338q121v142311/ | archive-date = 2013-07-30 | access-date = 2019-01-10 }}</ref>。計量型的核磁共振影像可以用計算[[體素|體素]]的方式估計特定腦區的容量。當阿茲海默症的病程持續進行，測量萎縮的腦區是否有所變化，是相當重要的診斷指標。目前許多研究都認為比起其他醫學影像的方式，這很有可能會提供較為平價的選擇<ref name="pmid18445747">{{cite journal | authors = O'Brien JT | title = Role of imaging techniques in the diagnosis of dementia | journal = The British Journal of Radiology |language=en| volume = 80 | issue = Spec No 2 | pages = S71–77 | date = 2007-12 | pmid = 18445747 | doi = 10.1259/bjr/33117326 }}</ref>。

目前針對Tau蛋白顯影的追蹤藥物，以氟-18標記的flortaucipir（Tauvid，AV-1451 F18）已被FDA允許用於Tau蛋白的正子電腦斷層掃描診斷<ref>{{Cite web|title=FDA Approves First Drug to Image Tau Pathology in Patients Being Evaluated for Alzheimer’s Disease|url=https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-image-tau-pathology-patients-being-evaluated-alzheimers-disease|accessdate=2020-06-01|date=2020-05-28|last=Commissioner|first=Office of the|work=FDA|language=en|archive-date=2021-02-04|archive-url=https://web.archive.org/web/20210204100230/https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-image-tau-pathology-patients-being-evaluated-alzheimers-disease|dead-url=no}}</ref>。

===早期診斷===
現在對阿茲海默症的研究致力於在症狀發生前診斷出病情<ref>{{cite journal|authors=Chong MS, Sahadevan S|title=Preclinical Alzheimer's disease: diagnosis and prediction of progression|language=en|journal=Lancet Neurology|volume=4|issue=9|pages=576–79|date=2005-09-01|doi=10.1016/s1474-4422(05)70168-x|pmid=16109364|publisher=[[柳葉刀_(雜誌)|The Lancet]]}}</ref>。目前已經發展出一些可用於早期檢驗的生物化學方法，這些檢驗包括分析[[腦脊液|腦脊液]]中β-澱粉樣蛋白、tau蛋白與tau<sub>181P</sub>（磷酸化tau蛋白）總量的濃度測定。但因為抽取腦脊髓液的過程十分疼痛，應避免重複抽取。檢測血液中循環的miRNA與發炎指標則是具有潛力的替代指標。<ref name="pmid27630867">{{cite journal|title=Exploring biomarkers for Alzheimer's disease|date= 2016-07|journal=J Clin Diagn Res|issue=7|doi=10.7860/JCDR/2016/18828.8166|volume=10|pages=KE01-6|language=en|type=Review|pmid=27630867|authors=Sharma N, Singh AN}}</ref>

== 參考文獻 ==
{{Reflist|2}}

== 延伸閱讀 ==
{{Library resources box |by=no |onlinebooks=no |others=yes |about=yes |label=阿茲海默症|lcheading=Alzheimers Disease}}
{{refbegin}}
* {{cite book|title=Alzheimer's Disease: Unraveling the Mystery|url=http://www.nia.nih.gov/alzheimers/publication/alzheimers-disease-unraveling-mystery|publisher=US Department of Health and Human Services, National Institute on Aging, NIH|year=2008|deadurl=yes|archive-url=https://web.archive.org/web/20120108204115/http://www.nia.nih.gov/alzheimers/publication/alzheimers-disease-unraveling-mystery|archive-date=2012-01-08|language=en}}
* {{cite book|title=Can Alzheimer's Disease Be Prevented?|url=http://www.globalaging.org/health/us/2009/prevented.pdf|publisher=US Department of Health and Human Services, National Institute on Aging, NIH|year=2009|deadurl=yes|archive-url=https://web.archive.org/web/20130502233551/http://www.globalaging.org/health/us/2009/prevented.pdf|archive-date=2013-05-02|language=en}}
* {{cite book|title=Caring for a Person with Alzheimer's Disease: Your Easy-to-Use Guide from the National Institute on Aging|url=http://www.nia.nih.gov/alzheimers/publication/caring-person-alzheimers-disease|publisher=US Department of Health and Human Services, National Institute on Aging, NIH|year=2009|deadurl=yes|archive-url=https://web.archive.org/web/20120108193219/http://www.nia.nih.gov/alzheimers/publication/caring-person-alzheimers-disease|archive-date=2012-01-08|language=en}}
* {{cite web|title=Alzheimer's Behavior Management: Learn to Manage Common Behavior Problems |url=http://www.helpguide.org/elder/alzheimers_behavior_problems.htm |authors=Russell D, Barston S, White M |publisher=helpguide.org |date=2007-12-19 |access-date=2008-02-29 |archive-url=https://web.archive.org/web/20080223082753/http://www.helpguide.org/elder/alzheimers_behavior_problems.htm |archive-date=2008-02-23 |deadurl=yes |language=en}}
* {{cite journal | author1 = Irvine K |author2={{tsl|en|Keith Laws||Laws KR}} |author3=Gale TM |author4=Kondel TK | title = Greater cognitive deterioration in women than men with Alzheimer's disease: a meta analysis | journal = Journal of Clinical and Experimental Neuropsychology | volume = 34 | issue = 9 | pages = 989–98 | year = 2012 | pmid = 22913619 | doi = 10.1080/13803395.2012.712676 | type = Meta-analysis |language=en}}
{{refend}}

== 外部連結 ==
{{Commons category|Alzheimer's disease}}
* {{dmoz|Health/Conditions_and_Diseases/Neurological_Disorders/Alzheimer%27s/}}
<!--{{Medical condition classification and resources
|DiseasesDB=490
|ICD10={{ICD10|G|30||g|30}}, {{ICD10|F|00||f|00}}
|ICD9={{ICD9|331.0}}, {{ICD9|290.1}}
|ICDO=
|OMIM=104300
|MedlinePlus=000760
|eMedicineSubj=neuro
|eMedicineTopic=13
|MeshID=D000544
|GeneReviewsNBK=NBK1161
|Scholia = Q11081
}}
{{Mental and behavioural disorders|selected=neurological}}
{{CNS diseases of the nervous system}}
{{Amyloidosis}}-->
{{Authority control}}
{{CC-notice|cc=by4|url=https://www.frontiersin.org/articles/10.3389/fpsyt.2018.00201/full|author(s)=Chun-Hung Chang, Hsien-Yuan Lane, and Chieh-Hsin Lin}}

[[Category:阿尔茨海默病|Category:阿尔茨海默病]]
[[Category:病因不明的疾病|Category:病因不明的疾病]]
[[Category:神经科学中的未解之谜|Category:神经科学中的未解之谜]]
[[Category:學習障礙|Category:學習障礙]]
[[Category:精神病学诊断|Category:精神病学诊断]]
[[Category:痴呆|Category:痴呆]]
[[Category:異常心理學|Category:異常心理學]]
[[Category:认知障碍|Category:认知障碍]]
[[Category:失語症|Category:失語症]]
[[Category:人名疾病|Category:人名疾病]]
[[Category:神经退行性疾病|Category:神经退行性疾病]]
{{Featured article}}